

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/Caplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/Caplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/Caplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/Caplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:52:23 ON 13 JUL 2007

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 08:52:38 ON 13 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2007 VOL 147 ISS 4

FILE LAST UPDATED: 12 Jul 2007 (20070712/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s capsaicin receptor?

9409 CAPSAICIN

59 CAPSAICINS

9418 CAPSAICIN

(CAPSAICIN OR CAPSAICINS)

843281 RECEPTOR?

L1 1876 CAPSAICIN RECEPTOR?

(CAPSAICIN(W) RECEPTOR?)

=> s l1 and vanilloid ligand?

1812 VANILLOID

203 VANILLOIDS

1848 VANILLOID

(VANILLOID OR VANILLOIDS)

442457 LIGAND?

17 VANILLOID LIGAND?

(VANILLOID(W) LIGAND?)

L2 16 L1 AND VANILLOID LIGAND?

=> s l2 and py<2002

21897513 PY<2002

L3 3 L2 AND PY<2002

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:395002 CAPLUS

DOCUMENT NUMBER: 135:118142

TITLE: Ligand-induced dynamic membrane changes and cell deletion conferred by vanilloid receptor 1

AUTHOR(S): Olah, Zoltan; Szabo, Tamas; Karai, Laszlo; Hough, Chris; Fields, R. Douglas; Caudle, Robert M.; Blumberg, Peter M.; Iadarola, Michael J.

CORPORATE SOURCE: Neuronal Gene Expression Unit, Pain and Neurosensory

2

Mechanisms Branch, NIDCR, National Institutes of Health, Bethesda, MD, 20892, USA

SOURCE: Journal of Biological Chemistry (2001), 276(14), 11021-11030
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The real time dynamics of vanilloid-induced cytotoxicity and the specific deletion of nociceptive neurons expressing the wild-type vanilloid receptor (VR1) were investigated. VR1 was C-terminally tagged with either the 27-kDa enhanced green fluorescent protein (eGFP) or a 12-amino acid ϵ -epitope. Upon exposure to resiniferatoxin, VR1eGFP- or VR1 ϵ -expressing cells exhibited pharmacol. responses similar to those of cells expressing the untagged VR1. Within seconds of vanilloid exposure, the intracellular free calcium ($[Ca^{2+}]_i$) was elevated in cells expressing VR1. A functional pool of VR1 also was localized to the endoplasmic reticulum that, in the absence of extracellular calcium, also was capable of releasing calcium upon agonist treatment. Confocal imaging disclosed that resiniferatoxin treatment induced vesiculation of the mitochondria and the endoplasmic reticulum (.apprx.1 min), nuclear membrane disruption (5-10 min), and cell lysis (1-2 h). Nociceptive primary sensory neurons endogenously express VR1, and resiniferatoxin treatment induced a sudden increase in $[Ca^{2+}]_i$ and mitochondrial disruption which was cell-selective, as glia and non-VR1-expressing neurons were unaffected. Early hallmarks of cytotoxicity were followed by specific deletion of VR1-expressing cells. These data demonstrate that vanilloids disrupt vital organelles within the cell body and, if administered to sensory ganglia, may be employed to rapidly and selectively delete nociceptive neurons.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:282211 CAPLUS

DOCUMENT NUMBER: 135:90395

TITLE: Effect of vanilloid drugs on gastrointestinal transit in mice

AUTHOR(S): Izzo, Angelo A.; Capasso, Raffaele; Pinto, Luisa; Di Carlo, Giulia; Mascolo, Nicola; Capasso, Francesco

CORPORATE SOURCE: Department of Experimental Pharmacology, University of Naples "Federico II", Naples, 80131, Italy

SOURCE: British Journal of Pharmacology (2001), 132(7), 1411-1416
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have studied the effect of capsaicin, piperine, and anandamide, drugs which activate vanilloid receptors and capsazepine, a vanilloid receptor antagonist, on upper gastrointestinal motility in mice. Piperine (0.5-20 mg kg⁻¹ i.p.) and anandamide (0.5-20 mg kg⁻¹ i.p.), dose-dependently delayed gastrointestinal motility, while capsaicin (up to 3 mg kg⁻¹ i.p.) was without effect. Capsazepine (15 mg kg⁻¹ i.p.) neither per se affected gastrointestinal motility nor did it counteract the inhibitory effect of both piperine (10 mg kg⁻¹) and anandamide (10 mg kg⁻¹). A per se non ED of SR141716A (0.3 mg kg⁻¹ i.p.), a cannabinoid CB1 receptor antagonist, counteracted the inhibitory effect of anandamide (10 mg kg⁻¹) but not of piperine (10 mg kg⁻¹). By contrast, the inhibitory effect of piperine (10 mg kg⁻¹) but not of anandamide (10 mg kg⁻¹) was strongly attenuated in capsaicin (75 mg kg⁻¹ in total, s.c.)-treated mice. Pretreatment of mice with NG-nitro-L-arginine Me ester (25 mg kg⁻¹ i.p.), yohimbine (1 mg kg⁻¹, i.p.), naloxone (2 mg kg⁻¹ i.p.), or hexamethonium (1 mg kg⁻¹ i.p.) did not modify the inhibitory effect of both piperine (10 mg kg⁻¹) and

anandamide (10 mg kg⁻¹). The present study indicates that the vanilloid ligands anandamide and piperine, but not capsaicin, can reduce upper gastrointestinal motility. The effect of piperine involves capsaicin-sensitive neurons, but not vanilloid receptors, while the effect of anandamide involves cannabinoid CB₁, but not vanilloid receptors.

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:928501 CAPLUS

DOCUMENT NUMBER: 124:49944

TITLE: Autoradiographic visualization and pharmacological characterization of vanilloid (capsaicin) receptors in several species, including man

AUTHOR(S): Szallasi, Arpad

CORPORATE SOURCE: Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, S-171 77, Swed.

SOURCE: Acta Physiologica Scandinavica, Supplementum (1995), 155(629), 1-68
CODEN: APSSAD; ISSN: 0302-2994

PUBLISHER: Blackwell

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A thesis with several hundred refs. Sensory neurons sensitive to vanilloids (the paradigm of which is capsaicin, the pungent principle in hot peppers) were visualized by [³H]resiniferatoxin (RTX) autoradiog. in several species, including man. Vanilloid binding sites were detected in somatic (trigeminal and dorsal root) and visceral (nodose) sensory ganglia, peripheral (vagal and sciatic) nerves, dorsal horn of the spinal cord, as well as in nuclei in the central nervous system receiving sensory input, such as the nucleus of the solitary tract (containing vagal afferents) and the spinal trigeminal nucleus. Twenty four hrs after ligation of the vagal or the sciatic nerves, a strong accumulation of specific RTX binding sites was observed proximal to the ligature, implying anterograde intraaxonal receptor transport from the nodose and dorsal root ganglia, resp., to the periphery. RTX induced a dose-dependent loss of vanilloid receptors in the spinal cord and urinary bladder of the rat which was entirely due to a reduction in B_{max}. This receptor loss was reversible in the bladder, where the recovery of the binding was accompanied by a restoration of the neurogenic plasma extravasation response, but was irreversible in the spinal cord. These findings suggest that vanilloid receptor loss after RTX treatment can be either reversible (desensitization) or irreversible (most likely reflecting neurotoxicity). Comparably high levels of specific RTX binding were found in human, guinea pig and rat bronchi (species known to respond to vanilloids differently), suggesting that vanilloid receptors can mediate distinct patterns of biol. activities among species. Of the species examined, none showed a close resemblance in RTX binding parameters to human vanilloid receptors in spinal cord. The vanilloid receptor antagonist capsazepine was shown to inhibit RTX binding consistent with a competitive mechanism. Both inter- and intraspecies heterogeneity was observed in the affinity by which vanilloid receptors recognize capsazepine. Protons were shown to inhibit RTX binding to rat spinal cord membranes. Thus, protons and/or putative proton-generated substances might represent endogenous modulators of vanilloid receptors. A novel vanilloid ligand, phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV), was developed which bound to cultured dorsal root ganglion neurons and induced calcium uptake by them in a non-cooperative fashion. RTX bound to vanilloid receptors in a pos. cooperative manner; however, in the presence of PPAHV, cooperative binding was no longer observed. These results suggest that pos. cooperativity is a ligand-induced feature rather than an inherent property of vanilloid receptors. Neuroleptic drugs (trifluoperazine and rimcazone) were found to inhibit RTX binding to porcine dorsal horn membranes consistent with a noncompetitive or mixed binding mechanism. This interaction may represent

a mechanism for their adjuvant analgesic action. In conclusion, specific binding of [3H]RTX provides a unique tool to visualize vanilloid receptors and to study their pharmacol. A heterogeneous vanilloid receptor system is emerging with types/subtypes, and marked species-related differences. The interaction of protons and neuroleptics at vanilloid receptors may provide a rational basis to explain their actions on primary sensory neurons.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

19.48

19.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-2.34

FILE 'STNGUIDE' ENTERED AT 08:53:47 ON 13 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 6, 2007 (20070706/UP).

=> d his

(FILE 'HOME' ENTERED AT 08:52:23 ON 13 JUL 2007)

FILE 'CAPLUS' ENTERED AT 08:52:38 ON 13 JUL 2007

L1 1876 S CAPSAICIN RECEPTOR?

L2 16 S L1 AND VANILLOID LIGAND?

L3 3 S L2 AND PY<2002

FILE 'STNGUIDE' ENTERED AT 08:53:47 ON 13 JUL 2007

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

19.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-2.34

STN INTERNATIONAL LOGOFF AT 08:56:57 ON 13 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEADLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/CAPLUS enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 05:27:01 ON 13 JUL 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 05:27:13 ON 13 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6

DICTIONARY FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10539031.str



chain nodes :

12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-14 7-12 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

2-14 7-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 13:Atom 14:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 05:27:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3721 TO ITERATE

53.7% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

25 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 70762 TO 78078

PROJECTED ANSWERS: 521 TO 1339

L2 25 SEA SSS SAM L1

=> d 1-5

L2 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2007 ACS on STN

RN 848171-00-6 REGISTRY


ED Entered STN: 10 Apr 2005

CN 4-Quinazolinamine, N-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

MF C24 H20 F3 N5


CI COM

SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 ANSWER 2 OF 25 REGISTRY COPYRIGHT 2007 ACS on STN
RN 714223-68-4 REGISTRY
ED Entered STN: 22 Jul 2004
CN Piperazine, 1-cyclopentyl-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)
MF C31 H28 F6 N6 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 3 OF 25 REGISTRY COPYRIGHT 2007 ACS on STN
RN 714221-81-5 REGISTRY
ED Entered STN: 22 Jul 2004
CN 4-Quinazolinamine, 2-[[[(1-methyl-4-piperidinyl)methoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)
MF C29 H27 F6 N5 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 25 REGISTRY COPYRIGHT 2007 ACS on STN
RN 714221-37-1 REGISTRY
ED Entered STN: 22 Jul 2004
CN 2-Quinazolinemethanol, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-, acetate (ester) (9CI) (CA INDEX NAME)
MF C23 H15 F6 N5 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 25 REGISTRY COPYRIGHT 2007 ACS on STN
RN 713141-14-1 REGISTRY
ED Entered STN: 20 Jul 2004
CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN (4-tert-Butylphenyl)[2-methyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine
MF C25 H23 F3 N4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 full

FULL SEARCH INITIATED 05:34:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 75943 TO ITERATE

100.0% PROCESSED 75943 ITERATIONS
SEARCH TIME: 00.00.02

740 ANSWERS

L3 740 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
186.80	187.01

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 05:34:09 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 12 Jul 2007 (20070712/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 34 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:437005 CAPLUS

TITLE: The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation

AUTHOR(S): Gavva, Narendra R.; Bannan, Anthony W.; Surapaneni, Sekhar; Hovland, David N., Jr.; Lehto, Sonya G.; Gore, Anu; Juan, Todd; Deng, Hong; Han, Bora; Kliensky, Lana; Kuang, Rongzhen; Le, April; Tamir, Rami; Wang, Jue; Youngblood, Brad; Zhu, Dawn; Norman, Mark H.; Magal, Ella; Treanor, James J. S.; Louis, Jean-Claude
CORPORATE SOURCE: Departments of Neuroscience, Thousand Oaks, CA, 91320-1799, USA

SOURCE: Journal of Neuroscience (2007), 27(13), 3366-3374
CODEN: JNRSDS; ISSN: 0270-6474

PUBLISHER: Society for Neuroscience

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The vanilloid receptor TRPV1 (transient receptor potential vanilloid 1) is a cation channel that serves as a polymodal detector of pain-producing stimuli such as capsaicin, protons (pH <5.7), and heat. TRPV1 antagonists block pain behaviors in rodent models of inflammatory, neuropathic, and cancer pain, suggesting their utility as analgesics. Here, we report that TRPV1 antagonists representing various chemotypes cause an increase in body temperature (hyperthermia), identifying a potential issue for their clinical development. Peripheral restriction of antagonists did not eliminate hyperthermia, suggesting that the site of action is predominantly outside of the blood-brain barrier. Antagonists that are ineffective against proton activation also caused hyperthermia, indicating that blocking capsaicin and heat activation of TRPV1 is sufficient to produce hyperthermia. All TRPV1 antagonists evaluated here caused hyperthermia, suggesting that TRPV1 is tonically activated in vivo and that TRPV1 antagonism and hyperthermia are not separable. TRPV1 antagonists caused hyperthermia in multiple species (rats, dogs, and monkeys), demonstrating that TRPV1 function in thermoregulation is conserved from rodents to primates. Together, these results indicate that tonic TRPV1 activation regulates body temperature


IT 573678-04-3

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)

(vanilloid receptor TRPV1 tonic activation in vivo and role in body temperature regulation)

RN 573678-04-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD: ALL CITATIONS AVAILABLE IN THE RE' FORMAT

L4 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:61837 CAPLUS
 DOCUMENT NUMBER: 146:156236
 TITLE: Cellular cholesterol absorption modifiers, and their therapeutic use
 INVENTOR(S): Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.
 PATENT ASSIGNEE(S): Kalypsys, Inc., USA
 SOURCE: PCT Int. Appl., 300pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007008541	A2	20070118	WO 2006-US26242	20060705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:
 US 2005-697659P P 20050708
 US 2005-697686P P 20050708
 US 2005-697814P P 20050708
 US 2005-727646P P 20051017
 US 2006-782303P P 20060313


OTHER SOURCE(S): MARPAT 146:156236

AB The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.

IT 920528-84-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cholesterol absorption modifiers and therapeutic use)

RN 920528-84-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[[3-(ethoxycarbonyl)phenyl]amino]-7-quinazolinyl]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:874485 CAPLUS

DOCUMENT NUMBER: 145:454983

TITLE: From arylureas to biarylamides to aminoquinazolines:
Discovery of a novel, potent TRPV1 antagonist

AUTHOR(S): Zheng, Xiaozhang; Hodgetts, Kevin J.; Brielmann, Harry; Hutchison, Alan; Burkamp, Frank; Jones, A. Brian; Blurton, Peter; Clarkson, Robert; Chandrasekhar, Jayaraman; Bakthavatchalam, Rajagopal; De Lombaert, Stephane; Crandall, Marci; Cortright, Daniel; Blum, Charles A.

CORPORATE SOURCE: Neurogen Corporation, Branford, CT, 06405, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(19), 5217-5221

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:454983

AB Bioisosteric replacement of piperazine with an aryl ring in lead VR1 antagonist (2R)-2-methyl-N-[4-(trifluoromethyl)phenyl]-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide led to the biarylamide series, e.g. N-(4-tert-butylphenyl)-4-[3-(trifluoromethyl)pyridin-2-yl]benzamide. The development of B-ring SAR led to the conformationally constrained analog 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazoline (70). The resulting aminoquinazoline 70 is a novel VR1 antagonist with improved in vitro potency and oral bioavailability vs. the analogous compds. from the lead series.


IT 573678-04-3P, 4-[[4-(Trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazoline

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biarylamides and aminoquinazolines as TRPV1 antagonists)

RN 573678-04-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1292167 CAPLUS

DOCUMENT NUMBER: 144:36369

TITLE: Preparation of quinone substituted quinazoline and quinoline kinase inhibitors for treatment of angiogenesis-related diseases

INVENTOR(S): Floyd, Middleton B., Jr.; Nittoli, Thomas; Wissner, Allan; Dushin, Russell George; Nilakantan, Ramaswamy; Ingalls, Charles; Fraser, Heidi Leigh; Johnson, Bernard Dean

PATENT ASSIGNEE(S): Wyeth, USA

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115145	A2	20051208	WO 2005-US16800	20050511
WO 2005115145	A3	20060223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW



RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-573251P P 20040520

OTHER SOURCE(S): MARPAT 144:36369

GI



AB Title compds. I [R1 = N, C-CN, CH, C-F, C-Cl, C, Br, C-I; G1-G4 = independently H, halo, alk(en/yn)yl, alkylsulfinyl, NH2 and derivs., etc., with the proviso that G3 or G4 are not -NH-R2; R2 = -CO-C.tplbond.C-R3, -CO-(R3)C:C(R3)2, etc.; R3 = independently H, alkyl, Ph, carboxy, etc.; X = NH, O, S, etc.; Z' = (un)substituted 1,4-benzoquinone, 1,4-naphthoquinone, 7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione; and their pharmaceutically acceptable salts] were prepared as protein kinases, particularly protein tyrosine kinases, inhibitors. I are useful for treatment of diseases that are characterized, at least in part, by excessive, abnormal, or inappropriate angiogenesis, such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis. I inhibit angiogenesis by inhibiting a tyrosine kinase receptor enzyme, specifically KDR, and binding to the KDR in an irreversible manner. For example, reacting 2-amino-4,5-dimethoxybenzonitrile with DMF di-Me acetal, refluxing of amidine with 4-chloro-2,5-dimethoxyaniline and oxidation of dimethoxy intermediate with ceric ammonium nitrate gave quinazoline II. Quinazoline II (100 nM concentration) gave 83% inhibition of KDR kinase activity.

Selected I were effective inhibitors of VEGF-dependent growth factor of HUVEC cells.


IT 870962-25-7, 2-[[6-Methoxy-7-(1-methylpiperidin-4-yl)quinazolin-4-yl]amino]-5-phenoxy-1,4-benzoquinone

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinone substituted quinazoline and quinoline kinase inhibitors for treatment of angiogenesis-related diseases)

RN 870962-25-7 CAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[[6-methoxy-7-(1-methyl-4-piperidinyl)-4-quinazolinyl]amino]-5-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1050866 CAPLUS

DOCUMENT NUMBER: 143:347195

TITLE: Preparation of substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)methanol analogues as VRI modulators

INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; De Lombaert, Stephane; Zheng, Xiaozhang

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 65 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005215575	A1	20050929	US 2004-892741	20040716
PRIORITY APPLN. INFO.:			US 2003-488551P	P 20030716
OTHER SOURCE(S):			MARPAT 143:347195	
GI				



AB The title compds. I [A, B and Z = CH, N, at least one of A and B = CH; R1 = halo, Me, halomethyl; R2 = halo, CN, (un)substituted alkyl, cycloalkyl; R3 = H, alkyl, benzyl, etc.; R4 = H, Me] that are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions related to capsaicin receptor activation in humans, domesticated companion animals and livestock animals, were prepared. E.g., a multi-step synthesis of II, starting from 6-amino-3'-trifluoromethyl-[2,2']bipyridinyl-5-carboxamide, was given (no characterization data for intermediates). II showed IC₅₀ of <10 μM in standard assay of capsaicin receptor activity. Pharmaceutical compns. and methods for using compds. I to treat disorders responsive to capsaicin receptor modulation are provided, as are methods for using such ligands for receptor localization studies.


IT	573686-45-0P	573686-46-1P	573686-66-5P
	573686-70-1P	573686-73-4P	573686-75-6P
	573686-77-8P	573686-78-9P	573686-91-6P
	573686-92-7P	573686-95-0P	573686-97-2P
	573686-98-3P	573686-99-4P	573687-11-3P
	573687-12-4P	573687-13-5P	573687-14-6P
	573687-15-7P	573687-16-8P	573687-20-4P
	573687-21-5P	573687-26-0P	573687-27-1P
	573687-28-2P	573687-32-8P	573687-33-9P
	573687-35-1P	573687-36-2P	573687-38-4P
	573687-39-5P	573687-40-8P	573687-41-9P
	573687-44-2P	573687-45-3P	573687-46-4P
	573687-47-5P	573687-53-3P	573687-54-4P
	573687-55-5P	573687-57-7P	573687-64-6P
	573687-66-8P	573689-26-6P	573689-27-7P
	573689-30-2P	573689-31-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

```
(preparation of substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)methanol analogs as VR1 modulators)
```


RN 573686-45-0 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-46-1 CAPLUS

CN 4-Quinazolinamine, 2-(2-methoxyethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-66-5 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573686-70-1 CAPLUS

CN 4-Quinazolinamine, N-(4-cyclopropylphenyl)-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-73-4 CAPLUS

CN 4-Quinazolinamine; N-[4-(1-methylethyl)phenyl]-2-[[tetrahydro-2H-pyran-4-yl)oxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-75-6 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-77-8 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-78-9 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)-2-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 573686-91-6 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-92-7 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(ethoxymethyl)- (9CI) (CA INDEX NAME)



RN 573686-95-0 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 573686-97-2 CAPLUS
 CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-98-3 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(ethoxymethyl)- (9CI) (CA INDEX NAME)




RN 573686-99-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 573687-11-3 CAPLUS

CN 4-Quinazolinamine, 2-[[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-12-4 CAPLUS

CN 4-Quinazolinamine, 2-[[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573687-13-5 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-14-6 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-15-7 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-16-8 CAPLUS


CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573687-20-4 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-
[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
INDEX NAME)




RN 573687-21-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-
[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
INDEX NAME)




RN 573687-26-0 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-7-(3-methyl-2-pyridinyl)-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-27-1 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573687-28-2 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-32-8 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-33-9 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-35-1 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573687-36-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

NAME)




RN 573687-38-4 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(1-methylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-39-5 CAPLUS

CN 2-Quinazolinemethanol, 7-(3-chloro-2-pyridinyl)-4-[[4-(1,1-dimethylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-40-8 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-41-9 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-44-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-45-3 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-2-
[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 573687-46-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(ethoxymethyl)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-47-5 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(ethoxymethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-53-3 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-54-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-55-5 CAPLUS

CN 2-Quinazolinemethanol, 7-(3-chloro-2-pyridinyl)-4-[[4-(1-methylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-57-7 CAPLUS

CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-2-[[[tetrahydro-2H-pyran-4-yl)oxy)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-64-6 CAPLUS

CN Benzeneacetonitrile, α,α -dimethyl-4-[[2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-66-8 CAPLUS

CN Benzeneacetonitrile, 4-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 573689-26-6 CAPLUS'

CN 4-Quinazolinamine, 2-(ethoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 573689-27-7 CAPLUS


CN 4-Quinazolinamine, 2-(ethoxymethyl)-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573689-30-2 CAPLUS


CN 4-Quinazolinamine, 2-(ethoxymethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-

(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573689-31-3 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1024809 CAPLUS

DOCUMENT NUMBER: 143:477933

TITLE: Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core

AUTHOR(S): Harris, Craig S.; Kettle, Jason G.; Williams, Emma J.

CORPORATE SOURCE: Centre de Recherches, AstraZeneca, Reims, 51689, Fr.

SOURCE: Tetrahedron Letters (2005), 46(43), 7381-7384

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:477933

AB The facile preparation of 4-(3-chloro-4-fluoroanilino)-6-alkoxy-7-aminoquinazolines from their corresponding 7-triflate and 7-fluoro precursors are highlighted.

IT 869475-53-6P 869475-54-7P 869475-55-8P

869475-56-9P 869475-60-5P 869475-61-6P

869475-62-7P 869475-63-8P 869475-64-9P

869475-65-0P 869475-66-1P 869475-70-7P


869475-71-8P 869475-72-9P 869475-79-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of anilinoquinazolinamines via direct amination of quinazoline core)


RN 869475-53-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-methoxy-7-(1-piperidinyl)-
(9CI) (CA INDEX NAME)




RN 869475-54-7 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-methoxy-7-(4-morpholinyl)-
(9CI) (CA INDEX NAME)




RN 869475-55-8 CAPLUS

CN 4-Piperidinol, 1-[4-[(3-chloro-4-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 869475-56-9 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 869475-60-5 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[3-(ethylamino)-1-pyrrolidinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 869475-61-6 CAPLUS

CN Carbamic acid, [1-[4-[(3-chloro-4-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 869475-62-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[4-[(3-chloro-4-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 869475-63-8 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[3-(4-morpholinyl)propoxy]-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 869475-64-9 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(4-morpholinyl)-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 869475-65-0 CAPLUS


CN 4-Piperidinol, 1-[4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(4-

morpholinyl)propoxy]-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 869475-66-1 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-6-[3-(4-morpholinyl)propoxy]- (9CI)
(CA INDEX NAME)




RN 869475-70-7 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[3-(ethylamino)-1-pyrrolidinyl]-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 869475-71-8 CAPLUS

CN Carbamic acid, [1-[4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(4-morpholinyl)propoxy]-7-quinazolinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 869475-72-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(4-morpholinyl)propoxy]-7-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 869475-79-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(1H-imidazol-1-yl)-6-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1021616 CAPLUS

DOCUMENT NUMBER: 143:326381

TITLE: Preparation of arylalkylamino-substituted quinazolines as type VR1 capsaicin receptor modulators

INVENTOR(S): Bakthavatchalam, Rajagopal; Chenard, Bertrand L.; Peterson, John M.; Steenstra, Cheryl K.

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087227	A1	20050922	WO 2005-US6697	20050301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



AU 2005221614	A1	20050922	AU 2005-221614	20050301
CA 2555867	A1	20050922	CA 2005-2555867	20050301
EP 1720542	A1	20061115	EP 2005-729370	20050301

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 1950081	A	20070418	CN 2005-80014044	20050301
IN 2006DN05721	A	20070622	IN 2006-DN5721	20060929
PRIORITY APPLN. INFO.:			US 2004-550216P	P 20040304
			WO 2005-US6697	W 20050301

OTHER SOURCE(S): MARPAT 143:326381

GI



AB The title compds. I [V, X, Y and Z = N, CR1, such that at least one of V and X = N; R1 = H, halo, OH, etc.; R2 = halo, NO2, CN, etc.; n = 1-3; R3 = H, CN, alkyl, etc.; R4 = H, CN, alkyl; or R3 together with R4 forms an oxo group; or CR3R4 forms a 3-7 membered carbocycle or heterocycle; Ar = (un)substituted 5-10 membered carbocycle or heterocycle; A1 = N, CRa, or A1 is taken together with a R3 group to form an optionally substituted fused 5-7 membered carbocycle or heterocycle; A2-A5 = N, CRa; Ra = H, OH, halo, etc.] that are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathol. receptor activation in humans, domesticated companion animals and livestock animals, were prepared Thus, reacting 4-chloro-7-(3-trifluoromethylpyridin-2-yl)quinazoline with 2-fluorophenethylamine afforded the quinazoline II. The compds. I were tested in various tests for evaluating the VR1 modulator activity (data given). Pharmaceutical compns. and methods for using the compds. I to treat condition responsive to capsaicin receptor modulation are provided, as are methods for using such ligands for receptor localization studies.

IT 865157-90-0P 865158-39-0P 865158-40-3P

865158-41-4P 865158-42-5P 865158-43-6P

865158-44-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylalkylamino-substituted quinazolines as type VR1 capsaicin receptor modulators)

RN 865157-90-0 CAPLUS


CN 4-Quinazolinamine, N-[(1R,2S)-2-phenylcyclopropyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865158-39-0 CAPLUS

CN 4-Quinazolinamine, N-(2,3-dihydro-1H-inden-2-yl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 865158-40-3 CAPLUS

CN 4-Quinazolinamine, N-(1,2,3,4-tetrahydro-2-naphthalenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 865158-41-4 CAPLUS

CN 4-Quinazolinamine, N-(2,3-dihydro-1H-inden-1-yl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 865158-42-5 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dihydro-2H-1-benzopyran-4-yl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 865158-43-6 CAPLUS

CN 4-Quinazolinamine, N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865158-44-7 CAPLUS

CN 4-Quinazolinamine, N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:979624 CAPLUS

DOCUMENT NUMBER: 143:286442

TITLE: Preparation of bicyclic pyrimidine derivatives as CCR4 function-controlling agents

INVENTOR(S): Kawano, Noriyuki; Igarashi, Susumu; Koganemaru, Yohei; Yamasaki, Shingo; Hattori, Kazuyuki; Masuda, Naoyuki; Ishikawa, Noriko; Miyazaki, Takahiro

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082865	A1	20050909	WO 2005-JP3207	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2004-53121 A 20040227
JP 2004-183083 A 20040621

OTHER SOURCE(S): MARPAT 143:286442

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted aryl, etc.; ring B = II, etc.; X = N, etc.; Y = N, etc.; Z = O, etc.; R1 = (un)substituted alkyl, etc.; R2 =

halo, etc.; n = 0-3; m = 0-4; j = 0-3; k = 0-2] were prepared For example, reaction of 2-[(1'-{4-[(4-chlorophenyl)amino]-6,7-dimethoxyquinazolin-2-yl)-1,4'-bipiperidin-3-yl)methyl]-1H-isoindol-1,3(2H)-dione with hydrazine hydrate followed by treating with HCl afforded compound III·2HCl. In GTPγS binding assays, the IC50 value of compound III·2HCl was 13 nM. Comps. I are claimed useful for the treatment of inflammation, allergy, etc.


IT 864290-45-9P 864290-87-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic pyrimidine derivs. as CCR4 function-controlling agents for treatment of inflammation, allergy, etc.)

RN 864290-45-9 CAPLUS


CN [1,4'-Bipiperidine]-3-methanol, 1'-[4-[(4-chloro-2-fluorophenyl)amino]-6-fluoro-7-(4-morpholinyl)-2-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 864290-87-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-[(4-chlorophenyl)amino]-6-fluoro-2-[3-(hydroxymethyl)[1,4'-bipiperidin]-1'-yl]-7-quinazolinyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


IT 864292-45-5P 864292-64-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic pyrimidine derivs. as CCR4 function-controlling agents for treatment of inflammation, allergy, etc.)


RN 864292-45-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-chloro-4-[(4-chlorophenyl)amino]-6-fluoro-7-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 864292-64-8 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(4-chloro-2-fluorophenyl)-6-fluoro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:672884 CAPLUS

DOCUMENT NUMBER: 143:172886

TITLE: Preparation of substituted quinazolines and pyridopyrimidines as vanilloid receptor ligands

INVENTOR(S): Norman, Mark H.; Ognyanov, Vassil I.; Pettus, Liping H.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 22 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005165032	A1	20050728	US 2005-41174	20050121
AU 2005206562	A1	20050804	AU 2005-206562	20050121
CA 2553969	A1	20050804	CA 2005-2553969	20050121
WO 2005070929	A1	20050804	WO 2005-US2057	20050121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1713807 A1 20061025 EP 2005-722499 20050121

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU


PRIORITY APPLN. INFO.:

US 2004-538702P P 20040123


WO 2005-US2057 W 20050121

OTHER SOURCE(S): CASREACT 143:172886; MARPAT 143:172886

GI



I



II

AB The title compds. I [J = O, NH, S, SO, SO₂; X = N, C; Y₁-Y₄ = X:C, X:X, XCXX, XNXX and XNX:X; m = 0-3; R₁ = substituted Ph, pyridyl, etc.; R₂ = PhCH₂, substituted pyridyl, etc.; R₄ = alkyl, haloalkyl, alkyl, etc.; R₅ = alkyl, halo, CN, etc.], useful for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders, were prepared E.g., a 3-step synthesis of II.HCl, starting from 2-amino-4-chlorobenzoic acid, was given. Compds. I are tested to evaluate their agonist properties at VR1 (no data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 573678-04-3P 573685-94-6P 861101-00-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinazolines and pyridopyrimidines as vanilloid receptor ligands)


RN 573678-04-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 573685-94-6 CAPLUS

CN 4-Quinazolinamine, 2-(1-piperidinylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 861101-00-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)cyclohexyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




IT 692257-48-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted quinazolines and pyridopyrimidines as vanilloid receptor ligands)

RN 692257-48-0 CAPLUS

CN 4-Quinazolinamine, 2-(chloromethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:601190 CAPLUS

DOCUMENT NUMBER: 143:244173

TITLE: High-Affinity Epidermal Growth Factor Receptor (EGFR) Irreversible Inhibitors with Diminished Chemical Reactivities as Positron Emission Tomography (PET)-Imaging Agent Candidates of EGFR Overexpressing Tumors

AUTHOR(S): Mishani, Eyal; Abourbeh, Galith; Jacobson, Orit; Dissoki, Samar; Daniel, Revital Ben; Rozen, Yulia; Shaul, Mazal; Levitzki, Alexander

CORPORATE SOURCE: Department of Medical Biophysics and Nuclear Medicine, Hadassah Hebrew University, Jerusalem, 91120, Israel

SOURCE: Journal of Medicinal Chemistry (2005), 48(16), 5337-5348

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:244173

AB Previous studies with the anilinoquinazoline epidermal growth factor receptor (EGFR) irreversible inhibitor [11C]-ML03 demonstrated a rapid metabolism of the tracer, which led to its low in vivo accumulation in EGFR overexpressing tumors. To enhance tumor uptake, the chemical structure of the compound was modified, and four new groups of EGFR inhibitors with a wide range of chemical reactivities were synthesized. Chemical reactivity assay

of the compds., performed with reduced glutathione (GSH), revealed that the group C (4-(dimethylamino)-but-2-enoic amide) derivative was the least chemical reactive against the nucleophilic attack of GSH. Nonetheless, it demonstrated a high inhibitory potency and bound irreversibly to the EGFR. Consequently, the blood stability of the group C compound (5a, ML04) labeled with 11C was studied. In a time frame of 60 min, no radioactive metabolites were detected in blood. The stability of [11C]-5a, as indicated both from in vitro blood-stability assays and injection into nude rats, was significantly higher as compared to [11C]-ML03. Since group C presented a greater promise for tumor accumulation, it represents, to date, the most suitable candidate for radiolabeling with long-lived positron emission tomog. (PET) radioisotopes.


IT 863488-67-9P 863488-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(11C-labeled anilinoquinazoline EGFR inhibitors: preparation as PET tumor imaging agents)


RN 863488-67-9 CAPLUS

CN 2-Propenamide, N-[4-[(4,5-dichloro-2-fluorophenyl)amino]-7-(4-methyl-1-piperazinyl)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 863488-68-0 CAPLUS

CN 2-Propenamide, N-[4-[(3-bromophenyl)amino]-7-(4-methyl-1-piperazinyl)-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 863488-63-5P 863488-64-6P 863488-65-7P
863488-66-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(11C-labeled anilinoquinazoline EGFR inhibitors: preparation as PET tumor imaging agents)


RN 863488-63-5 CAPLUS

CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-7-(4-methyl-1-piperazinyl)-6-nitro- (9CI) (CA INDEX NAME)




RN 863488-64-6 CAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-7-(4-methyl-1-piperazinyl)-6-nitro- (9CI) (CA INDEX NAME)



RN 863488-65-7 CAPLUS

CN 4,6-Quinazolinediamine, N4-(4,5-dichloro-2-fluorophenyl)-7-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 863488-66-8 CAPLUS

CN 4,6-Quinazolinediamine, N4-(3-bromophenyl)-7-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

OTHER SOURCE(S): MARPAT 142:316855
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein B, V, X, Y, W, Z = independently N, CR1, such that at least one of V and X is N; D = N, CR9; either EF forms an (un)substituted fused 5- to 7-membered carbocyclyl, or heterocyclyl; and A = N, CR1 with proviso; or AF forms an (un)substituted fused 5- to 7-membered carbocyclyl, or heterocyclyl; and E = N, CR9; each R1 = independently H, halo, OH, CN, NH2, NO2, CO2H and derivs., etc.; each R9 = independently H, halo, OH, CN, alkylsulfonyl, alkylsulfonamido, etc.; U = N, CR2, with the proviso that if V and X are both N, then U = CR2; R2 = H, halo, CN, CO2H, etc.; Ar = (un)substituted 5- to 10-membered aromatic carbocycles or heterocycles, such that Ar is not thiophene; and their pharmaceutically acceptable salts], useful for treating conditions related to capsaicin receptor activation, were prepared I modulate, preferably inhibit binding of vanilloid ligand to VR1 activation capsaicin receptor VR1 (vanilloid receptor subtype 1), exhibit no detectable agonist activity in an in vitro assay of capsaicin receptor agonism, show IC50 of ≤ 1 μM in a capsaicin receptor calcium mobilization assay; and reduce calcium conductance of a cellular capsaicin receptor. Radiolabeled compds. I are used for determining the presence or absence of capsaicin receptor

in a sample in receptor localization studies. A 7-step synthesis is given for title compound II•HCl (no data for the intermediates).


IT 848046-78-6P, (2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride
848046-79-7P, [7-(3-Trifluoromethylpyridin-2-yl)quinazolin-4-yl](2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amine hydrochloride
848046-88-8P, [2-(Benzyloxymethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amine 848046-99-1P, [2-(Benzyloxymethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)amine 848047-01-8P, (4,4-Dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 848047-06-3P, [2-(Benzyloxymethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of bicyclic quinazolin-4-ylamine derivs. as type VR1 capsaicin receptor modulators)

RN 848046-78-6 CAPLUS


CN 4-Quinazolinamine, N-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 848046-79-7 CAPLUS


CN 4-Quinazolinamine, N-(1,2,3,4-tetrahydro-2,4,4-trimethyl-7-isoquinolinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 848046-88-8 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-(1,2,3,4-tetrahydro-2,4,4-trimethyl-7-isoquinolinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 848046-99-1 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-quinolinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI). (CA INDEX NAME)




RN 848047-01-8 CAPLUS

CN 4-Quinazolinamine, N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-quinolinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848047-06-3 CAPLUS

CN 2H-1,4-Benzoxazin-6-amine, 3,4-dihydro-4-methyl-N-[2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:141062 CAPLUS

DOCUMENT NUMBER: 142:240454

TITLE: Preparation of halogenated quinazolinyl nitrofurans as antibacterial agents

INVENTOR(S): Chamberland, Suzanne; Malouin, Francois

PATENT ASSIGNEE(S): Ulysses Pharmaceutical Products Inc., Can.

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014585	A1	20050217	WO 2004-CA1466	20040806
WO 2005014585	A8	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004262533	A1	20050217	AU 2004-262533	20040806
CA 2534405	A1	20050217	CA 2004-2534405	20040806
EP 1660486	A1	20060531	EP 2004-761630	20040806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1832941	A	20060913	CN 2004-80022816	20040806
BR 2004013372	A	20061017	BR 2004-13372	20040806
JP 2007501809	T	20070201	JP 2006-522859	20040806
US 2006258693	A1	20061116	US 2006-567660	20060208
PRIORITY APPLN. INFO.:			US 2003-493336P	P 20030808
			WO 2004-CA1466	W 20040806
OTHER SOURCE(S):		CASREACT 142:240454; MARPAT 142:240454		
GI				



AB Title compds. [I; X = null, trans- or cis CH:CH; R1 = (hydroxy-substituted) alkyl, alkenyl, alkynyl, aryl; R2 = H, alkyl, aryl; R3, R4 = H, halo, solubilizing group; ≥1 of R3, R4 = halo], were prepared Thus, p-aminophenol and 6-fluoro-2-[2-(5-nitro-2-furyl)vinyl]-4-chloroquinazoline (preparation given) were heated together in DMF for 2 h at 70-90° to give 6-fluoro-2-[2-(5-nitro-2-furyl)vinyl]-4-(p-hydroxyanilino)quinazoline. The latter showed a min. inhibitory concentration of 0.03-0.06 µg/mL against. S. aureus ATCC 29213.

IT 844692-04-2P
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of halogenated quinazolinyl nitrofurans as antibacterial agents)



RN 844692-04-2 CAPLUS
 CN Phenol, 4-[[6-fluoro-7-(4-methyl-1-piperazinyl)-2-[2-(5-nitro-2-furyl)ethenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:534192 CAPLUS
 DOCUMENT NUMBER: 141:89101
 TITLE: Preparation of carboxylic acid, phosphate, or phosphonate substituted (quinazolin-4-yl)amines as capsaicin receptor modulators
 INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Caldwell, Timothy M.; De Lombaert, Stephane; Hodgetts, Kevin J.; Zheng, Xiaozhang
 PATENT ASSIGNEE(S): Neurogen Corporation, USA
 SOURCE: PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055004	A1	20040701	WO 2003-US39607	20031212
WO 2004055004	A8	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509239	A1	20040701	CA 2003-2509239	20031212
AU 2003300898	A1	20040709	AU 2003-300898	20031212
US 2004156869	A1	20040812	US 2003-735607	20031212
EP 1569926	A1	20050907	EP 2003-813411	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1726205	A	20060125	CN 2003-80105815	20031212
JP 2006515847	T	20060608	JP 2004-560828	20031212
US 2006089354	A1	20060427	US 2005-539031	20050613
PRIORITY APPLN. INFO.:			US 2002-433139P	P 20021213
			WO 2003-US39607	W 20031212
OTHER SOURCE(S):			MARPAT 141:89101	
GI				



AB Title acid-substituted (quinazolin-4-yl)amines and analogs (I) [wherein V, W, X, Y, and Z = independently N, CR1, with the proviso that at least one of V and X = N; U = N, CR2, with the proviso that if V and X = N, then U = CR2; R1 = independently H, halo, OH, CN, NH2, CO2H, (halo)alkyl, (halo)alkoxy, alkoxycarbonyl, (di)alkylamino; R2 = H, halo, CN, NO2, (un)substituted alkyl, alkenyl, or alkynyl optionally interrupted by O, S, SO, SO2, CO, OCO, CO2, OCO2, CHNH, NHCO, NHSO2, SO2NH, NH, OPO2(OH), or PO2(OH); Ar1 and Ar2 = independently (un)substituted carbocyclyl, heterocyclyl; and pharmaceutically acceptable forms thereof] were prepared as modulators of capsaicin receptors, especially the vanilloid receptor 1 (VR1).

For example, 2-tert-butyl-5-nitrophenol was condensed with 2-(tert-butyl dimethylsilyloxy)ethanol, and the resulting nitrophenyl ether reduced to give the substituted aniline. Condensation of the phenylamine with 4-chloro-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-ol, followed by deprotection, coupling with L-proline Me ester, and saponification provided

II. In competition binding assays, invention compds. exhibited $K_i \leq 1 \mu\text{M}$ for VR1 expressed in human embryonic kidney (HEK293) cells. Thus, I and their pharmaceutical compns. are useful for treating disorders associated with pathol. receptor activation, such as pain, in humans, domesticated companion animals, and livestock animals (no data).


IT 573681-10-4P 714221-47-3P 714221-53-1P
714221-64-4P 714221-65-5P 714221-69-9P
714223-56-0P 714223-57-1P 714223-58-2P
714223-59-3P 714223-66-2P 714229-65-9P
714229-66-0P 714956-37-3P 714956-38-4P
714956-39-5P 714956-40-8P 714956-41-9P
714956-42-0P 714956-43-1P 714956-45-3P
714956-46-4P 714956-47-5P 714956-48-6P
714956-49-7P 714956-53-3P 714956-54-4P
714956-64-6P 714956-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(VR1 inhibitor; preparation of acid-substituted (quinazolin-4-yl)amines as VR1 inhibitors for treatment of pain and other VR1-mediated conditions)


RN 573681-10-4 CAPLUS

CN 2-Quinazolinepropanoic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 714221-47-3 CAPLUS

CN 2-Quinazolinecarboxylic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714221-53-1 CAPLUS


CN Acetic acid, [[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 714221-64-4 CAPLUS

CN Propanoic acid, 2-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714221-65-5 CAPLUS

CN Butanoic acid, 2-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714221-69-9 CAPLUS


CN Butanoic acid, 2-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714223-56-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 714223-57-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 714223-58-2 CAPLUS

CN L-Proline, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]-


2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714223-59-3 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 714223-66-2 CAPLUS

CN L-Proline, 1-[[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714229-65-9 CAPLUS

CN L-Proline, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714229-66-0 CAPLUS


CN D-Proline, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714956-37-3 CAPLUS

CN 2-Quinazolinepropanoic acid, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 714956-38-4 CAPLUS

CN Glycine, N-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 714956-39-5 CAPLUS


CN Phosphonic acid, [[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-2-quinazolinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 714956-40-8 CAPLUS
 CN Phosphoric acid, [4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 714956-41-9 CAPLUS
 CN 2-Quinazolinemethanol, 4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)




RN 714956-42-0 CAPLUS

CN Phosphoric acid, bis(phenylmethyl) [4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 714956-43-1 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)




RN 714956-45-3 CAPLUS

CN Phosphonic acid, [[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)-2-quinazolinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 714956-46-4 CAPLUS

CN Phosphonic acid, [[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 714956-47-5 CAPLUS

CN Phosphonic acid, [[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]-, monoethyl ester (9CI) (CA INDEX NAME)



RN 714956-48-6 CAPLUS


CN Benzeneacetic acid, α,α -dimethyl-4-[[2-methyl-7-(3-methyl-2-pyridinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 714956-49-7 CAPLUS


CN L-Proline, 1-[2-[2-(1,1-dimethylethyl)-5-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714956-53-3 CAPLUS

CN Ethanol, 2-[2-(1,1-dimethylethyl)-5-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenoxy]-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)




RN 714956-54-4 CAPLUS

CN Phosphonic acid, [[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 714956-64-6 CAPLUS


CN Acetic acid, [2-(1,1-dimethylethyl)-5-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 714956-65-7 CAPLUS

CN Ethanol, 2-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]oxy]-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

INDEX NAME)




IT 714956-69-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of acid-substituted (quinazolin-4-yl)amines as VR1 inhibitors for treatment of pain and other VR1-mediated conditions)

RN 714956-69-1 CAPLUS

CN Ethanol, 2-[2-(1,1-dimethylethyl)-5-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:534191 CAPLUS

DOCUMENT NUMBER: 141:89100

TITLE: Preparation of (quinazolin-4-yl)amines as capsaicin receptor modulators

INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Caldwell, Timothy M.; De Lombaert, Stephane; Hodgetts, Kevin J.; Zheng, Xiaozhang

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 226 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055003	A1	20040701	WO 2003-US39606	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509233	A1	20040701	CA 2003-2509233	20031212
AU 2003296984	A1	20040709	AU 2003-296984	20031212
US 2004156869	A1	20040812	US 2003-735607	20031212
EP 1569925	A1	20050907	EP 2003-813410	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017168	A	20051101	BR 2003-17168	20031212
CN 1726205	A	20060125	CN 2003-80105815	20031212
JP 2006515846	T	20060608	JP 2004-560827	20031212
PRIORITY APPLN. INFO.:			US 2002-433139P	P 20021213
			WO 2003-US39606	W 20031212
OTHER SOURCE(S):		MARPAT 141:89100		
GI				



AB Title compds. I [wherein V, W, X, Y, and Z = independently N, CR₁, with the proviso that at least one of V and X = N; R = OR₇, NR₃R₄; R₁ = independently H, halo, OH, CN, NH₂, (halo)alkyl, (halo)alkoxy, alkoxy, carbonyl, (di)alkylamino; R₃ and R₄ = independently H, (un)substituted (aryl)alkyl, alkenyl, alkynyl, alkanoyl, etc.; or R₃ or R₄ taken together with R₅ or R₆ forms an (un)substituted heterocycle; or NR₃R₄ = heterocyclyl; R₅ and R₆ = independently H, (un)substituted alkyl; or CR₅R₆ = CO; R₇ = H, (aryl)alkyl, alkenyl, alkynyl, alkanoyl, etc.; or R₇ taken together with R₅ or R₆ forms an (un)substituted heterocycle; n = 1-3; Ar₁ and Ar₂ = independently (un)substituted aryl, heterocyclyl; and pharmaceutically acceptable forms thereof] were prepared as modulators of capsaicin receptors, especially the vanilloid receptor 1 (VR₁). For example, a solution of [2-(chloromethyl)-7-(3-(trifluoromethyl)pyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine•HCl and pyrrolidine was heated to 100° for 1 h to give II. In competition binding assays, invention compds. exhibited K_i ≤ 1 μM for VR₁ expressed in human embryonic kidney (HEK293) cells. Thus, I and their pharmaceutical compns. are useful for treating disorders associated with pathol. receptor activation, such as pain, in humans, domesticated companion animals, and livestock animals (no data).

IT 573680-38-3P 573680-97-4P 573681-10-4P

573681-14-8P 573681-43-3P 573681-50-2P
573681-53-5P 573681-55-7P 573681-58-0P
573681-61-5P 573681-66-0P 573681-69-3P
573681-74-0P 573681-76-2P 573681-79-5P
573681-82-0P 573681-84-2P 573681-87-5P
573681-89-7P 573681-91-1P 573681-94-4P
573681-96-6P 573681-98-8P 573682-00-5P
573682-03-8P 573682-06-1P 573682-08-3P
573682-11-8P 573682-17-4P 573682-20-9P
573682-23-2P 573682-26-5P 573682-29-8P
573682-32-3P 573682-35-6P 573682-37-8P
573682-39-0P 573682-41-4P 573682-44-7P
573682-47-0P 573682-50-5P 573682-53-8P
573682-56-1P 573682-59-4P 573682-61-8P
573682-64-1P 573682-69-6P 573682-71-0P
573682-73-2P 573682-75-4P 573682-77-6P
573682-79-8P 573682-81-2P 573682-83-4P
573682-87-8P 573682-89-0P 573682-91-4P
573682-93-6P 573682-95-8P 573682-97-0P
573682-99-2P 573683-01-9P 573683-06-4P
573683-08-6P 573683-17-7P 573683-18-8P
573683-20-2P 573683-22-4P 573683-25-7P
573683-26-8P 573683-28-0P 573683-30-4P
573683-35-9P 573683-37-1P 573683-39-3P
573683-40-6P 573683-46-2P 573683-51-9P
573683-52-0P 573683-54-2P 573683-59-7P
573683-61-1P 573683-65-5P 573683-68-8P
573683-70-2P 573683-74-6P 573683-76-8P
573683-78-0P 573683-80-4P 573683-82-6P
573683-84-8P 573683-86-0P 573683-87-1P
573683-89-3P 573683-91-7P 573683-93-9P
573683-94-0P 573683-96-2P 573683-97-3P
573683-99-5P 573684-02-3P 573684-05-6P
573684-07-8P 573684-10-3P 573684-12-5P
573684-14-7P 573684-19-2P 573684-21-6P
573684-24-9P 573684-26-1P 573684-29-4P
573684-31-8P 573684-33-0P 573684-34-1P
573684-36-3P 573684-38-5P 573684-42-1P
573684-45-4P 573684-47-6P 573684-49-8P
573684-53-4P 573684-55-6P 573684-57-8P
573684-59-0P 573684-61-4P 573684-63-6P
573684-65-8P 573684-67-0P 573684-69-2P
573684-71-6P 573684-73-8P 573684-75-0P
573684-77-2P 573684-79-4P 573684-82-9P
573684-86-3P 573684-89-6P 573684-92-1P
573684-95-4P 573684-98-7P 573685-01-5P
573685-04-8P 573685-07-1P 573685-10-6P
573685-12-8P 573685-14-0P 573685-16-2P
573685-18-4P 573685-20-8P 573685-22-0P
573685-24-2P 573685-26-4P 573685-28-6P
573685-30-0P 573685-32-2P 573685-36-6P
573685-40-2P 573685-42-4P 573685-44-6P
573685-46-8P 573685-48-0P 573685-49-1P
573685-50-4P 573685-51-5P 573685-52-6P
573685-53-7P 573685-55-9P 573685-56-0P
573685-58-2P 573685-59-3P 573685-60-6P
573685-61-7P 573685-62-8P 573685-64-0P
573685-65-1P 573685-67-3P 573685-68-4P
573685-69-5P 573685-70-8P 573685-71-9P
573685-72-0P 573685-73-1P 573685-74-2P
573685-76-4P 573685-77-5P 573685-78-6P
573685-79-7P 573685-80-0P 573685-81-1P
573685-82-2P 573685-85-5P 573685-86-6P


573685-87-7P 573685-88-8P 573685-89-9P
 573685-91-3P 573685-92-4P 573685-93-5P
 573685-94-6P 573685-95-7P 573685-97-9P
 573685-98-0P 573685-99-1P 573686-00-7P
 573686-01-8P 573686-05-2P 573686-06-3P
 573686-07-4P 573686-08-5P 573686-09-6P
 573686-10-9P 573686-11-0P 573686-12-1P
 573686-13-2P 573686-14-3P 573686-15-4P
 573686-16-5P 573686-17-6P 573686-18-7P
 573686-19-8P 573686-20-1P 573686-21-2P
 573686-22-3P 573686-23-4P 573686-24-5P
 573686-25-6P 573686-26-7P 573686-27-8P
 573686-28-9P 573686-29-0P 573686-30-3P
 573686-31-4P 573686-32-5P 573686-33-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(VR1 inhibitor; preparation of (quinazolin-4-yl)amines as VR1 inhibitors for
 treatment of pain and other VR1-mediated conditions)


RN 573680-38-3 CAPLUS

CN 4-Quinazolinamine, 2-(1-pyrrolidinylmethyl)-N-[4-(trifluoromethyl)phenyl]-
 7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573680-97-4 CAPLUS


CN 4-Quinazolinamine, 2-[3-(4-morpholinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-,
 hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 573681-10-4 CAPLUS


CN 2-Quinazolinepropanoic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573681-14-8 CAPLUS


CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573681-43-3 CAPLUS


CN 4-Piperidinemethanol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 573681-50-2 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(3-methyl-2-pyridinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573681-53-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(6-methyl-2-pyridinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573681-55-7 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(2-pyridinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573681-58-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(1-piperidinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573681-61-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(1-pyrrolidinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573681-66-0 CAPLUS


CN 4-Quinazolinamine, 2-[(hexahydro-3,3,5-trimethyl-1H-azepin-1-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573681-69-3 CAPLUS

CN 4-Quinazolinamine, 2-[2-(hexahydro-3,3,5-trimethyl-1H-azepin-1-yl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-


[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573681-74-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R)-2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-76-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-2-[[(2R)-2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-79-5 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[1-(2R)-2-methyl-4-(4-(trifluoromethyl)phenyl)morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-82-0 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-2-[[1-(2R,6R)-2,6-dimethyl-4-(3-(trifluoromethyl)-2-pyridinyl)morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-84-2 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-87-5 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-ethylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-89-7 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-91-1 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-94-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-96-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 573681-98-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-00-5 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-03-8 CAPLUS

CN 4-Quinazolinamine, 2-[[2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 573682-06-1 CAPLUS

CN 4-Quinazolinamine, 2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-08-3 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-ethylphenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-11-8 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-17-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-20-9 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-23-2 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(1-methylethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573682-26-5 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573682-29-8 CAPLUS
 CN Ethanone, 1-[4-[[7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 573682-32-3 CAPLUS
 CN Benzonitrile, 4-[[7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-35-6 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-[(1S,1S)-2-methylethyl]phenyl]-2-[[2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-37-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-[(1S,1S)-2-methylethyl]sulfonyl]phenyl]-2-[[2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-39-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-2-
[[(2S)-2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-41-4 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-44-7 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-47-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-50-5 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-53-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-56-1 CAPLUS

CN 4-Quinazolinamine, 2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-59-4 CAPLUS

CN 4-Quinazolinamine, 2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-61-8 CAPLUS

CN 4-Quinazolinamine, 2-[[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-(trifluoromethyl)phenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-64-1 CAPLUS

CN 4-Quinazolinamine, 2-[[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-69-6 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-71-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-73-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-75-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-(1-methylethyl)phenyl]methyl]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-77-6 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-(1-methylethyl)phenyl]methyl]-N-(4-ethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573682-79-8 CAPLUS

CN 4-Quinazolinamine, 2-[(1,1-dioxido-4-thiomorpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573682-81-2 CAPLUS

CN 4-Quinazolinamine, 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573682-83-4 CAPLUS


CN 4-Quinazolinamine, 2-[(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573682-87-8 CAPLUS


CN 4-Quinazolinamine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573682-89-0 CAPLUS

CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573682-91-4 CAPLUS
 CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573682-93-6 CAPLUS
 CN 4-Quinazolinamine, 2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573682-95-8 CAPLUS
 CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573682-97-0 CAPLUS


CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573682-99-2 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R, 6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573683-01-9 CAPLUS

CN 4-Quinazolinamine, 2-[[2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573683-06-4 CAPLUS


CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 573683-08-6 CAPLUS

CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573683-17-7 CAPLUS


CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573683-18-8 CAPLUS

CN 4-Quinazolinamine, 2-[2-(2-ethyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[(2-ethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[(2-methyl-1-piperidinyl)ethyl]-N-[4-

(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
INDEX NAME)




RN 573683-25-7 CAPLUS

CN 4-Quinazolinamine, 2-[(2-methyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
INDEX NAME)




RN 573683-26-8 CAPLUS


CN 4-Quinazolinamine, 2-[2-(3,3-dimethyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
INDEX NAME)




RN 573683-28-0 CAPLUS
 CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-30-4 CAPLUS
 CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-35-9 CAPLUS
 CN 4-Quinazolinamine, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-37-1 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,5-dimethyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[(3,5-dimethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-40-6 CAPLUS

CN 4-Quinazolinamine, 2-[(3,5-dimethyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-46-2 CAPLUS

CN 3-Piperidinol, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 573683-51-9 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3-methyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-52-0 CAPLUS


CN 4-Quinazolinamine, 2-[(3-methyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-54-2 CAPLUS


CN 4-Quinazolinamine, 2-[(3-methyl-1-piperidinyl)methyl]-N-[4-

(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-59-7 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-pyrrolidinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-61-1 CAPLUS

CN 4-Quinazolinamine, 2-[(4-cyclopentyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-65-5 CAPLUS

CN 4-Quinazolinamine, 2-[(4-ethyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-68-8 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 573683-70-2 CAPLUS


CN 4-Quinazolinamine, 2-[[4-(1-methylethyl)-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-74-6 CAPLUS
 CN 4-Quinazolinamine, 2-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573683-76-8 CAPLUS
 CN 4-Quinazolinamine, 2-[(4-methyl-1-piperazinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573683-78-0 CAPLUS

CN 4-Quinazolinamine, 2-[(4-methyl-1-piperazinyl)methyl]-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-80-4 CAPLUS

CN 4-Quinazolinamine, 2-[(4-methyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-82-6 CAPLUS

CN 4-Quinazolinamine, 2-[2-(4-methyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-84-8 CAPLUS

CN 4-Quinazolinamine, 2-[(4-methyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-86-0 CAPLUS


CN 4-Quinazolinamine, 2-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(5H-tetrazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-

(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-89-3 CAPLUS


CN 2-Quinazolinemethanamine, N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[5-(trifluoromethyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573683-91-7 CAPLUS

CN 2-Quinazolinemethanamine, N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573683-93-9 CAPLUS

CN 2-Quinazolinemethanamine, N-(2-methylpropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-94-0 CAPLUS

CN 2-Quinazolinemethanamine, N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-96-2 CAPLUS

CN 4-Quinazolinamine, 2-[2-(octahydro-1(2H)-quinolinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-97-3 CAPLUS

CN 4-Quinazolinamine, 2-[(octahydro-1(2H)-quinolinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-99-5 CAPLUS

CN 2-Quinazolinemethanamine, N-(1,1-dimethylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-02-3 CAPLUS

CN 2-Quinazolinemethanamine, N-[(2-methoxyphenyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573684-05-6 CAPLUS


CN 2-Quinazolinemethanamine, N-(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573684-07-8 CAPLUS


CN 2-Quinazolinemethanamine, N-(3-methylbutyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-10-3 CAPLUS

CN 2-Quinazolinemethanamine, N-[(4-methoxyphenyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-12-5 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-14-7 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-19-2 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclopropyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-21-6 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-24-9 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-26-1 CAPLUS


CN 2-Quinazolineethanamine, N-butyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573684-29-4 CAPLUS
 CN 2-Quinazolinemethanamine, N-butyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-31-8 CAPLUS
 CN 2-Quinazolineethanamine, N-butyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-33-0 CAPLUS

CN 2-Quinazolinemethanamine, N-butyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-34-1 CAPLUS

CN 2-Quinazolineethanamine, N-cyclohexyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-36-3 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclohexyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-38-5 CAPLUS

CN 2-Quinazolineethanamine, N-cyclohexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-42-1 CAPLUS


CN 2-Quinazolinemethanamine, N-cyclohexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-45-4 CAPLUS


CN 2-Quinazolineethanamine, N-(cyclopropylmethyl)-N-propyl-4-[[4-

(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-47-6 CAPLUS

CN 2-Quinazolinemethanamine, N-(cyclopropylmethyl)-N-propyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-49-8 CAPLUS


CN 2-Quinazolinemethanamine, N-(cyclopropylmethyl)-N-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-53-4 CAPLUS
 CN 2-Quinazolinemethanamine, N-ethyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-55-6 CAPLUS
 CN 2-Quinazolineethanamine, N-hexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-57-8 CAPLUS
 CN 2-Quinazolinemethanamine, N-hexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)



RN 573684-59-0 CAPLUS
 CN 2-Quinazolinemethanamine, N-(2,3-dihydro-1H-inden-1-yl)-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-61-4 CAPLUS
 CN 2-Quinazolineethanamine, N-ethyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-63-6 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-65-8 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-67-0 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-propyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-69-2 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-propyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-71-6 CAPLUS

CN 2-Quinazolinemethanamine, N-(tetrahydro-2H-thiopyran-4-yl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-73-8 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-75-0 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-77-2 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-79-4 CAPLUS

CN 4-Quinazolinamine, 2-[2-(4-methyl-1-piperazinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-82-9 CAPLUS

CN 2-Quinazolineethanamine, N-cyclopropyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-86-3 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-89-6 CAPLUS

CN 2-Quinazolineethanamine, N-(2,3-dihydro-1H-inden-1-yl)-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-92-1 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(2-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-95-4 CAPLUS

CN 4-Quinazolinamine, 2-[3-(2,6-dimethyl-4-morpholinyl)propyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-98-7 CAPLUS


CN 4-Quinazolinamine, 2-[3-(2,6-dimethyl-4-morpholinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-01-5 CAPLUS


CN 4-Quinazolinamine, 2-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 573685-04-8 CAPLUS

CN 4-Quinazolinamine, 2-[3-(3-methyl-1-piperidinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-07-1 CAPLUS

CN 4-Quinazolinamine, 2-[3-(4-methyl-1-piperazinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-10-6 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[2-(diethylamino)ethyl]-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-12-8 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[2-(dimethylamino)ethyl]-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-14-0 CAPLUS

CN 4-Quinazolinamine, 2-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-16-2 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-18-4 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-20-8 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[3-(dimethylamino)propyl]-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-22-0 CAPLUS

CN 2-Quinazolinemethanamine, N-[(2-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-24-2 CAPLUS

CN 2-Quinazolinemethanamine, N-[(3-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573685-26-4 CAPLUS


CN 2-Quinazolinemethanamine, N-(2-pyridinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573685-28-6 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-


pyridinyl]-4-[[5-(trifluoromethyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573685-30-0 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(2,2,2-trifluoro-1-methylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-32-2 CAPLUS


CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-36-6 CAPLUS
 CN 2-Quinazolinemethanamine, N-ethyl-N-(2-methyl-2-propenyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573685-40-2 CAPLUS
 CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573685-42-4 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylpropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-44-6 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-[(2-methylphenyl)methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-46-8 CAPLUS


CN 2-Quinazolinemethanamine, N-methyl-N-(2-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573685-48-0 CAPLUS
 CN 2-Quinazolineethanamine, N-[(2-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573685-49-1 CAPLUS
 CN 2-Quinazolineethanamine, N-[(3-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573685-50-4 CAPLUS


CN 2-Quinazolineethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573685-51-5 CAPLUS
CN 2-Quinazolineethanamine, N-ethyl-N-(2-methyl-2-propenyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-52-6 CAPLUS
CN 2-Quinazolineethanamine, N-methyl-N-(1-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-53-7 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(1-phenylpropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-55-9 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-[(2-methylphenyl)methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-56-0 CAPLUS

CN 4-Quinazolinamine, 2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-58-2 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-1H-azepin-1-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-59-3 CAPLUS

CN 4-Quinazolinamine, 2-[2-(hexahydro-1(2H)-azocinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-. (9CI) (CA INDEX NAME)




RN 573685-60-6 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-1(2H)-azocinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-61-7 CAPLUS


CN 2-Quinazolinemethanamine, N-cyclohexyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-62-8 CAPLUS


CN 2-Quinazolineethanamine, N,N-di-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)

(CA INDEX NAME)




RN 573685-64-0 CAPLUS

CN 2-Quinazolinemethanamine, N,N-di-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-65-1 CAPLUS

CN 2-Quinazolineethanamine, N,N-dibutyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-67-3 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dibutyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-68-4 CAPLUS

CN 2-Quinazolinethanamine, N,N-diethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-69-5 CAPLUS

CN 2-Quinazolinemethanamine, N,N-diethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-70-8 CAPLUS

CN 2-Quinazolineethanamine, N,N-dihexyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-71-9 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-72-0 CAPLUS

CN 2-Quinazolineethanamine, N,N-dipentyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-73-1 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dipentyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-74-2 CAPLUS


CN 2-Quinazolineethanamine, N,N-dipropyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-76-4 CAPLUS


CN 2-Quinazolinemethanamine, N,N-dipropyl-7-[3-(trifluoromethyl)-2-pyridinyl]-

4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573685-77-5 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dipropyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-78-6 CAPLUS


CN 2-Quinazolinemethanamine, N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-79-7 CAPLUS


CN 2-Quinazolinemethanamine, N-hexyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-

[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-80-0 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-ylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-81-1 CAPLUS


CN 2-Quinazolinemethanamine, N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-82-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-(4-morpholinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-85-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573685-86-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-87-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-88-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 573685-89-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-91-3 CAPLUS

CN 2-Quinazolinemethanamine, N-octyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-92-4 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-93-5 CAPLUS

CN 4-Quinazolinamine, 2-(1-piperidinylmethyl)-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-94-6 CAPLUS

CN 4-Quinazolinamine, 2-(1-piperidinylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-95-7 CAPLUS

CN 4-Quinazolinamine, 2-[2-(4-thiomorpholinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-97-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-thiomorpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-98-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-thiomorpholinylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-99-1 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 573686-00-7 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(trifluoromethyl)-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 573686-01-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573686-05-2 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[(3,5-dimethyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573686-06-3 CAPLUS
 CN 4-Piperidinemethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-07-4 CAPLUS

CN 2-Piperidinemethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-08-5 CAPLUS

CN 3-Piperidinemethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-09-6 CAPLUS

CN 4-Piperidinemethanol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-10-9 CAPLUS

CN 3-Piperidinemethanol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 573686-11-0 CAPLUS


CN 4-Piperidinol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 573686-12-1 CAPLUS


CN 3-Piperidinol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-

(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 573686-13-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 573686-14-3 CAPLUS

CN 4-Piperidinol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 573686-15-4 CAPLUS

CN 3-Piperidinol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-16-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-17-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 573686-18-7 CAPLUS

CN 4-Piperidinol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-19-8 CAPLUS

CN 3-Piperidinol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-20-1 CAPLUS

CN Piperazine, 1-acetyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-21-2 CAPLUS

CN Pyrrolidine, 1-[1-oxo-3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-22-3 CAPLUS

CN 4-Piperidineethanol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-23-4 CAPLUS

CN Ethanol, 2-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 573686-24-5 CAPLUS

CN 4-Piperidineethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-25-6 CAPLUS

CN 4-Piperidineethanol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 573686-26-7 CAPLUS

CN 1-Piperazineethanol, 4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-27-8 CAPLUS

CN 1-Piperazineethanol, 4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)


RN 573686-30-3 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dimethyl-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-31-4 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 573686-32-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)-2-(4-thiomorpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 573686-33-6 CAPLUS

CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



IT	573686-34-7P	573686-35-8P	573686-36-9P
	573686-37-0P	573686-38-1P	573686-39-2P
	573686-40-5P	573686-41-6P	573686-42-7P
	573686-43-8P	573686-44-9P	573686-53-0P
	573686-70-1P	573686-72-3P	573686-73-4P
	573686-75-6P	573686-77-8P	573686-78-9P
	573686-79-0P	573686-83-6P	573686-84-7P
	573686-85-8P	573686-86-9P	573686-87-0P
	573686-91-6P	573686-92-7P	573686-95-0P
	573686-96-1P	573686-97-2P	573686-99-4P
	573687-00-0P	573687-01-1P	573687-02-2P
	573687-03-3P	573687-04-4P	573687-05-5P
	573687-06-6P	573687-07-7P	573687-08-8P
	573687-09-9P	573687-10-2P	573687-11-3P
	573687-12-4P	573687-13-5P	573687-14-6P
	573687-15-7P	573687-16-8P	573687-17-9P
	573687-18-0P	573687-19-1P	573687-20-4P
	573687-21-5P	573687-22-6P	573687-26-0P
	573687-27-1P	573687-28-2P	573687-32-8P
	573687-33-9P	573687-34-0P	573687-35-1P
	573687-36-2P	573687-38-4P	573687-39-5P
	573687-40-8P	573687-41-9P	573687-44-2P
	573687-45-3P	573687-46-4P	573687-47-5P
	573687-53-3P	573687-54-4P	573687-55-5P
	573687-57-7P	573687-59-9P	573687-64-6P
	573687-66-8P	573687-70-4P	573687-71-5P
	573687-72-6P	573687-74-8P	573687-77-1P
	573687-78-2P	573687-79-3P	573687-80-6P
	573687-81-7P	573687-82-8P	573687-83-9P
	573687-84-0P	573687-85-1P	573687-86-2P
	573687-87-3P	573687-88-4P	573687-89-5P
	573687-90-8P	573687-91-9P	573687-92-0P
	573687-93-1P	573687-94-2P	573687-95-3P
	573687-96-4P	573687-97-5P	573687-98-6P
	573687-99-7P	573688-00-3P	573688-01-4P
	573688-02-5P	573688-03-6P	573688-04-7P
	573688-05-8P	573688-06-9P	573688-07-0P
	573688-08-1P	573688-09-2P	573688-10-5P
	573688-11-6P	573688-12-7P	573688-13-8P
	573688-30-9P	573688-31-0P	573688-32-1P
	573688-35-4P	573688-36-5P	573688-37-6P
	573688-41-2P	573688-45-6P	573688-46-7P
	573688-47-8P	573688-51-4P	573688-54-7P


573688-55-8P 573688-56-9P 573688-57-0P
 573688-58-1P 573688-60-5P 573688-61-6P
 573688-62-7P 573688-63-8P 573688-64-9P
 573688-65-0P 573688-66-1P 573688-67-2P
 573688-68-3P 573688-69-4P 573688-70-7P
 573688-71-8P 573688-72-9P 573688-73-0P
 573688-74-1P 573688-75-2P 573688-76-3P
 573688-78-5P 573688-80-9P 573688-82-1P
 573688-85-4P 573688-86-5P 573688-87-6P
 573688-91-2P 573688-92-3P 573688-93-4P
 573688-95-6P 573688-96-7P 573688-97-8P
 573688-98-9P 573689-00-6P 573689-01-7P
 573689-02-8P 573689-03-9P 573689-04-0P
 573689-06-2P 573689-07-3P 573689-08-4P
 573689-09-5P 573689-10-8P 573689-11-9P
 573689-13-1P 573689-14-2P 573689-19-7P
 573689-20-0P 573689-26-6P 573689-27-7P
 573689-30-2P 573689-31-3P 573689-66-4P
 573689-67-5P 573689-72-2P 714221-27-9P
 714221-31-5P 714221-32-6P 714221-35-9P
 714221-37-1P 714221-46-2P 714221-47-3P
 714221-52-0P 714221-53-1P 714221-63-3P
 714221-64-4P 714221-65-5P 714221-69-9P
 714221-81-5P 714223-26-4P 714223-27-5P
 714223-28-6P 714223-29-7P 714223-30-0P
 714223-31-1P 714223-32-2P 714223-33-3P
 714223-34-4P 714223-35-5P 714223-36-6P
 714223-48-0P 714223-54-8P 714223-56-0P
 714223-57-1P 714223-58-2P 714223-59-3P
 714223-66-2P 714223-67-3P 714223-68-4P
 714223-69-5P 714223-70-8P 714223-71-9P
 714229-65-9P 714229-66-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(VR1 inhibitor; preparation of (quinazolin-4-yl)amines as VR1 inhibitors for
 treatment of pain and other VR1-mediated conditions)


RN 573686-34-7 CAPLUS

CN 2-Quinazolinemethanamine, N-ethyl-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-
 methyl-2-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 573686-35-8 CAPLUS


CN 2-Quinazolinemethanamine, N-methyl-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-
 methyl-2-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 573686-36-9 CAPLUS
 CN 2-Quinazolinemethanamine, N-ethyl-N-(1-methylethyl)-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-37-0 CAPLUS
 CN 2-Quinazolinemethanamine, N-methyl-N-(1-methylethyl)-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-38-1 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-39-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-40-5 CAPLUS

CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-41-6 CAPLUS

CN 4-Quinazolinamine, 2-(6-methoxy-3-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-42-7 CAPLUS


CN 4-Quinazolinamine, 2-[6-(1-pyrrolidinyl)-3-pyridinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-43-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(4-pyridinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573686-44-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[2,6-dimethyl-4-morpholinyl)methyl]-7-(3-pyridinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573686-53-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(phenylmethoxy)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-70-1 CAPLUS

CN 4-Quinazolinamine, N-(4-cyclopropylphenyl)-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-72-3 CAPLUS

CN 4-Quinazolinamine, 2-(2-methoxyethyl)-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-73-4 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-2-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-75-6 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-77-8 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-78-9 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)-2-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 573686-79-0 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(methylsulfonyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-83-6 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-84-7 CAPLUS


CN 4-Quinazolinamine, 2-[[(1R)-3-(diethylamino)-1-methylpropoxy]methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573686-85-8 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(diethylamino)propoxy]methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-86-9 CAPLUS


CN 4-Quinazolinamine, 2-[[3-(dimethylamino)propoxy]methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-87-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[3-(4-(dimethylamino)phenyl)propoxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-

morpholinyl)propoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573686-91-6 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-92-7 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(ethoxymethyl)- (9CI) (CA INDEX NAME)




RN 573686-95-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 573686-96-1 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-97-2 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-99-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 573687-00-0 CAPLUS

CN 4-Quinazolinamine, 2-[[[(1-methyl-4-piperidinyl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-01-1 CAPLUS

CN 4-Quinazolinamine, 2-[[2-(diethylamino)ethoxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-02-2 CAPLUS

CN 4-Quinazolinamine, 2-[[2-(dimethylamino)ethoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-03-3 CAPLUS


CN 4-Quinazolinamine, 2-[[2-(1-piperidinyl)ethoxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-04-4 CAPLUS


CN 4-Quinazolinamine, 2-[3-(phenylmethoxy)propyl]-7-[3-(trifluoromethyl)-2-

pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-05-5 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[3-(phenylmethoxy)propyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-06-6 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(diethylamino)propoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-07-7 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(dimethylamino)-2,2-dimethylpropoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-08-8 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(dimethylamino)propoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-09-9 CAPLUS

CN 4-Quinazolinamine, 2-[(3-pyridinylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-10-2 CAPLUS

CN 4-Quinazolinamine, 2-[(4-pyridinylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-11-3 CAPLUS


CN 4-Quinazolinamine, 2-[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-12-4 CAPLUS


CN 4-Quinazolinamine, 2-[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)

(CA INDEX NAME)




RN 573687-13-5 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-14-6 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-15-7 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-16-8 CAPLUS


CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573687-17-9 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(trifluoromethoxy)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-18-0 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 573687-19-1 CAPLUS


CN 4-Quinazolinamine, N-[4-(methanesulfonyl)phenyl]-2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-20-4 CAPLUS
 CN 4-Quinazolinamine, N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-
 [(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
 INDEX NAME)



RN 573687-21-5 CAPLUS
 CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-
 [(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
 INDEX NAME)




RN 573687-22-6 CAPLUS
 CN 1H-Indole, 2,3-dihydro-1-(methylsulfonyl)-5-[[2-[(phenylmethoxy)methyl]-7-
 [3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX
 NAME)




RN 573687-26-0 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-7-[(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 573687-27-1 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573687-28-2 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-32-8 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-33-9 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-34-0 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-((trifluoromethyl)sulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-35-1 CAPLUS


CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573687-36-2 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-38-4 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(1-methylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-39-5 CAPLUS


CN 2-Quinazolinemethanol, 7-(3-chloro-2-pyridinyl)-4-[[4-(1,1-dimethylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 573687-40-8 CAPLUS


CN 2-Quinazolinemethanol, 4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-

(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-41-9 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-44-2 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[[tetrahydro-2H-pyran-4-yl]oxy]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-45-3 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-2-[[[tetrahydro-2H-pyran-4-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 573687-46-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(ethoxymethyl)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-47-5 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(ethoxymethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-53-3 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-54-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-55-5 CAPLUS


CN 2-Quinazolinemethanol, 7-(3-chloro-2-pyridinyl)-4-[[4-(1-methylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 573687-57-7 CAPLUS


CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-2-[[[tetrahydro-2H-pyran-4-

yl)oxy)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-59-9 CAPLUS

CN 2-Quinazolinemethanol, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-64-6 CAPLUS

CN Benzeneacetonitrile, α,α -dimethyl-4-[[2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-66-8 CAPLUS

CN Benzeneacetonitrile, 4-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 573687-70-4 CAPLUS

CN 2-Quinazolinepropanol, 4-[[6-(1,1-dimethylethyl)-3-pyridinyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-71-5 CAPLUS

CN 2-Quinazolinepropanol, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-72-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 573687-74-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


CN1CCCCC1CC2=NC3=CC=C(C(=N3)C4=CC=C(C=C4)C(=O)N5C=CC(=CC=C5)C(F)(F)F)C6=CC=C(C=C6)C(F)(F)F

RN 573687-78-2 CAPLUS

Cc1ccc(NC2=NC=CC=C2C3=CC=CC=C3C(F)(F)F)N=C4C=CC(=C5C(=C4)N=CC=C5C(F)(F)F)C6=CC=CC=C6C(F)(F)F


RN 573687-79-3 CAPLUS

CN 4-Quinazolinamine, 2-[(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-80-6 CAPLUS

CN 4-Quinazolinamine, 2-[(2-ethyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-81-7 CAPLUS

CN 4-Quinazolinamine, 2-[(2-methyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-82-8 CAPLUS

CN 4-Quinazolinamine, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573687-83-9 CAPLUS


CN 4-Quinazolinamine, 2-[(4-methyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573687-84-0 CAPLUS


CN 4-Quinazolinamine, 2-[(octahydro-1(2H)-quinolinyl)methyl]-7-[3-

(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573687-85-1 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-2-propenyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-86-2 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclopropyl-N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-87-3 CAPLUS

CN 2-Quinazolinemethanamine, N-butyl-N-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-88-4 CAPLUS

CN 2-Quinazolinemethanamine, N-butyl-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-89-5 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclohexyl-N-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-90-8 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclohexyl-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-91-9 CAPLUS


CN 2-Quinazolinemethanamine, N-ethyl-N-(1-methylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573687-92-0 CAPLUS
 CN 2-Quinazolinemethanamine, N-hexyl-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-93-1 CAPLUS
 CN 2-Quinazolinemethanamine, N-(2,3-dihydro-1H-inden-1-yl)-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-94-2 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-methylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-(9CI) (CA INDEX NAME)




RN 573687-95-3 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(2-phenylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-(9CI) (CA INDEX NAME)




RN 573687-96-4 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-(9CI) (CA INDEX NAME)




RN 573687-97-5 CAPLUS

CN 2-Quinazolinemethanamine, N-[(2-fluorophenyl)methyl]-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-98-6 CAPLUS

CN 2-Quinazolinemethanamine, N-[(3-fluorophenyl)methyl]-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-99-7 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-00-3 CAPLUS

CN 2-Quinazolinemethanamine, N-ethyl-N-(2-methyl-2-propenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-01-4 CAPLUS


CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-02-5 CAPLUS
 CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylpropyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-03-6 CAPLUS
 CN 2-Quinazolinemethanamine, N-methyl-N-[(2-methylphenyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-04-7 CAPLUS
 CN 4-Quinazolinamine, 2-[(hexahydro-1H-azepin-1-yl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573688-05-8 CAPLUS
 CN 4-Quinazolinamine, 2-[(hexahydro-1(2H)-azocinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573688-06-9 CAPLUS
 CN 2-Quinazolinemethanamine, N,N-di-2-propenyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-07-0 CAPLUS
 CN 2-Quinazolinemethanamine, N,N-dibutyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573688-08-1 CAPLUS
 CN 2-Quinazolinemethanamine, N,N-diethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-09-2 CAPLUS
 CN 2-Quinazolinemethanamine, N,N-diethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-10-5 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dimethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-11-6 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dipentyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-12-7 CAPLUS

CN 4-Quinazolinamine, 2-(1-piperidinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-13-8 CAPLUS

CN 4-Quinazolinamine, 2-(1-pyrrolidinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-30-9 CAPLUS

CN Morpholine, 4-[[4-[[2-[[methyl(1-methylethyl)amino]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-31-0 CAPLUS

CN Morpholine, 4-[[4-[[2-[(methylpropylamino)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-32-1 CAPLUS

CN Morpholine, 4-[[4-[[2-[(dimethylamino)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-35-4 CAPLUS

CN Morpholine, 4-[[4-[[2-[(cyclopentyloxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-36-5 CAPLUS

CN Morpholine, 4-[[4-[[2-[(cyclopropylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-37-6 CAPLUS

CN Morpholine, 4-[[4-[[2-(ethoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-41-2 CAPLUS

CN Morpholine, 4-[[4-[[2-[(1-methylethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-45-6 CAPLUS

CN Morpholine, 4-[[4-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-46-7 CAPLUS

CN Morpholine, 4-[[4-[[2-[[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-47-8 CAPLUS

CN Piperidine, 1-[[4-[[2-(hydroxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573688-51-4 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-(hydroxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 573688-54-7 CAPLUS


CN Morpholine, 2,6-dimethyl-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]carbonyl]-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573688-55-8 CAPLUS


CN 4-Quinazolinamine, N-(4-cyclopropylphenyl)-2-[(2,2-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-56-9 CAPLUS

CN 4-Quinazolinamine, N-(4-cyclopropylphenyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-57-0 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylpropyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573688-58-1 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[(1,1-dioxido-2-isothiazolidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-60-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[2,6-dimethyl-4-morpholinyl)methyl]-7-(5-pyrimidinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-61-6 CAPLUS

CN 4-Quinazolinamine, 7-(2,4-dimethoxy-5-pyrimidinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[2,6-dimethyl-4-morpholinyl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-62-7 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-2-[[2-methyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-63-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R)-2-methyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-64-9 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R)-2-methyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-65-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-2-[[(2S)-2-methyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-66-1 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[2-(2-methyl-4-(trifluoromethyl)phenyl)-2-pyridinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-67-2 CAPLUS

CN 4-Quinazolinamine, 2-[(2S)-1-propyl-2-pyrrolidinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-68-3 CAPLUS

CN 4-Quinazolinamine, 2-[[(2S)-2-methyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-69-4 CAPLUS

CN 4-Quinazolinamine, 2-(2S)-2-pyrrolidinyl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-70-7 CAPLUS


CN 4-Quinazolinamine, 2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573688-71-8 CAPLUS

CN 4-Quinazolinamine, 2-[(tetrahydro-1,1-dioxo-2H-1,2'-thiazin-2-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573688-72-9 CAPLUS

CN 4-Quinazolinamine, 2-(1-ethyl-4-piperidinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-73-0 CAPLUS

CN Piperidine, 1-(methylsulfonyl)-4-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 573688-74-1 CAPLUS

CN 4-Quinazolinamine, 2-(1-propyl-4-piperidinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-75-2 CAPLUS

CN 4-Quinazolinamine, 2-[1-(4-pyridinylmethyl)-4-piperidinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-76-3 CAPLUS
 CN 4-Quinazolinamine, 2-[(2,2-dimethyl-4-morpholinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-78-5 CAPLUS
 CN 4-Quinazolinamine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(2-methoxyphenyl)-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-80-9 CAPLUS


CN 4-Quinazolinamine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573688-82-1 CAPLUS

CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573688-85-4 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(ethoxymethyl)-7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-86-5 CAPLUS

CN 4-Quinazolinamine, 2-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573688-87-6 CAPLUS

CN 4-Quinazolinamine, 2-[2-(2,6-dimethyl-4-morpholinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-91-2 CAPLUS

CN 2-Quinazolinemethanamine, N,N-diethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-92-3 CAPLUS

CN 2-Quinazolineethanamine, N,N-dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-93-4 CAPLUS

CN 2-Quinazolinemethanamine, 7-(3-methyl-2-pyridinyl)-N,N-dipropyl-4-[[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-95-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-ylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-96-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-piperidinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-97-8 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[(2,2-dimethyl-4-morpholinyl)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573688-98-9 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573689-00-6 CAPLUS
 CN 2-Pyrrolidinemethanol, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 573689-01-7 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-2-quinazolinyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573689-02-8 CAPLUS


CN 3-Pyrrolidinemethanol, 1-[[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-2-quinazolinyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573689-03-9 CAPLUS
 CN 3-Pyrrolidinol, 1-[[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-2-quinazolinyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573689-04-0 CAPLUS
 CN Ethanone, 1-[2-[2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-quinazolinyl]phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 573689-06-2 CAPLUS
 CN Piperidine, 1-acetyl-4-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 573689-07-3 CAPLUS
 CN Piperidine, 1-(1-oxopropyl)-4-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 573689-08-4 CAPLUS
 CN Ethanol, 2-[[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]propylamino]- (9CI) (CA INDEX NAME)




RN 573689-09-5 CAPLUS

CN 1-Propanol, 2-methyl-2-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 573689-10-8 CAPLUS

CN 2-Quinazolinecarboxamide, N,N-dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-11-9 CAPLUS


CN 2-Quinazolinecarboxamide, N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573689-13-1 CAPLUS
 CN 2-Quinazolinecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573689-14-2 CAPLUS
 CN 1,3-Propanediamine, N,N,N'-trimethyl-N'-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573689-19-7 CAPLUS

CN 4-Quinazolinamine, 2-[[4-(dimethylamino)butoxy)methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-20-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[4-(4-morpholinyl)butoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-26-6 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573689-27-7 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573689-30-2 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-31-3 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-66-4 CAPLUS

CN 2-Propanol; 1-(dimethylamino)-3-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]phenyl]quinazolin-6-yl]-2-pyridinecarboxylate (9CI) (CA INDEX NAME)




RN 573689-67-5 CAPLUS

CN 2-Quinazolineethanol, 4-[[4-(1,1-dimethylethyl)phenyl]amino]-β,β-dimethyl-7-[[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-72-2 CAPLUS

CN 2-Quinazolineethanol, β,β -dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 714221-27-9 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 714221-31-5 CAPLUS

CN 2-Quinazolinepropanoic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 714221-32-6 CAPLUS

CN 2-Quinazolinepropanoic acid, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 714221-35-9 CAPLUS

CN 2-Quinazolineacetic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 714221-37-1 CAPLUS

CN 2-Quinazolinemethanol, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 714221-46-2 CAPLUS

CN 2-Quinazolinecarboxylic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 714221-47-3 CAPLUS

CN 2-Quinazolinecarboxylic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 714221-52-0 CAPLUS

CN Acetic acid, [[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 714221-53-1 CAPLUS


CN Acetic acid, [[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 714221-63-3 CAPLUS

CN Butanoic acid, 2-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-3-methyl-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714221-64-4 CAPLUS

CN Propanoic acid, 2-[[[4-[(1,1-dimethylethyl)phenyl]amino]-7-[[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714221-65-5 CAPLUS

CN Butanoic acid, 2-[[[4-[(1,1-dimethylethyl)phenyl]amino]-7-[[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714221-69-9 CAPLUS


CN Butanoic acid, 2-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714221-81-5 CAPLUS

CN 4-Quinazolinamine, 2-[[[(1-methyl-4-piperidinyloxy)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 714223-26-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 714223-27-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 714223-28-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 714223-29-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 714223-30-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 714223-31-1 CAPLUS

CN 4-Piperidineethanol, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 714223-32-2 CAPLUS

CN 4-Piperidinemethanol, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 714223-33-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]-, propyl ester
(9CI) (CA INDEX NAME)




RN 714223-34-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]-, ethyl ester
(9CI) (CA INDEX NAME)




RN 714223-35-5 CAPLUS

CN 3-Piperidinemethanol, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 714223-36-6 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]-, ethyl ester
(9CI) (CA INDEX NAME)



RN 714223-48-0 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]-, phenylmethyl ester, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714223-54-8 CAPLUS

CN Morpholine, 4-[[4-[[2-[[ethyl(1-methylethyl)amino]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)




RN 714223-56-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 714223-57-1 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 714223-58-2 CAPLUS


CN L-Proline, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714223-59-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 714223-66-2 CAPLUS

CN L-Proline, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-


(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl)methyl]-4-hydroxy-, (4R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714223-67-3 CAPLUS

CN Piperidine, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 714223-68-4 CAPLUS

CN Piperazine, 1-cyclopentyl-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 714223-69-5 CAPLUS

CN 2-Quinazolinecarboxamide, N-(3-methylbutyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 714223-70-8 CAPLUS

CN 2-Quinazolinecarboxamide, N-(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 714223-71-9 CAPLUS
 CN 2-Quinazolinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 714229-65-9 CAPLUS
 CN L-Proline, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714229-66-0 CAPLUS
 CN D-Proline, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 573681-12-6P, 1-(Morpholin-4-yl)-3-[4-[(4-trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propan-1-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of (quinazolin-4-yl)amines as VR1 inhibitors for treatment of pain and other VR1-mediated conditions)
 RN 573681-12-6 CAPLUS
 CN Morpholine, 4-[1-oxo-3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




IT 573680-46-3, [2-(Chloromethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine hydrochloride
 573680-92-9, 2-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]ethanol hydrochloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (quinazolin-4-yl)amines as VR1 inhibitors for treatment of pain and other VR1-mediated conditions)
 RN 573680-46-3 CAPLUS
 CN 4-Quinazolinamine, 2-(chloromethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 573680-92-9 CAPLUS
 CN 2-Quinazolineethanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:531361 CAPLUS

DOCUMENT NUMBER: 141:76702

TITLE: Combination therapy comprising a heteroarylamine VR1 antagonist and a narcotic analgesic for the treatment of pain with reduced addictive side effects

INVENTOR(S): Herzberg, Uri; Cortright, Daniel; Hurtt, Mark M.; Krause, James E.

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054582	A1	20040701	WO 2003-US37209	20031119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2509616	A1	20040701	CA 2003-2509616	20031119
AU 2003300791	A1	20040709	AU 2003-300791	20031119
US 2004142958	A1	20040722	US 2003-718034	20031119
EP 1581225	A1	20051005	EP 2003-813341	20031119
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006511535	T	20060406	JP 2004-560329	20031119
PRIORITY APPLN. INFO.:			US 2002-433363P	P 20021213
			WO 2003-US37209	W 20031119

GI



I




II

AB The invention relates to compns. comprising a nontoxic vanilloid receptor 1 (VR1) antagonist, optionally in combination with an addictive therapeutic agent, for the treatment of pain. Compns. and methods are further provided for inhibiting the development of tolerance to addictive therapeutic agents (especially narcotic analgesics) in patients treated with such agents, for minimizing adverse effects (e.g., dependence) resulting


from treatment with such addictive agents, and for enhancing pain relief resulting from narcotic analgesic administration. Patients may be treated with a VR1 antagonist before, during, or after administration of the addictive therapeutic agent to prevent, decrease the severity of, delay, or treat tolerance and/or other adverse effects of the addictive agent in the patient. Examples include synthetic methods and limited data for the preparation of representation heteroarylamine VR1 antagonists, as well as capsaicin receptor binding assays and numerous pain model assays. For instance, coupling of 7-bromo-4-chloroquinazoline with 2-amino-5-trifluoromethylpyridine, followed by addition of 3-fluoro-2-tributylstannylpyridine provided I. In a bioassay testing the inhibition of tolerance to morphine, rats receiving morphine plus II exhibited statistically significantly higher withdrawal thresholds than any other treatment group, indicating that the VR1 antagonist prevents tolerance to repeated morphine dosing.

IT 573674-89-2P, (4-Trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine hydrochloride
 573675-62-4P, [7-(3-Fluoropyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573675-64-6P, (4-tert-Butylphenyl)[7-(pyridin-2-yl)quinazolin-4-yl]amine
 573675-71-5P, (4-tert-Butylphenyl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride 573675-95-3P, [7-(3-Methylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
 573676-11-6P, [6-(Propan-2-ylsulfonyl)pyridin-3-yl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride
 713141-14-1P, (4-tert-Butylphenyl)[2-methyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (VR1 antagonist; preparation of heteroarylamine VR1 antagonists for use in combination with narcotic analgesics for treatment of pain with reduced addictive side effects)
 RN 573674-89-2 CAPLUS
 CN 4-Quinazolinamine, 7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 573675-62-4 CAPLUS
 CN 4-Quinazolinamine, 7-(3-fluoro-2-pyridinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573675-64-6 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-(2-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 573675-71-5 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 573675-95-3 CAPLUS

CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 573676-11-6 CAPLUS


CN 4-Quinazolinamine, N-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 713141-14-1 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




IT 573676-26-3, (6-Trifluoromethylpyridin-3-yl) [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573678-65-6, [2-Methyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (5-trifluoromethylpyridin-2-yl)amine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(VR1 antagonist; preparation of heteroarylamine VR1 antagonists for use in combination with narcotic analgesics for treatment of pain with reduced addictive side effects)


RN 573676-26-3 CAPLUS

CN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-65-6 CAPLUS

CN 4-Quinazolinamine, 2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 573680-46-3P, [2-(Chloromethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine hydrochloride


573680-90-7P, [2-(2-Benzyloxyethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine hydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heteroarylamine VR1 antagonists for use in combination with narcotic analgesics for treatment of pain with reduced addictive side effects)

RN 573680-46-3 CAPLUS


CN 4-Quinazolinamine, 2-(chloromethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 573680-90-7 CAPLUS

CN 4-Quinazolinamine, 2-[2-(phenylmethoxy)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:841844 CAPLUS

DOCUMENT NUMBER: 140:77101

TITLE: The design and synthesis of novel orally active inhibitors of AP-1 and NF- κ B mediated transcriptional activation. SAR of In vitro and In vivo studies

AUTHOR(S): Palanki, Moorthy S. S.; Erdman, Paul E.; Ren, Minghuan; Suto, Mark; Bennett, Brydon L.; Manning, Anthony; Ransone, Lynn; Spooner, Cheryl; Desai, Sonal; Ow, Arnie; Totsuka, Ryuichi; Tsao, Peter; Toriumi, Wataru

CORPORATE SOURCE: Celgene, San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(22), 4077-4080

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:77101

AB We have developed novel orally active quinazoline analogs as inhibitors of AP-1 and NF- κ B mediated transcriptional activation. Among the derivs. prepared, 1-[2-(2-thienyl)quinazolin-4-ylamino]-3-methyl-3-pyrroline-2,5-dione showed significant activity in an adjuvant-induced arthritis rat model by reducing the swelling by 65% in the non-injected foot. The synthesis, structure-activity relationship, and in vivo activity are described.


IT 219774-04-6P 640297-61-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure-activity relationships of quinazoline analogs as orally active inhibitors of AP-1 and NF- κ B mediated transcriptional activation)


RN 219774-04-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[7-(1-piperidinyl)-2-(trifluoromethyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 640297-61-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[7-(4-morpholinyl)-2-(2-thienyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:591156 CAPLUS

DOCUMENT NUMBER: 139:149640

TITLE: Preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain

INVENTOR(S): Bakthavatchatam, Rajagopal; Blum, Charles A.; Brielmann, Harry L.; Caldwell, Timothy M.; De Lombaert, Stephane

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 294 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062209	A2	20030731	WO 2003-US1563	20030117
WO 2003062209	A3	20030904		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2473796	A1	20030731	CA 2003-2473796	20030117
BR 2003006982	A	20041026	BR 2003-6982	20030117
EP 1471910	A2	20041103	EP 2003-703887	20030117


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1627944	A	20050615	CN 2003-802452	20030117
HU 200500200	A2	20050728	HU 2005-200	20030117
JP 2005526714	T	20050908	JP 2003-562090	20030117
US 2004106616	A1	20040603	US 2003-347210	20030121
US 7074799	B2	20060711		
IN 2004DN01958	A	20050401	IN 2004-DN1958	20040708
ZA 2004005641	A	20050715	ZA 2004-5641	20040715
NO 2004003411	A	20040924	NO 2004-3411	20040816
US 2006173003	A1	20060803	US 2006-345926	20060201

PRIORITY APPLN. INFO.:

US 2002-349920P	P	20020117
US 2002-350527P	P	20020122
WO 2003-US1563	W	20030117
US 2003-347210	A3	20030121

OTHER SOURCE(S): MARPAT 139:149640
GI



AB Substituted quinazolin-4-ylamine analogs (shown as I; variables defined below; e.g. (4-trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine) are provided. Such compds. are ligands that may be used to modulate VR1 capsaicin receptor activity in vivo or in vitro (no data), and are particularly useful in the treatment of conditions associated with pathol. receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. For I; V, X, W, Y and Z are each independently N or CR1, with the proviso that at least one of V and X is N; U is N or CR2, with the proviso that if V and X are N, then U is CR2; R1 = H, halogen, hydroxy, amino, C1-C8 alkyl, haloC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkoxy and mono- and di(C1-C8alkyl)amino. R2 = (i) H, halogen, cyano, or -COOH; (ii) C1-C8alkanoyl, C2-C8alkanone, or C1-C8carbamate, each of which is (un)substituted with 1-9 substituents = Rb, or (iii) -Rc-M-A-Ry, wherein: Rc is C0-C3alkyl; M is a bond, N(Rz), O, S, SO2, (C:O)pN(Rz), N(Rz)(C:O)p, SO2N(Rz), or N(Rz)SO2, wherein p is 0 or 1; A is a bond or C1-C8alkyl, (un)substituted with 1-3 Rb. Ry and Rz, if present, are: (a) independently H, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C6-C10arylC1-C8alkyl, C2-C8alkyl ether, C1-C8alkoxy, a 4- to 10-membered carbocycle or heterocycle, or joined to R1 to form a 4- to 10-membered carbocycle or heterocycle, wherein each Ry and Rz = (un)substituted with 1-9 Rb; or (b) joined to form a 4- to 10-membered carbocycle or heterocycle that is (un)substituted with 1-9 Rb; Ar2 is a 5- to 7-membered aromatic heterocycle, (un)substituted with 1-3 LRa. Ar1 is a 5- to 10-membered aromatic carbocycle or heterocycle, (un)substituted with 1-3 LRa; L = bond, -O-, -C(O)-, -OC(O)-, -C(O)O-, -O-C(O)O-, -S(O)m-, -NRx-,


-C(O)NHRx-, -NHRxC(O)-, -NRxS(O)m-, -S(O)mNRx- and -N[S(O)mRx]S(O)m-;
 wherein m = 0, 1 and 2; and Rx = H and C1-C8alkyl; Ra = (i) H, halogen,
 cyano and nitro; and (ii) C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl,
 C2-C8alkyl ether, 3- to 10-membered heterocycles, mono- and
 di(C1-C8alkyl)amino and (3- to 10-membered heterocycle)C1-C6 alkyl, each
 of which is (un)substituted with 1-9 Rb. Rb = hydroxy, halogen, amino,
 aminocarbonyl, amido, cyano, nitro, C1-C8alkyl, C1-C8alkoxy,
 C1-C8alkylthio, C1-C8alkyl ether, hydroxyC1-C8alkyl, haloC1-C8alkyl, Ph,
 phenyl(C1-C8alkyl), mono and di(C1-C6 alkyl)amino, (SO2)C1-C8alkyl, 5- to
 7-membered heterocycle and (5- to 7-membered heterocycle)(C1-C8alkyl).
 Although the methods of preparation are not claimed, many example preps. and
 characterization data for >500 examples of I are included.

IT 573680-92-9P, 2-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-2-yl]ethanol monohydrochloride
 573681-12-6P, 1-(Morpholin-4-yl)-3-[4-[(4-
 trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-
 yl]propan-1-one 573686-53-0P, [2-[3-(Benzyloxy)propyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation);
 THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study);
 PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and receptor detector; preparation of substituted
 quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for
 relieving pain and for detecting receptors)

RN 573680-92-9 CAPLUS


CN 2-Quinazolineethanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-
 (trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 573681-12-6 CAPLUS

CN Morpholine, 4-[1-oxo-3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-
 (trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX
 NAME)

CC1=NC2=CC=CC=C2C(=N1)NC3=CC=C(C=C3)C(F)(F)F

IT 573674-89-2P, (4-Trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine monohydrochloride
573675-62-4P, [7-(3-Fluoropyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573675-64-6P,
(4-tert-Butylphenyl)[7-(pyridin-2-yl)quinazolin-4-yl]amine
573675-71-5P, (4-tert-Butylphenyl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride 573675-85-1P,
(4-tert-Butylphenyl)[2-methyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride 573675-95-3P, [7-(3-Methylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573676-11-6P,
[6-(Propan-2-ylsulfonfyl)pyridin-3-yl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride 573676-20-7P,
(5-Trifluoromethylpyridin-2-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-24-1P, [2-Methyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573676-26-3P, (6-Trifluoromethylpyridin-3-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-28-5P,
(5-Chloropyridin-2-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-32-1P, [7-(2-Trifluoromethylphenyl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573676-34-3P,
[7-(Pyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573676-36-5P, (5-tert-Butylisoxazol-3-yl)[7-(pyridin-2-yl)quinazolin-4-yl]amine 573676-46-7P, (4-tert-Butylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 573676-50-3P,

[7-(1-Oxo-3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573676-52-5P, [7-(1-Oxopyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573676-56-9P, (4-tert-Butylphenyl) [2-methyl-7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 573676-58-1P, [2-Methyl-7-(2-trifluoromethylphenyl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573676-60-5P, (4-tert-Butylphenyl) [2-isopropyl-7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 573676-63-8P, [4-(1,2,2,2-Tetrafluoro-1-trifluoromethylethyl)phenyl] [7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 573676-67-2P, [2-Ethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [1-(methanesulfonyl)-2,3-dihydro-1H-indol-5-yl]amine 573676-73-0P, N,N-Dimethyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573676-78-5P, [4-(Trifluoromethanesulfonyl)phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-82-1P, [4-[(Pyrrolidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-84-3P, [4-[(3-Dimethylaminopyrrolidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-86-5P, [4-[(Piperidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-88-7P, [4-[(Morpholin-4-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-92-3P, [4-[(2-Methylpiperidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-94-5P, [4-[(cis-2,6-Dimethylpiperidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-96-7P, [4-[(2-Methylpyrrolidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-98-9P, [4-[(2,5-Dimethylpyrrolidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-00-6P, [4-[(2,6-Dimethylmorpholin-4-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-02-8P, [4-[[[(2S)-2-Methoxymethylpyrrolidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-04-0P, [4-[[[(2R)-2-Methoxymethylpyrrolidin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-06-2P, N,N-Diisopropyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-08-4P, N-(2-Hydroxy-1,1-dimethylethyl)-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-10-8P, N-Cyclohexyl-N'-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]urea 573677-12-0P, N-Ethyl-N'-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]urea 573677-14-2P, [(2S)-1-[4-[[7-(3-Trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]pyrrolidin-2-yl]methanol 573677-16-4P, [(2R)-1-[4-[[7-(3-Trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]pyrrolidin-2-yl]methanol 573677-18-6P, (3R)-1-[4-[[7-(3-Trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]pyrrolidin-3-ol 573677-20-0P, N2-Isobutyl-N4-(4-trifluoromethylphenyl)-7-(3-trifluoromethylpyridin-2-yl)quinazoline-2,4-diamine 573677-27-7P, (6-Chloropyridin-3-yl) [7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 573677-29-9P, 1,1,1,3,3,3-Hexafluoro-2-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]propan-2-ol 573677-31-3P, (4-Trifluoromethoxyphenyl) [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-33-5P, N-Isopropyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-35-7P, [4-[(4-Methylpiperazin-1-yl)sulfonyl]phenyl] [7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-37-9P, (Pyrrolidin-1-yl) [4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]methanone 573677-39-1P, N,N-Bis(2-methoxyethyl)-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-41-5P, N-(3-Chloropropyl)-4-

[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-44-8P, [4-(Methanesulfonyl)phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-49-3P, 4-[4-[(Azetidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-52-8P, [4-(Propan-1-ylsulfonyl)phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-55-1P, (6-Isobutylpyridin-3-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-58-4P, N-tert-Butyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-60-8P, [4-[(4-Fluoropiperidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-62-0P, N-tert-Butyl-N-methyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-64-2P, 2-Methyl-2-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]propan-1-ol 573677-66-4P, [4-(2,2,2-Trifluoro-1-methylethyl)phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-68-6P, [2-Chloromethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl][4-(2,2,2-trifluoro-1-methylethyl)phenyl]amine 573677-70-0P, [2-Ethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl][4-(2,2,2-trifluoro-1-methylethyl)phenyl]amine 573677-72-2P, (4-Cyclohexylphenyl)[7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]amine 573677-74-4P, [4-(Trifluoromethyl)phenyl][2-isopropyl-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]amine 573677-76-6P, (4-tert-Butylphenyl)[2-(trifluoromethyl)-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]amine 573677-78-8P, [4-[1,2,2,2-Tetrafluoro-1-(trifluoromethyl)ethyl]phenyl][7-(2-chlorophenyl)quinazolin-4-yl]amine 573677-80-2P, [4-[1,2,2,2-Tetrafluoro-1-(trifluoromethyl)ethyl]phenyl][7-(2-fluorophenyl)quinazolin-4-yl]amine 573677-82-4P, [4-[1,2,2,2-Tetrafluoro-1-(trifluoromethyl)ethyl]phenyl][7-(2-methoxyphenyl)quinazolin-4-yl]amine 573677-84-6P, (5-tert-Butylisoxazol-3-yl)[7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]amine 573677-88-0P, (5-tert-Butyl-1,3,4-thiadiazol-2-yl)[7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]amine 573677-90-4P, [6-(Trifluoromethyl)pyridin-3-yl][2-[(6-trifluoromethylpyridin-3-yl)amino]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573677-92-6P, (6-Methylpyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573677-94-8P, [4-(Trifluoromethyl)phenyl][7-(pyridin-2-yl)quinazolin-4-yl]amine 573677-96-0P, (4-tert-Butylphenyl)[7-(3-fluoropyridin-2-yl)quinazolin-4-yl]amine 573677-98-2P, [4-(Trifluoromethyl)phenyl][7-(3-fluoropyridin-2-yl)quinazolin-4-yl]amine 573678-00-9P, (4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-02-1P, [4-(Trifluoromethyl)phenyl][7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-04-3P, [4-(Trifluoromethyl)phenyl][7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-06-5P, (4-Fluorophenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-08-7P, (4-Chlorophenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-10-1P, (4-Acetylphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-12-3P, (4-Cyanophenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-14-5P, [4-[1,2,2,2-Tetrafluoro-1-(trifluoromethyl)ethyl]phenyl][7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-16-7P, [4-(Trifluoromethyl)phenyl][2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-18-9P, [4-(Trifluoromethyl)phenyl][2-(2-hydroxyethoxy)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-20-3P, [4-(Trifluoromethyl)phenyl][2-[2-(dimethylamino)ethoxy]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-25-8P, [4-(Trifluoromethyl)phenyl][2-[3-(dimethylamino)propoxy]-7-[3-

(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-27-0P
, [4-(Trifluoromethyl)phenyl][2-methylamino-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-29-2P, [4-(Trifluoromethyl)phenyl][2-(dimethylamino)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-31-6P, (4-Isopropylphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-33-8P
, (6-Methoxypyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-35-0P, (4-Isopropyl-3-methylphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-37-2P
, [4-(Trifluoromethyl)phenyl][7-(3-methoxypyridin-2-yl)quinazolin-4-yl]amine 573678-39-4P, [4-(Trifluoromethyl)phenyl][7-(3-propoxypyridin-2-yl)quinazolin-4-yl]amine 573678-41-8P, (4-Isopropylphenyl)[7-(3-propoxypyridin-2-yl)quinazolin-4-yl]amine 573678-43-0P, [4-(Trifluoromethyl)phenyl][7-(2-chlorophenyl)quinazolin-4-yl]amine 573678-45-2P, [4-(Trifluoromethyl)phenyl][7-(2,4-dichlorophenyl)quinazolin-4-yl]amine 573678-47-4P, (4-tert-Butylphenyl)[7-(2-chlorophenyl)quinazolin-4-yl]amine 573678-49-6P, (4-tert-Butylphenyl)[7-(2,4-dichlorophenyl)quinazolin-4-yl]amine 573678-51-0P, [6-(Trifluoromethyl)pyridin-3-yl][7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-53-2P, [4-(Trifluoromethyl)phenyl][2-(morpholin-4-yl)-7-[2-(trifluoromethyl)phenyl]quinazolin-4-yl]amine 573678-55-4P, (3-Methoxyphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-57-6P, (6-tert-Butylpyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-59-8P, (6-tert-Butylpyridin-3-yl)[7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-61-2P, (6-tert-Butylpyridin-3-yl)[7-(3-propoxypyridin-2-yl)quinazolin-4-yl]amine 573678-63-4P, [4-(Isopropylsulfonyl)phenyl][7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-65-6P, [5-(Trifluoromethyl)pyridin-2-yl][2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-67-8P, (6-tert-Butylpyridin-3-yl)[2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-69-0P, [6-(Trifluoromethyl)pyridin-3-yl][2-(trifluoromethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-71-4P, [6-(Trifluoromethyl)pyridin-3-yl][2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-73-6P
, (6-tert-Butylpyridin-3-yl)[2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-75-8P, [5-(Trifluoromethyl)pyridin-2-yl][2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-77-0P, [6-(Trifluoromethyl)pyridin-3-yl][2-ethyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-79-2P, (6-tert-Butylpyridin-3-yl)[2-(trifluoromethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-81-6P, [4-(tert-Butylaminosulfonyl)phenyl][2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-83-8P, (6-Isopropylpyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-85-0P
, (6-Isopropylpyridin-3-yl)[2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-87-2P, (6-Isopropylpyridin-3-yl)[2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-89-4P, (6-tert-Butylpyridin-3-yl)[2-(2-hydroxyethoxy)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-91-8P
, [6-(Trifluoromethyl)pyridin-3-yl][2-chloro-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-94-1P, [6-(Trifluoromethyl)pyridin-3-yl][2-(3-methylbutylamino)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-96-3P
, [4-(Trifluoromethyl)phenyl][2-cyano-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-98-5P, [4-(Trifluoromethyl)phenyl][2-phenyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573679-00-2P, [5-(Trifluoromethyl)pyridin-2-yl][2-(chloromethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573679-02-4P

, [6-(Trifluoromethyl)pyridin-3-yl][7-(3-nitropyridin-2-yl)quinazolin-4-yl]amine 573679-04-6P, [4-(Trifluoromethyl)phenyl][2-[(methylsulfonyl)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573679-06-8P, [6-(Trifluoromethyl)pyridin-3-yl][2-[(methylsulfonyl)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573679-08-0P, [6-(Trifluoromethyl)pyridin-3-yl][2-methyl-7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573679-10-4P***, [4-[(Trifluoromethyl)sulfonyl]phenyl][7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine ***573679-12-6P, [4-(Trifluoromethyl)phenyl][2-(cyanomethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573679-14-8P, (4-tert-Butylphenyl)[7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine 573679-16-0P, [6-(Trifluoromethyl)pyridin-3-yl][7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine 573679-18-2P, (4-Isopropylphenyl)[7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine 573679-20-6P, (4-Ethylphenyl)[7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine 573680-38-3P, [2-Pyrrolidin-1-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573680-84-9P, [2-[2-(Pyrrolidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573680-97-4P, [2-[3-(Morpholin-4-yl)propyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine hydrochloride 573681-14-8P, (4-Trifluoromethylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 573681-31-9P, [2-[(cis-2,6-Dimethylmorpholin-4-yl)oxy]methyl]-7-(2-trifluoromethylphenyl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573681-43-3P, [1-[3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propyl]piperidin-4-yl]methanol 573681-50-2P, (4-tert-Butylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine 573681-53-5P, (4-tert-Butylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-(6-methylpyridin-2-yl)quinazolin-4-yl]amine 573681-55-7P, (4-tert-Butylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-pyridin-2-ylquinazolin-4-yl]amine 573681-58-0P, (4-tert-Butylphenyl)[2-(piperidin-1-ylmethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573681-61-5P, (4-tert-Butylphenyl)[2-(pyrrolidin-1-ylmethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573681-66-0P, (4-Trifluoromethylphenyl)[7-(3-trifluoromethylpyridin-2-yl)-2-[(3,3,5-trimethylazepan-1-yl)methyl]quinazolin-4-yl]amine 573681-69-3P, (4-Trifluoromethylphenyl)[7-(3-trifluoromethylpyridin-2-yl)-2-[2-(3,3,5-trimethylazepan-1-yl)ethyl]quinazolin-4-yl]amine 573681-74-0P, (4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)-2-[(R)-2-methylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573681-76-2P, [7-(3-Chloropyridin-2-yl)-2-[(R)-2-methylmorpholin-4-yl)methyl]quinazolin-4-yl](4-isopropylphenyl)amine 573681-79-5P, [7-(3-Chloropyridin-2-yl)-2-[(R)-2-methylmorpholin-4-yl)methyl]quinazolin-4-yl](4-trifluoromethylphenyl)amine 573681-82-0P, (4-Chlorophenyl)[2-[(R,R)-2,6-dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573681-84-2P, (4-Chlorophenyl)[7-(3-chloropyridin-2-yl)-2-[(R,R)-2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573681-87-5P, (4-Ethylphenyl)[7-(3-chloropyridin-2-yl)-2-[(R,R)-2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573681-89-7P, (4-Fluorophenyl)[7-(3-chloropyridin-2-yl)-2-[(R,R)-2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573681-91-1P, (R,R)-(4-Isopropylphenyl)[7-(3-chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573681-94-4P, (R,R)-(4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573681-96-6P, (R,R)-(6-tert-Butylpyridin-3-yl)[2-[(2,6-dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573681-98-8P, (R,R)-(6-tert-Butylpyridin-3-yl)[7-(3-chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-

yl]amine 573682-00-5P, (R,R)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573682-03-8P, (R,R)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573682-06-1P, (R,R)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573682-08-3P, (R,R)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-ethylphenyl)amine 573682-11-8P, (R,R)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl][4-(propan-2-ylsulfonyl)phenyl]amine 573682-17-4P, (R,R)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](4-trifluoromethylphenyl)amine 573682-20-9P, (R,R)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573682-23-2P, (R,R)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](6-isopropoxy-pyridin-3-yl)amine 573682-26-5P, (R,R)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl][4-(propan-2-ylsulfonyl)phenyl]amine 573682-29-8P, (R,R)-1-[4-[[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amino]phenyl]ethanone 573682-32-3P, (R,R)-4-[[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amino]benzonitrile 573682-35-6P, (4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)-2-[(S)-2-methylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573682-37-8P, [7-(3-Chloropyridin-2-yl)-2-[(S)-2-methylmorpholin-4-yl)methyl]quinazolin-4-yl][4-(propan-2-ylsulfonyl)phenyl]amine 573682-39-0P, [7-(3-Chloropyridin-2-yl)-2-[(S)-2-methylmorpholin-4-yl)methyl]quinazolin-4-yl](4-isopropylphenyl)amine 573682-41-4P, (4-Chlorophenyl)[2-[(S,S)-2,6-dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573682-44-7P, (S,S)-(4-Chlorophenyl)[7-(3-chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573682-47-0P, (S,S)-(4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573682-50-5P, (S,S)-(6-tert-Butylpyridin-3-yl)[2-[(2,6-dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573682-53-8P, (S,S)-(6-tert-Butylpyridin-3-yl)[7-(3-chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573682-56-1P, (S,S)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573682-59-4P, (S,S)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573682-61-8P, (S,S)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-ethylphenyl)amine 573682-64-1P, (S,S)-[2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl][4-(propan-2-ylsulfonyl)phenyl]amine 573682-69-6P, (S,S)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](4-trifluoromethylphenyl)amine 573682-71-0P, (S,S)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573682-73-2P, (S,S)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl][4-(propan-2-ylsulfonyl)phenyl]amine 573682-75-4P, (S,S)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](4-isopropylphenyl)amine 573682-77-6P, (S,S)-[7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](4-ethylphenyl)amine 573682-79-8P, [2-[(1,1-Dioxothiomorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573682-81-2P, [2-[(1,4-Dioxo-8-azaspiro[4.5]dec-8-


yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573682-83-4P, [2-[(1-Methyl-3,4-dihydro-1H-isoquinolin-2-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573682-87-8P, [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573682-89-0P, [2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573682-91-4P, [2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573682-93-6P, [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573682-95-8P, [2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (5-trifluoromethylpyridin-2-yl)amine 573682-97-0P, [2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-(2,2,2-trifluoro-1-methylethyl)phenyl]amine 573682-99-2P, [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573683-01-9P, [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (5-trifluoromethylpyridin-2-yl)amine 573683-06-4P, [2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-(trifluoromethanesulfonyl)phenyl]amine 573683-08-6P, [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-(trifluoromethanesulfonyl)phenyl]amine 573683-17-7P, [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-pyridin-2-ylquinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-18-8P, [2-[2-(2-Ethylpiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-20-2P, [2-[2-(2-Ethylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-22-4P, [2-[2-(2-Methylpiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-25-7P, [2-[2-(2-Methylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-26-8P, [2-[2-(3,3-Dimethylpiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-28-0P, [2-[(3,3-Dimethylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-30-4P, [2-[(3,3-Dimethylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573683-35-9P, [2-[(3,4-Dihydro-1H-isoquinolin-2-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-37-1P, [2-[2-(3,5-Dimethylpiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-39-3P, [2-[(3,5-Dimethylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-40-6P, [2-[(3,5-Dimethylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573683-46-2P, [2-[2-(3-Hydroxypiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573683-49-5P, [2-[2-(3-Methoxypiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine

RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate and receptor detector; preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain and for detecting receptors)

RN 573674-89-2 CAPLUS


CN 4-Quinazolinamine, 7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 573675-62-4 CAPLUS


CN 4-Quinazolinamine, 7-(3-fluoro-2-pyridinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573675-64-6 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 573675-71-5 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 573675-85-1 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




CN 4-Quinazolinamine, N-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 573676-20-7 CAPLUS


CN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573676-24-1 CAPLUS

CN 4-Quinazolinamine, 2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573676-26-3 CAPLUS

CN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573676-28-5 CAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-pyridinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573676-32-1 CAPLUS


CN 4-Quinazolinamine, 7-[2-(trifluoromethyl)phenyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573676-34-3 CAPLUS


CN 4-Quinazolinamine, 7-(2-pyridinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573676-36-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-7-(2-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573676-46-7 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-50-3 CAPLUS

CN 4-Quinazolinamine, 7-[1-oxido-3-(trifluoromethyl)-2-pyridinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-52-5 CAPLUS

CN 4-Quinazolinamine, 7-(1-oxido-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-56-9 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-methyl-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-58-1 CAPLUS

CN 4-Quinazolinamine, 2-methyl-7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-60-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(1-methylethyl)-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-63-8 CAPLUS


CN 4-Quinazolinamine, N-[4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573676-67-2 CAPLUS
 CN 1H-Indole, 5-[[2-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]-2,3-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 573676-73-0 CAPLUS
 CN Benzenesulfonamide, N,N-dimethyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573676-78-5 CAPLUS

CN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 573676-82-1 CAPLUS

CN Pyrrolidine, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-84-3 CAPLUS

CN 3-Pyrrolidinamine, N,N-dimethyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-86-5 CAPLUS

CN Piperidine, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-88-7 CAPLUS

CN Morpholine, 4-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573676-92-3 CAPLUS


CN Piperidine, 2-methyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573676-94-5 CAPLUS


CN Piperidine, 2,6-dimethyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573676-96-7 CAPLUS

CN Pyrrolidine, 2-methyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-98-9 CAPLUS

CN Pyrrolidine, 2,5-dimethyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573677-00-6 CAPLUS


CN Morpholine, 2,6-dimethyl-4-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573677-02-8 CAPLUS

CN Pyrrolidine, 2-(methoxymethyl)-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573677-04-0 CAPLUS


CN Pyrrolidine, 2-(methoxymethyl)-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573677-06-2 CAPLUS

CN Benzenesulfonamide, N,N-bis(1-methylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-08-4 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxy-1,1-dimethylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-10-8 CAPLUS
 CN Benzenesulfonamide, N-[(cyclohexylamino)carbonyl]-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 573677-12-0 CAPLUS


CN Benzenesulfonamide, N-[(ethylamino)carbonyl]-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 573677-14-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573677-16-4 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573677-18-6 CAPLUS


CN 3-Pyrrolidinol, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573677-20-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(2-methylpropyl)-N4-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-27-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-3-pyridinyl)-7-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 573677-29-9 CAPLUS

CN Benzenemethanol, α,α -bis(trifluoromethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-31-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(trifluoromethoxy)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-33-5 CAPLUS

CN Benzenesulfonamide, N-(1-methylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-35-7 CAPLUS

CN Piperazine, 1-methyl-4-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573677-37-9 CAPLUS

CN Pyrrolidine, 1-[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 573677-39-1 CAPLUS

CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-41-5 CAPLUS

CN Benzenesulfonamide, N-(3-chloropropyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-44-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(methanesulfonyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-49-3 CAPLUS

CN Azetidine, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573677-52-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(propylsulfonyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-55-1 CAPLUS

CN 4-Quinazolinamine, N-[6-(2-methylpropyl)-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-58-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-60-8 CAPLUS

CN Piperidine, 4-fluoro-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573677-62-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-N-methyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-64-2 CAPLUS

CN Benzeneethanol, β,β-dimethyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-66-4 CAPLUS

CN 4-Quinazolinamine, N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-68-6 CAPLUS

CN 4-Quinazolinamine, 2-(chloromethyl)-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-70-0 CAPLUS

CN 4-Quinazolinamine, 2-ethyl-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-72-2 CAPLUS

CN 4-Quinazolinamine, N-(4-cyclohexylphenyl)-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573677-74-4 CAPLUS

CN 4-Quinazolinamine, 2-(1-methylethyl)-7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573677-76-6 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(trifluoromethyl)-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573677-78-8 CAPLUS


CN 4-Quinazolinamine, 7-(2-chlorophenyl)-N-[4-[1,2,2,2-tetrafluoro-1-

(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 573677-80-2 CAPLUS

CN 4-Quinazolinamine, 7-(2-fluorophenyl)-N-[4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 573677-82-4 CAPLUS

CN 4-Quinazolinamine, 7-(2-methoxyphenyl)-N-[4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 573677-84-6 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573677-88-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573677-90-4 CAPLUS

CN 2,4-Quinazolinediamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N,N'-bis[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-92-6 CAPLUS

CN 4-Quinazolinamine, N-(6-methyl-3-pyridinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-94-8 CAPLUS

CN 4-Quinazolinamine, 7-(2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573677-96-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-(3-fluoro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573677-98-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-fluoro-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573678-00-9 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573678-02-1 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 573678-04-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-
(CA INDEX NAME)




RN 573678-06-5 CAPLUS

CN 4-Quinazolinamine, N-(4-fluorophenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-
(9CI) (CA INDEX NAME)




RN 573678-08-7 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-
(9CI) (CA INDEX NAME)




RN 573678-10-1 CAPLUS

CN Ethanone, 1-[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 573678-12-3 CAPLUS

CN Benzonitrile, 4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573678-14-5 CAPLUS

CN 4-Quinazolinamine, N-[4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573678-16-7 CAPLUS

CN 4-Quinazolinamine, 2-methyl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-18-9 CAPLUS

CN Ethanol, 2-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 573678-20-3 CAPLUS

CN 4-Quinazolinamine, 2-[2-(dimethylamino)ethoxy]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-25-8 CAPLUS


CN 4-Quinazolinamine, 2-[3-(dimethylamino)propoxy]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-27-0 CAPLUS


CN 2,4-Quinazolinediamine, N2-methyl-N4-[4-(trifluoromethyl)phenyl]-7-[3-

(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-29-2 CAPLUS

CN 2,4-Quinazolinediamine, N2,N2-dimethyl-N4-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-31-6 CAPLUS


CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-33-8 CAPLUS


CN 4-Quinazolinamine, N-(6-methoxy-3-pyridinyl)-7-[3-(trifluoromethyl)-2-

pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-35-0 CAPLUS

CN 4-Quinazolinamine, N-[3-methyl-4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-37-2 CAPLUS


CN 4-Quinazolinamine, 7-(3-methoxy-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573678-39-4 CAPLUS


CN 4-Quinazolinamine, 7-(3-propoxy-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-

(9CI) (CA INDEX NAME)




RN 573678-41-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-propoxy-2-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 573678-43-0 CAPLUS


CN 4-Quinazolinamine, 7-(2-chlorophenyl)-N-[4-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



RN 573678-45-2 CAPLUS


CN 4-Quinazolinamine, 7-(2,4-dichlorophenyl)-N-[4-(trifluoromethyl)phenyl]-

(9CI) (CA INDEX NAME)




RN 573678-47-4 CAPLUS

CN 4-Quinazolinamine, 7-(2-chlorophenyl)-N-[4-(1,1-dimethylethyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 573678-49-6 CAPLUS


CN 4-Quinazolinamine, 7-(2,4-dichlorophenyl)-N-[4-(1,1-dimethylethyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 573678-51-0 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(trifluoromethyl)-3-

pyridinyl]- (9CI) . (CA INDEX NAME)




RN 573678-53-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinyl)-7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573678-55-4 CAPLUS

CN 4-Quinazolinamine, N-(3-methoxyphenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-57-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-59-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-61-2 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-7-(3-propoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573678-63-4 CAPLUS

CN 4-Quinazolinamine, N-[4-[(1-methylethyl)sulfonyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-65-6 CAPLUS


CN 4-Quinazolinamine, 2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573678-67-8 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-69-0 CAPLUS

CN 4-Quinazolinamine, 2-(trifluoromethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-
N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-71-4 CAPLUS

CN 4-Quinazolinamine, 2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-73-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-75-8 CAPLUS


CN 4-Quinazolinamine, 2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573678-77-0 CAPLUS

CN 4-Quinazolinamine, 2-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-79-2 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(trifluoromethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-81-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-methyl-7-[(3-(trifluoromethyl)-2-pyridinyl)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573678-83-8 CAPLUS

CN 4-Quinazolinamine, N-[6-(1-methylethyl)-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-85-0 CAPLUS

CN 4-Quinazolinamine, N-[6-(1-methylethyl)-3-pyridinyl]-2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-87-2 CAPLUS

CN 4-Quinazolinamine, 2-methyl-N-[6-(1-methylethyl)-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-89-4 CAPLUS

CN Ethanol, 2-[[4-[[6-(1,1-dimethylethyl)-3-pyridinyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 573678-91-8 CAPLUS

CN 4-Quinazolinamine, 2-chloro-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-94-1 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-methylbutyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N4-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-96-3 CAPLUS

CN 2-Quinazolinecarbonitrile, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-98-5 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573679-00-2 CAPLUS


CN 4-Quinazolinamine, 2-(chloromethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573679-02-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-nitro-2-pyridinyl)-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573679-04-6 CAPLUS

CN 4-Quinazolinamine, 2-[(methylsulfonyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573679-06-8 CAPLUS

CN 4-Quinazolinamine, 2-[(methylsulfonyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573679-08-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-methyl-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573679-10-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-
[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 573679-12-6 CAPLUS


CN 2-Quinazolineacetonitrile, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-
(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573679-14-8 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-(3-methyl-2-

pyridinyl)- (9CI) (CA INDEX NAME)




RN 573679-16-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573679-18-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 573679-20-6 CAPLUS


CN 4-Quinazolinamine, N-(4-ethylphenyl)-7-(3-methyl-2-pyridinyl)- (9CI) (CA

INDEX NAME)




RN 573680-38-3 CAPLUS

CN 4-Quinazolinamine, 2-(1-pyrrolidinymethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573680-84-9 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1-pyrrolidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573680-97-4 CAPLUS

CN 4-Quinazolinamine, 2-[3-(4-morpholinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 573681-14-8 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573681-31-9 CAPLUS


CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]oxy]methyl]-7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573681-43-3 CAPLUS


CN 4-Piperidinemethanol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 573681-50-2 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(3-methyl-2-pyridinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573681-53-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(6-methyl-2-pyridinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573681-55-7 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(2-pyridinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573681-58-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(1-piperidinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573681-61-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[(1-(3-(trifluoromethyl)-2-pyridinyl)methyl)pyrrolidinylmethyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573681-66-0 CAPLUS


CN 4-Quinazolinamine, 2-[(hexahydro-3,3,5-trimethyl-1H-azepin-1-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573681-69-3 CAPLUS

CN 4-Quinazolinamine, 2-[2-(hexahydro-3,3,5-trimethyl-1H-azepin-1-yl)ethyl]-N-


[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573681-74-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R)-2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-76-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-2-[[(2R)-2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-79-5 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[1-(2R)-2-methyl-4-(4-(trifluoromethyl)phenyl)morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-82-0 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-2-[[1-(2R,6R)-2,6-dimethyl-4-(3-(trifluoromethyl)-2-pyridinyl)morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-84-2 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-87-5 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-ethylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-89-7 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-91-1 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-94-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573681-96-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 573681-98-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-00-5 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-03-8 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R, 6R)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 573682-06-1 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R, 6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-08-3 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-ethylphenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-11-8 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-17-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-20-9 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[1(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-23-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[1(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(1-methylethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-26-5 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-29-8 CAPLUS

CN Ethanone, 1-[4-[[7-(3-chloro-2-pyridinyl)-2-[[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-32-3 CAPLUS

CN Benzonitrile, 4-[[7-(3-chloro-2-pyridinyl)-2-[[[(2R,6R)-2,6-dimethyl-4-morpholinyl]methyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-35-6 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-((1S,2S)-2-methylethyl)phenyl]-2-[[[(2S)-2-methyl-4-morpholinyl)methyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-37-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-((1S,2S)-2-methylethyl)sulfonyl]phenyl]-2-[[[(2S)-2-methyl-4-morpholinyl)methyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-39-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-2-
[[(2S)-2-methyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-41-4 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-44-7 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-47-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-50-5 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-53-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-56-1 CAPLUS

CN 4-Quinazolinamine, 2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-59-4 CAPLUS

CN 4-Quinazolinamine, 2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-61-8 CAPLUS

CN 4-Quinazolinamine, 2-[[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-ethylphenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-64-1 CAPLUS

CN 4-Quinazolinamine, 2-[[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-69-6 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-71-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-73-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(1-methylethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-75-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573682-77-6 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-(4-ethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573682-79-8 CAPLUS

CN 4-Quinazolinamine, 2-[(1,1-dioxido-4-thiomorpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573682-81-2 CAPLUS

CN 4-Quinazolinamine, 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573682-83-4 CAPLUS


CN 4-Quinazolinamine, 2-[(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573682-87-8 CAPLUS


CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(3-(trifluoromethyl)phenyl)-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573682-89-0 CAPLUS

CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573682-91-4 CAPLUS


CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573682-93-6 CAPLUS


CN 4-Quinazolinamine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573682-95-8 CAPLUS


CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573682-97-0 CAPLUS


CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573682-99-2 CAPLUS

CN 4-Quinazolinamine, 2-[(2R,6S)-2,6-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573683-01-9 CAPLUS

CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 573683-06-4 CAPLUS


CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 573683-08-6 CAPLUS

CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573683-17-7 CAPLUS


CN 4-Quinazolinamine, 2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573683-18-8 CAPLUS

CN 4-Quinazolinamine, 2-[2-(2-ethyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[(2-ethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[2-(2-methyl-1-piperidinyl)ethyl]-N-[4-

(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-25-7 CAPLUS

CN 4-Quinazolinamine, 2-[(2-methyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-26-8 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,3-dimethyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-28-0 CAPLUS

CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-30-4 CAPLUS

CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-35-9 CAPLUS

CN 4-Quinazolinamine, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-37-1 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,5-dimethyl-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[(3,5-dimethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-40-6 CAPLUS

CN 4-Quinazolinamine, 2-[(3,5-dimethyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-46-2 CAPLUS

CN 3-Piperidinol, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 573683-49-5 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3-methoxy-1-piperidiny)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 573683-51-9P, [2-[2-(3-Methylpiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-52-0P, [2-[(3-Methylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl) amine
 573683-54-2P, [2-[(3-Methylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-59-7P, [2-[3-(Pyrrolidin-1-yl)propyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-61-1P, [2-[(4-Cyclopentylpiperazin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-63-3P, [2-[2-(4-Ethoxypiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-65-5P, [2-[(4-Ethylpiperazin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-68-8P, [2-[2-(4-Hydroxypiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-70-2P, [2-[(4-Isopropylpiperazin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-72-4P, [2-[2-(4-Methoxypiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-74-6P, [2-[(4-Methyl-[1,4]diazepan-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573683-76-8P, [2-[(4-Methylpiperazin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (5-trifluoromethylpyridin-2-

yl)amine 573683-78-0P, [2-[(4-Methylpiperazin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl][4-(2,2,2-trifluoro-1-methylethyl)phenyl]amine 573683-80-4P, [2-[(4-Methylpiperazin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-82-6P, [2-[2-(4-Methylpiperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-84-8P, [2-[(4-Methylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-86-0P, [2-[(5,6-Dihydro-4H-pyrimidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-87-1P, [2-(5H-Tetrazol-5-yl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-89-3P, [2-(Benzylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573683-91-7P, [2-(Benzylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573683-93-9P, [2-(Isobutylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-94-0P, [2-(Isopropylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-96-2P, [2-[2-(Octahydroquinolin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-97-3P, [2-[(Octahydroquinolin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573683-99-5P, [2-(tert-Butylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-02-3P, [2-[[2-(Methoxybenzyl)amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573684-05-6P, [2-[[2-(Methoxyethyl)amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-07-8P, [2-[[3-(Methylbutyl)amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-10-3P, [2-[[4-(Methoxybenzyl)amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573684-12-5P, [2-[2-(Allylmethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-14-7P, [2-[(Allylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-19-2P, [2-[(Benzylcyclopropylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-21-6P, [2-[(Benzylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573684-24-9P, [2-[(Benzylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-26-1P, [2-[2-(Butylethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-29-4P, [2-[(Butylethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-31-8P, [2-[2-(Butylmethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-33-0P, [2-[(Butylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-34-1P, [2-[2-(Cyclohexylethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-36-3P, [2-[(Cyclohexylethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-38-5P, [2-[2-(Cyclohexylmethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-42-1P, [2-[(Cyclohexylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-45-4P, [2-[2-[(Cyclopropylmethyl)(propyl)amino]ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-47-6P, [2-[[2-[(Cyclopropylmethyl)(propyl)amino]methyl]-7-(3-

trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-49-8P, [2-[(Cyclopropylmethyl)(propyl)amino]methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-
yl)amine 573684-53-4P, [2-[(Ethylisopropylamino)methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-55-6P, [2-[2-(Hexylmethylamino)ethyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-57-8P, [2-[(Hexylmethylamino)methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-59-0P, [2-[(Indan-1-ylmethylamino)methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-61-4P, [2-[2-(Isopropylethylamino)ethyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-63-6P, [2-[2-(Isopropylmethylamino)ethyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-65-8P, [2-[(Isopropylmethylamino)methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-67-0P, [2-[(Methylpropylamino)methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-69-2P, [2-[2-(Propylmethylamino)ethyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573684-71-6P, [2-[(Tetrahydrothiopyran-4-yl)amino]methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-
yl)amine 573684-73-8P, [2-[2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-
yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-
trifluoromethylphenyl)amine 573684-75-0P, [2-[2-(1-Methyl-3,4-
dihydro-1H-isoquinolin-2-yl)ethyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-77-2P,
[2-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-7-(3-trifluoromethylpyridin-
2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-79-4P
, [2-[2-(4-Methylpiperazin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-82-9P,
[2-[2-(Benzylcyclopropylamino)ethyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-86-3P,
[2-[2-(Benzylmethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-89-6P,
[2-[2-(Indan-1-ylmethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-92-1P,
[2-[2-(Methylphenethylamino)ethyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573684-95-4P,
[2-[3-(2,6-Dimethylmorpholin-4-yl)propyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine
573684-98-7P, [2-[3-(2,6-Dimethylmorpholin-4-yl)propyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573685-01-5P, [2-[3-(cis-2,6-Dimethylmorpholin-4-yl)propyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573685-04-8P, [2-[3-(3-Methylpiperidin-1-yl)propyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573685-07-1P, [2-[3-(4-Methylpiperazin-1-yl)propyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573685-10-6P, [2-[[4-(2-Diethylaminoethyl)piperazin-1-yl]methyl]-7-
(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-
trifluoromethylphenyl)amine 573685-12-8P,
[2-[[4-(2-Dimethylaminoethyl)piperazin-1-yl]methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573685-14-0P, [2-[[4-(2-Methoxyethyl)piperazin-1-yl]methyl]-7-(3-
trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
573685-16-2P, [2-[[4-[2-(Morpholin-4-yl)ethyl]piperazin-1-
yl]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-
trifluoromethylphenyl)amine 573685-18-4P, [2-[[4-[2-(Pyrrolidin-
1-yl)ethyl]piperazin-1-yl]methyl]-7-(3-trifluoromethylpyridin-2-
yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-20-8P,
[2-[[4-(3-Dimethylaminopropyl)piperazin-1-yl]methyl]-7-(3-

trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-22-0P, [2-[[(2-Fluorobenzyl) (methyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-24-2P, [2-[[(3-Fluorobenzyl) (methyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-26-4P, [2-[[(Pyridin-2-yl) methyl] amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl) amine 573685-28-6P, [2-[[Bis (2-methoxyethyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (5-trifluoromethylpyridin-2-yl) amine 573685-30-0P, [2-[[Bis (2-methoxyethyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-(2,2,2-trifluoro-1-methoxyethyl) phenyl] amine 573685-32-2P, [2-[[Bis (2-methoxyethyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-36-6P, [2-[[(Ethyl) (2-methylallyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-40-2P, [2-[[(Methyl) (1-phenylethyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-42-4P, [2-[[(Methyl) (1-phenylpropyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-44-6P, [2-[[(Methyl) (2-methylbenzyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-46-8P, [2-[[(Methyl) (2-phenylethyl) amino] methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-48-0P, [2-[2-[[(2-Fluorobenzyl) (methyl) amino] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-49-1P, [2-[2-[[(3-Fluorobenzyl) (methyl) amino] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-50-4P, [2-[2-[[Bis (2-methoxyethyl) amino] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-51-5P, [2-[2-[[Ethyl (2-methylallyl) amino] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-52-6P, [2-[2-[[Methyl (1-phenylethyl) amino] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-53-7P, [2-[2-[[Methyl (1-phenylpropyl) amino] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-55-9P, [2-[2-[[Methyl (2-methylbenzyl) amino] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-56-0P, [2-[2-[[Azepan-1-yl] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-58-2P, [2-[[Azepan-1-ylmethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-59-3P, [2-[2-[[Azocan-1-yl] ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-60-6P, [2-[[Azocan-1-ylmethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-61-7P, [2-Cyclohexylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-62-8P, [2-(2-Diallylaminoethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-64-0P, [2-(Diallylaminoethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-65-1P, [2-(2-Dibutylaminoethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-67-3P, [2-(Dibutylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-68-4P, [2-(2-Diethylaminoethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-69-5P, [2-Diethylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-70-8P, [2-(2-Dihexylaminoethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573685-71-9P, [2-Dimethylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-

trifluoromethylphenyl)amine 573685-72-0P, [2-(2-Dipentylaminoethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-73-1P, [2-(Dipentylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-74-2P, [2-(2-Dipropylaminoethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-76-4P, [2-(Dipropylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573685-77-5P, [2-(Dipropylaminomethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-78-6P, [2-Ethylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-79-7P, [2-Hexylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-80-0P, [2-Imidazol-1-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573685-81-1P, [2-Methylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-82-2P, [2-(2-Morpholin-4-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-85-5P, [2-Morpholin-4-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573685-86-6P, [2-Morpholin-4-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(2,2,2-trifluoro-1-methylethyl)phenyl)amine 573685-87-7P, [2-Morpholin-4-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573685-88-8P, [2-Morpholin-4-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(trifluoromethanesulfonyl)phenyl)amine 573685-89-9P, [2-Morpholin-4-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-91-3P, [2-Octylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-92-4P, [2-[2-(Piperidin-1-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-93-5P, [2-Piperidin-1-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(2,2,2-trifluoro-1-methylethyl)phenyl)amine 573685-94-6P, [2-Piperidin-1-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-95-7P, [2-[2-(Thiomorpholin-4-yl)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-97-9P, [2-Thiomorpholin-4-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573685-98-0P, [2-Thiomorpholin-4-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573685-99-1P, [7-(3-Chloropyridin-2-yl)-2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-00-7P, [7-(3-Chloropyridin-2-yl)-2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573686-01-8P, [7-(3-Chloropyridin-2-yl)-2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]quinazolin-4-yl](4-(trifluoromethanesulfonyl)phenyl)amine 573686-05-2P, [7-(3-Chloropyridin-2-yl)-2-[(3,5-dimethylpiperazin-1-yl)methyl]quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-06-3P, [1-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperidin-4-yl]methanol 573686-07-4P, [1-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperidin-2-yl]methanol 573686-08-5P, [1-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperidin-3-yl]methanol 573686-09-6P, [1-[[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperidin-4-yl]methanol 573686-10-9P, [1-[[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperidin-3-

yl]methanol 573686-11-0P, 1-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperidin-4-ol
 573686-12-1P, 1-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperidin-3-ol
 573686-13-2P, 1-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperidine-4-carboxylic acid amide 573686-14-3P, 1-[[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperidin-4-ol 573686-15-4P
 1-[[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperidin-3-ol 573686-16-5P, 1-[[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperidine-4-carboxylic acid amide 573686-17-6P, 1-[2-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]ethyl]piperidine-4-carboxylic acid amide 573686-18-7P, 1-[3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propyl]piperidin-4-ol 573686-19-8P, 1-[3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propyl]piperidin-3-ol 573686-20-1P, 1-[4-[[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperazin-1-yl]ethanone 573686-21-2P, 1-(Pyrrolidin-1-yl)-3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propan-1-one 573686-22-3P, 2-[1-[3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propyl]piperidin-4-yl]ethanol 573686-23-4P, 2-[[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]amino]ethanol 573686-24-5P, 2-[1-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperidin-4-yl]ethanol 573686-25-6P, 2-[1-[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperidin-4-yl]ethanol 573686-26-7P, 2-[4-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]piperazin-1-yl]ethanol 573686-27-8P, 2-[4-[[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]methyl]piperazin-1-yl]ethanol 573686-28-9P, 4-[2-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]ethyl]piperazine-1-carboxaldehyde 573686-29-0P, N-[[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]methanesulfonamide 573686-30-3P, [2-Dimethylaminomethyl-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573686-31-4P, (4-Isopropylphenyl)[7-(3-methylpyridin-2-yl)-2-morpholin-4-ylmethylquinazolin-4-yl]amine 573686-32-5P, (4-Isopropylphenyl)[7-(3-methylpyridin-2-yl)-2-thiomorpholin-4-ylmethylquinazolin-4-yl]amine 573686-33-6P, [2-[(3,3-Dimethylpiperidin-1-yl)methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573686-34-7P, [2-[(Ethylpropylamino)methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573686-35-8P, (4-Isopropylphenyl)[2-[(methylpropylamino)methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine 573686-36-9P, [2-[(Ethylisopropylamino)methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573686-37-0P, [2-[(Isopropylmethylamino)methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573686-38-1P, [2-[[Bis(2-methoxyethyl)amino]methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573686-39-2P, [2-Pyridin-4-yl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-40-5P, [2-Pyridin-3-yl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-41-6P, [2-(6-Methoxypyridin-3-yl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-42-7P,


[2-[6-(Pyrrolidin-1-yl)pyridin-3-yl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-43-8P,
 (4-tert-Butylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-pyridin-4-yl]quinazolin-4-yl]amine 573686-44-9P, (4-tert-Butylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-pyridin-3-yl]quinazolin-4-yl]amine 573686-45-0P, [2-Isopropoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-46-1P, [2-(2-Methoxyethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-49-4P,
 3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propan-1-ol 573686-66-5P,
 [2-Methoxymethyl-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-68-7P, [1-(Methanesulfonyl)-2,3-dihydro-1H-indol-5-yl][2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-70-1P, (4-Cyclopropylphenyl)[2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-72-3P, (4-Isopropylphenyl)[2-(2-methoxyethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-73-4P,
 (4-Isopropylphenyl)[2-[(tetrahydropyran-4-yl)oxy]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-75-6P,
 (4-Isopropylphenyl)[2-methoxymethyl-7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine 573686-77-8P, (4-Isopropylphenyl)[2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-78-9P,
 (4-Isopropylphenyl)[7-(3-methylpyridin-2-yl)-2-[(tetrahydropyran-4-yl)oxy]methyl]quinazolin-4-yl]amine 573686-79-0P,
 [4-(Methanesulfonyl)phenyl][2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-83-6P, (4-tert-Butylphenyl)[2-(2-methoxyethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-84-7P, (4-tert-Butylphenyl)[2-[(R)-3-diethylamino-1-methylpropoxy]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-85-8P, (4-tert-Butylphenyl)[2-(3-diethylaminopropoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-86-9P, (4-tert-Butylphenyl)[2-[(3-dimethylaminopropoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-87-0P, (4-tert-Butylphenyl)[2-[[3-(morpholin-4-yl)propoxy]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-91-6P, (4-tert-Butylphenyl)[2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-92-7P,
 (4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)-2-ethoxymethyl]quinazolin-4-yl]amine 573686-95-0P, (4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)-2-methoxymethyl]quinazolin-4-yl]amine 573686-96-1P,
 (6-tert-Butylpyridin-3-yl)[2-(2-methoxyethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-97-2P, (6-tert-Butylpyridin-3-yl)[2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573686-98-3P, (6-tert-Butylpyridin-3-yl)[7-(3-chloropyridin-2-yl)-2-ethoxymethyl]quinazolin-4-yl]amine 573686-99-4P,
 (6-tert-Butylpyridin-3-yl)[7-(3-chloropyridin-2-yl)-2-(methoxymethyl)quinazolin-4-yl]amine 573687-00-0P,
 [2-[(1-Methylpiperidin-4-yl)oxy]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-01-1P, [2-(2-Diethylaminoethoxymethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-02-2P, [2-[(2-Dimethylaminoethoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate and receptor detector; preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain and for detecting receptors)

RN 573683-51-9 CAPLUS


CN 4-Quinazolinamine, 2-[2-(3-methyl-1-piperidinyl)ethyl]-N-[4-

(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-52-0 CAPLUS

CN 4-Quinazolinamine, 2-[(3-methyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-54-2 CAPLUS


CN 4-Quinazolinamine, 2-[(3-methyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-59-7 CAPLUS
 CN 4-Quinazolinamine, 2-[3-(1-pyrrolidinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-61-1 CAPLUS
 CN 4-Quinazolinamine, 2-[(4-cyclopentyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-63-3 CAPLUS
 CN 4-Quinazolinamine, 2-[2-(4-ethoxy-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-65-5 CAPLUS

CN 4-Quinazolinamine, 1-[2-[(4-ethyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-68-8 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 573683-70-2 CAPLUS

CN 4-Quinazolinamine, 2-[[4-(1-methylethyl)-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-72-4 CAPLUS

CN 4-Quinazolinamine, 2-[2-(4-methoxy-1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-74-6 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-76-8 CAPLUS


CN 4-Quinazolinamine, 2-[(4-methyl-1-piperazinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573683-78-0 CAPLUS

CN 4-Quinazolinamine, 2-[(4-methyl-1-piperazinyl)methyl]-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-80-4 CAPLUS

CN 4-Quinazolinamine, 2-[(4-methyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-82-6 CAPLUS

CN 4-Quinazolinamine, 2-[2-(4-methyl-1-piperidiny)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-84-8 CAPLUS

CN 4-Quinazolinamine, 2-[(4-methyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-86-0 CAPLUS

CN 4-Quinazolinamine, 2-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-87-1 CAPLUS

CN 4-Quinazolinamine, 2-(5H-tetrazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573683-89-3 CAPLUS


CN 2-Quinazolinemethanamine, N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[5-(trifluoromethyl)-2-pyridinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573683-91-7 CAPLUS

CN 2-Quinazolinemethanamine, N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-(9CI) (CA INDEX NAME)




RN 573683-93-9 CAPLUS

CN 2-Quinazolinemethanamine, N-(2-methylpropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-94-0 CAPLUS

CN 2-Quinazolinemethanamine, N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573683-96-2 CAPLUS

CN 4-Quinazolinamine, 2-[2-(octahydro-1(2H)-quinolinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-97-3 CAPLUS

CN 4-Quinazolinamine, 2-[(octahydro-1(2H)-quinolinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573683-99-5 CAPLUS

CN 2-Quinazolinemethanamine, N-(1,1-dimethylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-02-3 CAPLUS

CN 2-Quinazolinemethanamine, N-[(2-methoxyphenyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573684-05-6 CAPLUS


CN 2-Quinazolinemethanamine, N-(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573684-07-8 CAPLUS


CN 2-Quinazolinemethanamine, N-(3-methylbutyl)-4-[[4-

(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-10-3 CAPLUS

CN 2-Quinazolinemethanamine, N-[(4-methoxyphenyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-12-5 CAPLUS


CN 2-Quinazolineethanamine, N-methyl-N-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-14-7 CAPLUS
 CN 2-Quinazolinemethanamine, N-methyl-N-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-19-2 CAPLUS
 CN 2-Quinazolinemethanamine, N-cyclopropyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-21-6 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-24-9 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-26-1 CAPLUS

CN 2-Quinazolineethanamine, N-butyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-29-4 CAPLUS

CN 2-Quinazolinemethanamine, N-butyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-31-8 CAPLUS

CN 2-Quinazolineethanamine, N-butyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-33-0 CAPLUS

CN 2-Quinazolinemethanamine, N-butyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-34-1 CAPLUS

CN 2-Quinazolineethanamine, N-cyclohexyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-36-3 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclohexyl-N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-38-5 CAPLUS

CN 2-Quinazolineethanamine, N-cyclohexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-42-1 CAPLUS


CN 2-Quinazolinemethanamine, N-cyclohexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-45-4 CAPLUS


CN 2-Quinazolineethanamine, N-(cyclopropylmethyl)-N-propyl-4-[[4-

(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-47-6 CAPLUS

CN 2-Quinazolinemethanamine, N-(cyclopropylmethyl)-N-propyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-49-8 CAPLUS

CN 2-Quinazolinemethanamine, N-(cyclopropylmethyl)-N-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-53-4 CAPLUS

CN 2-Quinazolinemethanamine, N-ethyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-55-6 CAPLUS

CN 2-Quinazolineethanamine, N-hexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-57-8 CAPLUS

CN 2-Quinazolinemethanamine, N-hexyl-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-59-0 CAPLUS

CN 2-Quinazolinemethanamine, N-(2,3-dihydro-1H-inden-1-yl)-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-61-4 CAPLUS

CN 2-Quinazolineethanamine, N-ethyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-63-6 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-65-8 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-methylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-67-0 CAPLUS


CN 2-Quinazolinemethanamine, N-methyl-N-propyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-69-2 CAPLUS
 CN 2-Quinazolineethanamine, N-methyl-N-propyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-71-6 CAPLUS
 CN 2-Quinazolinemethanamine, N-(tetrahydro-2H-thiopyran-4-yl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573684-73-8 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-75-0 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-77-2 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-79-4 CAPLUS

CN 4-Quinazolinamine, 2-[2-(4-methyl-1-piperazinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-82-9 CAPLUS

CN 2-Quinazolineethanamine, N-cyclopropyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573684-86-3 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-89-6 CAPLUS

CN 2-Quinazolineethanamine, N-(2,3-dihydro-1H-inden-1-yl)-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573684-92-1 CAPLUS


CN 2-Quinazolineethanamine, N-methyl-N-(2-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573684-95-4 CAPLUS
 CN 4-Quinazolinamine, 2-[3-(2,6-dimethyl-4-morpholinyl)propyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573684-98-7 CAPLUS
 CN 4-Quinazolinamine, 2-[3-(2,6-dimethyl-4-morpholinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-01-5 CAPLUS


CN 4-Quinazolinamine, 2-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 573685-04-8 CAPLUS


CN 4-Quinazolinamine, 2-[3-(3-methyl-1-piperidinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-07-1 CAPLUS
 CN 4-Quinazolinamine, 2-[3-(4-methyl-1-piperazinyl)propyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-10-6 CAPLUS
 CN 4-Quinazolinamine, 2-[[4-[2-(diethylamino)ethyl]-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-12-8 CAPLUS
 CN 4-Quinazolinamine, 2-[[4-[2-(dimethylamino)ethyl]-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-14-0 CAPLUS

CN 4-Quinazolinamine, 2-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-16-2 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-18-4 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-20-8 CAPLUS

CN 4-Quinazolinamine, 2-[[4-[3-(dimethylamino)propyl]-1-piperazinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-22-0 CAPLUS

CN 2-Quinazolinemethanamine, N-[(2-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-24-2 CAPLUS

CN 2-Quinazolinemethanamine, N-[(3-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573685-26-4 CAPLUS


CN 2-Quinazolinemethanamine, N-(2-pyridinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573685-28-6 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-2-pyridinyl- (9CI)


pyridinyl]-4-[[5-(trifluoromethyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573685-30-0 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(2,2,2-trifluoro-1-methylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-32-2 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-36-6 CAPLUS

CN 2-Quinazolinemethanamine, N-ethyl-N-(2-methyl-2-propenyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-40-2 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-42-4 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylpropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-44-6 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-[(2-methylphenyl)methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-46-8 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(2-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-48-0 CAPLUS

CN 2-Quinazolineethanamine, N-[(2-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-49-1 CAPLUS

CN 2-Quinazolineethanamine, N-[(3-fluorophenyl)methyl]-N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-50-4 CAPLUS

CN 2-Quinazolineethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-51-5 CAPLUS

CN 2-Quinazolineethanamine, N-ethyl-N-(2-methyl-2-propenyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-52-6 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(1-phenylethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-53-7 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-(1-phenylpropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-55-9 CAPLUS

CN 2-Quinazolineethanamine, N-methyl-N-[(2-methylphenyl)methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-56-0 CAPLUS

CN 4-Quinazolinamine, 2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-58-2 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-1H-azepin-1-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-59-3 CAPLUS

CN 4-Quinazolinamine, 2-[2-(hexahydro-1(2H)-azocinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-60-6 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-1(2H)-azocinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-61-7 CAPLUS


CN 2-Quinazolinemethanamine, N-cyclohexyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-62-8 CAPLUS


CN 2-Quinazolineethanamine, N,N-di-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)

(CA INDEX NAME)




RN 573685-64-0 CAPLUS

CN 2-Quinazolinemethanamine, N,N-di-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573685-65-1 CAPLUS

CN 2-Quinazolineethanamine, N,N-dibutyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-67-3 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dibutyl-4-[[4-(trifluoromethyl)phenyl]amino]-
7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-68-4 CAPLUS

CN 2-Quinazolineethanamine, N,N-diethyl-4-[[4-(trifluoromethyl)phenyl]amino]-
7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-69-5 CAPLUS

CN 2-Quinazolinemethanamine, N,N-diethyl-4-[[4-(trifluoromethyl)phenyl]amino]-
7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-70-8 CAPLUS

CN 2-Quinazolineethanamine, N,N-dihexyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-71-9 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-72-0 CAPLUS

CN 2-Quinazolineethanamine, N,N-dipentyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-73-1 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dipentyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-74-2 CAPLUS


CN 2-Quinazolineethanamine, N,N-dipropyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-76-4 CAPLUS


CN 2-Quinazolinemethanamine, N,N-dipropyl-7-[3-(trifluoromethyl)-2-pyridinyl]-

4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573685-77-5 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dipropyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-78-6 CAPLUS


CN 2-Quinazolinemethanamine, N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-79-7 CAPLUS


CN 2-Quinazolinemethanamine, N-hexyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-

[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-80-0 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-ylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-81-1 CAPLUS


CN 2-Quinazolinemethanamine, N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-82-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-(4-morpholinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-85-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573685-86-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-87-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-88-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-((trifluoromethyl)sulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573685-89-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-morpholinylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-91-3 CAPLUS

CN 2-Quinazolinemethanamine, N-octyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-92-4 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1-piperidinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-93-5 CAPLUS

CN 4-Quinazolinamine, 2-(1-piperidinylmethyl)-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-94-6 CAPLUS

CN 4-Quinazolinamine, 2-(1-piperidinylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-95-7 CAPLUS

CN 4-Quinazolinamine, 2-[2-(4-thiomorpholinyl)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-97-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-thiomorpholinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573685-98-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-thiomorpholinylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573685-99-1 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 573686-00-7 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[6-(trifluoromethyl)-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 573686-01-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573686-05-2 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[(3,5-dimethyl-1-piperazinyl)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573686-06-3 CAPLUS
 CN 4-Piperidinemethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-07-4 CAPLUS

CN 2-Piperidinemethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-08-5 CAPLUS

CN 3-Piperidinemethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-09-6 CAPLUS

CN 4-Piperidinemethanol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-10-9 CAPLUS

CN 3-Piperidinemethanol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 573686-11-0 CAPLUS


CN 4-Piperidinol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 573686-12-1 CAPLUS


CN 3-Piperidinol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-

(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 573686-13-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 573686-14-3 CAPLUS

CN 4-Piperidinol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 573686-15-4 CAPLUS

CN 3-Piperidinol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-16-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-17-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 573686-18-7 CAPLUS

CN 4-Piperidinol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-19-8 CAPLUS

CN 3-Piperidinol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-20-1 CAPLUS

CN Piperazine, 1-acetyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-21-2 CAPLUS

CN Pyrrolidine, 1-[1-oxo-3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-22-3 CAPLUS

CN 4-Piperidineethanol, 1-[3-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 573686-23-4 CAPLUS

CN Ethanol, 2-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 573686-24-5 CAPLUS

CN 4-Piperidineethanol, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-25-6 CAPLUS

CN 4-Piperidineethanol, 1-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-26-7 CAPLUS

CN 1-Piperazineethanol, 4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-27-8 CAPLUS

CN 1-Piperazineethanol, 4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-28-9 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[2-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 573686-29-0 CAPLUS

CN Methanesulfonamide, N-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573686-30-3 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dimethyl-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-31-4 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 573686-32-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)-2-(4-thiomorpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 573686-33-6 CAPLUS

CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-34-7 CAPLUS

CN 2-Quinazolinemethanamine, N-ethyl-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 573686-35-8 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 573686-36-9 CAPLUS

CN 2-Quinazolinemethanamine, N-ethyl-N-(1-methylethyl)-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-37-0 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-methylethyl)-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-38-1 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-4-[[4-(1-methylethyl)phenyl]amino]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573686-39-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-40-5 CAPLUS

CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-41-6 CAPLUS

CN 4-Quinazolinamine, 2-(6-methoxy-3-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-42-7 CAPLUS
 CN 4-Quinazolinamine, 2-[6-(1-pyrrolidinyl)-3-pyridinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-43-8 CAPLUS
 CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(4-pyridinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573686-44-9 CAPLUS
 CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl)methyl]-7-(3-pyridinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573686-45-0 CAPLUS
 CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-46-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-methoxyethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-49-4 CAPLUS

CN 2-Quinazolinepropanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-66-5 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573686-68-7 CAPLUS


CN 1H-Indole, 2,3-dihydro-5-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 573686-70-1 CAPLUS
 CN 4-Quinazolinamine, N-(4-cyclopropylphenyl)-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-72-3 CAPLUS
 CN 4-Quinazolinamine, 2-(2-methoxyethyl)-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-73-4 CAPLUS
 CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-2-[[[tetrahydro-2H-pyran-4-yl]oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-75-6 CAPLUS
 CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 573686-77-8 CAPLUS
 CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-78-9 CAPLUS
 CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)-2-[[tetrahydro-2H-pyran-4-yl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 573686-79-0 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(methoxymethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-83-6 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573686-84-7 CAPLUS


CN 4-Quinazolinamine, 2-[[(1R)-3-(diethylamino)-1-methylpropoxy]methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573686-85-8 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(diethylamino)propoxy]methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-86-9 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(dimethylamino)propoxy]methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-87-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[3-(4-(trifluoromethyl)-2-pyridinyl)propoxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573686-91-6 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-92-7 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(ethoxymethyl)- (9CI) (CA INDEX NAME)




RN 573686-95-0 CAPLUS
 CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 573686-96-1 CAPLUS
 CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-97-2 CAPLUS
 CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573686-98-3 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(ethoxymethyl)- (9CI) (CA INDEX NAME)



RN 573686-99-4 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 573687-00-0 CAPLUS


CN 4-Quinazolinamine, 2-[[[(1-methyl-4-piperidinyl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)

(CA INDEX NAME)




RN 573687-01-1 CAPLUS

CN 4-Quinazolinamine, 2-[[2-(diethylamino)ethoxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573687-02-2 CAPLUS

CN 4-Quinazolinamine, 2-[[2-(dimethylamino)ethoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 573687-03-3P, [2-[[2-(Piperidin-1-yl)ethoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-04-4P, [2-[3-(Benzyloxy)propyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-05-5P, [2-[3-(Benzyloxy)propyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-tert-butylpyridin-3-yl)amine 573687-06-6P, [2-(3-Diethylaminopropoxymethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573687-07-7P, [2-[(3-Dimethylamino-2,2-dimethylpropoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573687-08-8P, [2-[(3-Dimethylaminopropoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573687-09-9P, [2-[[(Pyridin-3-yl)methoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-10-2P, [2-[[(Pyridin-4-yl)methoxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-11-3P, [2-[[(Tetrahydropyran-4-yl)oxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573687-12-4P, [2-[[(Tetrahydropyran-4-yl)oxy)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-13-5P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(2,2,2-trifluoro-1-methylethyl)phenyl)amine 573687-14-6P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573687-15-7P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-16-8P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573687-17-9P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethoxyphenyl)amine 573687-18-0P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(trifluoromethanesulfonyl)phenyl)amine 573687-19-1P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(methanesulfonyl)phenyl)amine 573687-20-4P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(2-methoxy-1,1-dimethylethyl)phenyl)amine 573687-21-5P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-tert-butylphenyl)amine 573687-22-6P, [2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](1-(methanesulfonyl)-2,3-dihydro-1H-indol-5-yl)amine 573687-26-0P, [2-Isopropoxymethyl-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573687-27-1P, [2-Isopropoxymethyl-7-(3-methylpyridin-2-yl)quinazolin-4-yl](4-isopropylphenyl)amine 573687-28-2P, [2-Isopropoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-32-8P, [2-Methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573687-33-9P, [2-Methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine 573687-34-0P, [2-Methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-(trifluoromethanesulfonyl)phenyl)amine 573687-35-1P, [2-Methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573687-36-2P, [4-(2-Methoxy-1,1-dimethylethyl)phenyl][2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573687-38-4P, [4-[(4-Isopropylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methanol 573687-39-5P, [4-[(4-tert-Butylphenyl)amino]-7-(3-chloropyridin-2-yl)quinazolin-2-yl]methanol 573687-40-8P, [4-[(4-tert-Butylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methanol 573687-41-9P, [4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-

yl)quinazolin-2-yl)methyl 573687-44-2P, [7-(3-Chloropyridin-2-yl)-2-[[[(tetrahydropyran-4-yl)oxy]methyl]quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573687-45-3P, [7-(3-Chloropyridin-2-yl)-2-[[[(tetrahydropyran-4-yl)oxy]methyl]quinazolin-4-yl] (4-isopropylphenyl)amine 573687-46-4P, [7-(3-Chloropyridin-2-yl)-2-ethoxymethylquinazolin-4-yl] (4-isopropylphenyl)amine 573687-47-5P, [7-(3-Chloropyridin-2-yl)-2-ethoxymethylquinazolin-4-yl] (4-trifluoromethylphenyl)amine 573687-53-3P, [7-(3-Chloropyridin-2-yl)-2-(methoxymethyl)quinazolin-4-yl] (4-isopropylphenyl)amine 573687-54-4P, [7-(3-Chloropyridin-2-yl)-2-(methoxymethyl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573687-55-5P, [7-(3-Chloropyridin-2-yl)-4-[(4-isopropylphenyl)amino]quinazolin-2-yl)methanol 573687-57-7P, [7-(3-Methylpyridin-2-yl)-2-[[[(tetrahydropyran-4-yl)oxy]methyl]quinazolin-4-yl] (4-trifluoromethylphenyl)amine 573687-59-9P, [7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl)methanol 573687-64-6P, 2-[4-[[2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]-2-methylpropionitrile 573687-66-8P, 2-[4-[[2-Methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]-2-methylpropionitrile 573687-70-4P, 3-[4-[(6-tert-Butylpyridin-3-yl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propan-1-ol 573687-71-5P, 3-[7-(3-Trifluoromethylpyridin-2-yl)-4-[(6-trifluoromethylpyridin-3-yl)amino]quinazolin-2-yl]propan-1-ol 573687-72-6P, 4-[[2-Benzyloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]-N-tert-butylbenzenesulfonamide 573687-74-8P, N-tert-Butyl-4-[[2-methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573687-77-1P, (6-Trifluoromethylpyridin-3-yl)[7-(3-trifluoromethylpyridin-2-yl)-2-[(3,3,5-trimethylazepan-1-yl)methyl]quinazolin-4-yl]amine 573687-78-2P, [2-[(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-79-3P, [2-[(1-Methyl-3,4-dihydro-1H-isoquinolin-2-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-80-6P, [2-[(2-Ethylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-81-7P, [2-[(2-Methylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-82-8P, [2-[(3,4-Dihydro-1H-isoquinolin-2-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-83-9P, [2-[(4-Methylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-84-0P, [2-[(Octahydroquinolin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-85-1P, [2-[(Allylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-86-2P, [2-[(Benzylcyclopropylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-87-3P, [2-[(Butylethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-88-4P, [2-[(Butylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-89-5P, [2-[(Cyclohexylethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-90-8P, [2-[(Cyclohexylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-91-9P, [2-[(Ethylisopropylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-92-0P, [2-[(Hexylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-93-1P, [2-[(Octylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-94-2P, [2-[(Decylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-95-3P, [2-[(Dodecylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-96-4P, [2-[(Tetradecylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-97-5P, [2-[(Hexadecylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-98-6P, [2-[(Octadecylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-99-7P, [2-[(Eicosylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-100-8P, [2-[(Docosylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-101-9P, [2-[(Triacontylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-102-0P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-103-1P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-104-2P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-105-3P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-106-4P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-107-5P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-108-6P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-109-7P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-110-8P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-111-9P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-112-0P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-113-1P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-114-2P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-115-3P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-116-4P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-117-5P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-118-6P, [2-[[[2,2,2-Trifluoroethyl]amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyrid

yl)amine 573687-93-1P, [2-[(Indan-1-ylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-94-2P, [2-[(Isopropylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-95-3P, [2-[(Methylphenethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-96-4P, [2-[(Methylpropylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-97-5P, [2-[[2-Fluorobenzyl] (methyl) amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-98-6P, [2-[[3-Fluorobenzyl] (methyl) amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573687-99-7P, [2-[[Bis(2-methoxyethyl) amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-00-3P, [2-[[Ethyl(2-methylallyl) amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-01-4P, [2-[[Methyl(1-phenylethyl) amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-02-5P, [2-[[Methyl(1-phenylpropyl) amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-03-6P, [2-[[Methyl(2-methylbenzyl) amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-04-7P, [2-(Azepan-1-ylmethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-05-8P, [2-(Azocan-1-ylmethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-06-9P, [2-[(Diallylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-07-0P, [2-[(Dibutylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-08-1P, [2-Diethylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-09-2P, [2-[(Dihexylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-10-5P, [2-Dimethylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-11-6P, [2-[(Dipentylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-12-7P, [2-Piperidin-1-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-13-8P, [2-Pyrrolidin-1-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-yl)amine 573688-29-6P, [2-[(Ethylpropylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-30-9P, [2-[(Isopropylmethylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-31-0P, [2-[(Methylpropylamino)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-32-1P, [2-Dimethylaminomethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-35-4P, [2-Cyclopentylloxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-36-5P, [2-Cyclopropylmethoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-37-6P, [2-Ethoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-41-2P, [2-Isopropoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-45-6P, [2-Methoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] [4-[(morpholin-4-yl)sulfonyl]phenyl]amine 573688-46-7P,

[4-[(Morpholin-4-yl)sulfonyl]phenyl][2-[(tetrahydropyran-4-yl)oxy]methyl]-
 7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine
 573688-47-8P, [4-[4-[(Piperidin-1-yl)sulfonyl]phenyl]amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-2-yl]methanol 573688-51-4P
 , N-tert-Butyl-4-[[2-hydroxymethyl-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl]amino]-N-methylbenzenesulfonamide 573688-53-6P
 , 4-Trifluoromethylphenyl[2-[(2,6-dimethylmorpholin-4-yl)methyl]-7-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 573688-54-7P,
 (cis-2,6-Dimethylmorpholin-4-yl)[4-[(4-trifluoromethylphenyl)amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-2-yl]methanone 573688-55-8P
 , (4-Cyclopropylphenyl)[2-[(2,2-dimethylmorpholin-4-yl)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573688-56-9P,
 (4-Cyclopropylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573688-57-0P,
 (4-sec-Butylphenyl)[7-(3-chloropyridin-2-yl)-2-[(cis-2,6-dimethylmorpholin-
 4-yl)methyl]quinazolin-4-yl]amine 573688-58-1P,
 (4-tert-Butylphenyl)[2-[(1,1-dioxoisothiazolidin-2-yl)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573688-60-5P,
 (4-tert-Butylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-(3-
 pyrimidin-5-yl)quinazolin-4-yl]amine 573688-61-6P,
 (4-tert-Butylphenyl)[7-(2,4-dimethoxypyrimidin-5-yl)-2-[(cis-2,6-
 dimethylmorpholin-4-yl)methyl]quinazolin-4-yl]amine 573688-62-7P
 , (4-Isopropylphenyl)[2-[(R)-2-methylmorpholin-4-yl)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573688-63-8P,
 (4-tert-Butylphenyl)[2-[(R)-2-methylmorpholin-4-yl)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573688-64-9P,
 [2-[(R)-2-Methylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-65-0P,
 (4-Isopropylphenyl)[2-[(S)-2-methylmorpholin-4-yl)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573688-66-1P,
 (4-tert-Butylphenyl)[2-[(S)-2-methylmorpholin-4-yl)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573688-67-2P,
 [2-((S)-1-Propylpyrrolidin-2-yl)-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-68-3P,
 [2-[(S)-2-Methylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-69-4P,
 [2-((S)-Pyrrolidin-2-yl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-
 yl](4-trifluoromethylphenyl)amine 573688-70-7P,
 [2-[(S,S)-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-
 2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-71-8P
 , [2-[(1,1-Dioxo[1,2]thiazinan-2-yl)methyl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-72-9P,
 [2-(1-Ethylpiperidin-4-yl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-
 yl](4-trifluoromethylphenyl)amine 573688-73-0P,
 [2-[1-(Methanesulfonyl)piperidin-4-yl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-74-1P,
 [2-(1-Propylpiperidin-4-yl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-
 yl](4-trifluoromethylphenyl)amine 573688-75-2P,
 [2-[1-[(Pyridin-4-yl)methyl]piperidin-4-yl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-76-3P,
 [2-[(2,2-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573688-78-5P,
 [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(2-methoxyphenyl)quinazolin-
 4-yl](4-trifluoromethylphenyl)amine 573688-80-9P,
 [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl](4-isopropylphenyl)amine 573688-82-1P,
 [2-[(3,3-Dimethylpiperidin-1-yl)methyl]-7-(3-methylpyridin-2-yl)quinazolin-
 4-yl](4-trifluoromethylphenyl)amine 573688-85-4P,
 [2-[[Bis(ethoxymethyl)amino]methyl]-7-(3-methylpyridin-2-yl)quinazolin-4-
 yl](4-trifluoromethylphenyl)amine 573688-86-5P,
 [2-[1-[(1-Methyl-1H-imidazol-2-yl)methyl]piperidin-4-yl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
 573688-87-6P, [2-[2-(2,6-Dimethylmorpholin-4-yl)ethyl]-7-(3-

trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573688-91-2P, [2-[(Dihexylamino)methyl]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573688-92-3P, [2-(2-Dimethylaminoethyl)-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573688-93-4P, [2-(Dipropylaminomethyl)-7-(3-methylpyridin-2-
 yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine 573688-95-6P,
 [2-Imidazol-1-ylmethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-
 trifluoromethylphenyl) amine 573688-96-7P, [2-Piperidin-4-yl-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573688-97-8P, [7-(3-Chloropyridin-2-yl)-2-[(2,2-dimethylmorpholin-
 4-yl)methyl]quinazolin-4-yl] (4-trifluoromethylphenyl) amine
 573688-98-9P, [7-(3-Chloropyridin-2-yl)-2-[(cis-2,6-
 dimethylmorpholin-4-yl)methyl]quinazolin-4-yl] (4-isopropylphenyl) amine
 573689-00-6P, [1-[[4-[(4-tert-Butylphenyl)amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]pyrrolidin-2-
 yl]methanol 573689-01-7P, [(3R)-1-[[7-(3-Methylpyridin-2-yl)-4-
 [(4-trifluoromethylphenyl)amino]quinazolin-2-yl]methyl]pyrrolidin-3-
 yl]methanol 573689-02-8P, [(3S)-1-[[7-(3-Methylpyridin-2-yl)-4-
 [(4-trifluoromethylphenyl)amino]quinazolin-2-yl]methyl]pyrrolidin-3-
 yl]methanol 573689-03-9P, (3R)-1-[[7-(3-Methylpyridin-2-yl)-4-
 [(4-trifluoromethylphenyl)amino]quinazolin-2-yl]methyl]pyrrolidin-3-ol
 573689-04-0P, 1-[2-[2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-4-
 [(4-trifluoromethylphenyl)amino]quinazolin-7-yl]phenyl]ethanone
 573689-06-2P, 1-[4-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-2-yl]piperidin-1-yl]ethanone
 573689-07-3P, 1-[4-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-2-yl]piperidin-1-yl]propan-1-one
 573689-08-4P, 2-[[[4-[(4-tert-Butylphenyl)amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl](propyl)amino]ethanol
 573689-09-5P, 2-Methyl-2-[[[4-[(4-trifluoromethylphenyl)amino]-7-
 (3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]methyl]amino]propan-1-ol
 573689-10-8P, 4-[(4-Trifluoromethylphenyl)amino]-7-(3-
 trifluoromethylpyridin-2-yl)quinazoline-2-carboxylic acid
 N,N-dimethylamide 573689-11-9P, 4-[(4-
 Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazoline-
 2-carboxylic acid methylamide 573689-12-0P, 4-[(4-
 Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazoline-
 2-carboxylic acid N-(2-dimethylaminoethyl)amide 573689-13-1
 P, 4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-
 yl)quinazoline-2-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide
 573689-14-2P, N,N,N'-Trimethyl-N'-[[4-[(4-
 trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-
 yl]methyl]propane-1,3-diamine 573689-19-7P, (4-tert-
 Butylphenyl)[2-[(4-dimethylaminobutoxy)methyl]-7-(3-trifluoromethylpyridin-
 2-yl)quinazolin-4-yl]amine 573689-20-0P, (4-tert-Butylphenyl)[2-
 [[4-(morpholin-4-yl)butoxy]methyl]-7-(3-trifluoromethylpyridin-2-
 yl)quinazolin-4-yl]amine 573689-26-6P, [2-Ethoxymethyl-7-(3-
 methylpyridin-2-yl)quinazolin-4-yl] (4-isopropylphenyl) amine
 573689-27-7P, [2-Ethoxymethyl-7-(3-methylpyridin-2-yl)quinazolin-4-
 yl] (4-trifluoromethylphenyl) amine 573689-30-2P,
 [2-Ethoxymethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-
 trifluoromethylphenyl) amine 573689-31-3P, [2-Ethoxymethyl-7-(3-
 trifluoromethylpyridin-2-yl)quinazolin-4-yl] (6-trifluoromethylpyridin-3-
 yl)amine 573689-66-4P, 1-Dimethylamino-3-[[4-[(4-
 trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-
 yl]methoxy]propan-2-ol 573689-67-5P, 2-[4-[(4-tert-
 Butylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]-2-
 methylpropan-1-ol 573689-72-2P, 2-Methyl-2-[4-[(4-
 trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-
 yl]propan-1-ol


RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC
 (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic


use); ANST (Analytical study); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(drug candidate and receptor detector; preparation of substituted
quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for
relieving pain and for detecting receptors)

RN 573687-03-3 CAPLUS


CN 4-Quinazolinamine, 2-[[2-(1-piperidinyl)ethoxy)methyl]-7-[3-
(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)






RN 573687-06-6 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(diethylamino)propoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-07-7 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(dimethylamino)-2,2-dimethylpropoxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-08-8 CAPLUS

CN 4-Quinazolinamine, 2-[[3-(dimethylamino)propoxy)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-09-9 CAPLUS

CN 4-Quinazolinamine, 2-[(3-pyridinylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-10-2 CAPLUS


CN 4-Quinazolinamine, 2-[(4-pyridinylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




CN 4-Quinazolinamine, 2-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



CN 4-Quinazolinamine, 2-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-14-6 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-15-7 CAPLUS


CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-16-8 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573687-17-9 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-N-[4-(trifluoromethoxy)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-18-0 CAPLUS

CN 4-Quinazolinamine, 2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-(trifluoromethylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-19-1 CAPLUS

CN 4-Quinazolinamine, N-[4-(methylsulfonyl)phenyl]-2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-20-4 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-21-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-22-6 CAPLUS

CN 1H-Indole, 2,3-dihydro-1-(methylsulfonyl)-5-[[2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-26-0 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-27-1 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573687-28-2 CAPLUS

CN 4-Quinazolinamine, 2-[(1-methylethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-32-8 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-33-9 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-34-0 CAPLUS

CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 573687-35-1 CAPLUS


CN 4-Quinazolinamine, 2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 573687-36-2 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-38-4 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(1-methylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-39-5 CAPLUS


CN 2-Quinazolinemethanol, 7-(3-chloro-2-pyridinyl)-4-[[4-(1,1-dimethylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 573687-40-8 CAPLUS


CN 2-Quinazolinemethanol, 4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-41-9 CAPLUS

CN 2-Quinazolinemethanol, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573687-44-2 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[[tetrahydro-2H-pyran-4-yl]oxy]methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-45-3 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-2-

[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 573687-46-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(ethoxymethyl)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-47-5 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(ethoxymethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-53-3 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(methoxymethyl)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-54-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573687-55-5 CAPLUS


CN 2-Quinazolinemethanol, 7-(3-chloro-2-pyridinyl)-4-[[4-(1-methylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 573687-57-7 CAPLUS


CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-2-[[4-(1-methylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

yl)oxy)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573687-59-9 CAPLUS

CN 2-Quinazolinemethanol, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-64-6 CAPLUS

CN Benzeneacetonitrile, α,α -dimethyl-4-[[2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-66-8 CAPLUS

CN Benzeneacetonitrile, 4-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 573687-70-4 CAPLUS

CN 2-Quinazolinepropanol, 4-[[6-(1,1-dimethylethyl)-3-pyridinyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-71-5 CAPLUS

CN 2-Quinazolinepropanol, 7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-72-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-[(phenylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-74-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-77-1 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-3,3,5-trimethyl-1H-azepin-1-yl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-78-2 CAPLUS

CN 4-Quinazolinamine, 2-[(1,4-dioxaspiro[4.5]dec-8-yl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-79-3 CAPLUS

CN 4-Quinazolinamine, 2-[(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-80-6 CAPLUS

CN 4-Quinazolinamine, 2-[(2-ethyl-1-piperidiny)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-81-7 CAPLUS

CN 4-Quinazolinamine, 2-[(2-methyl-1-piperidiny)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573687-82-8 CAPLUS

CN 4-Quinazolinamine, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573687-83-9 CAPLUS


CN 4-Quinazolinamine, 2-[(4-methyl-1-piperidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 573687-84-0 CAPLUS


CN 4-Quinazolinamine, 2-[(octahydro-1(2H)-quinolinyl)methyl]-7-[3-

(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573687-85-1 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-2-propenyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME).




RN 573687-86-2 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclopropyl-N-(phenylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-87-3 CAPLUS

CN 2-Quinazolinemethanamine, N-butyl-N-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-88-4 CAPLUS

CN 2-Quinazolinemethanamine, N-butyl-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-89-5 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclohexyl-N-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-90-8 CAPLUS

CN 2-Quinazolinemethanamine, N-cyclohexyl-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-91-9 CAPLUS


CN 2-Quinazolinemethanamine, N-ethyl-N-(1-methylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573687-92-0 CAPLUS
 CN 2-Quinazolinemethanamine, N-hexyl-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-93-1 CAPLUS
 CN 2-Quinazolinemethanamine, N-(2,3-dihydro-1H-inden-1-yl)-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-94-2 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(1-methylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 573687-95-3 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-(2-phenylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 573687-96-4 CAPLUS

CN 2-Quinazolinemethanamine, N-methyl-N-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-97-5 CAPLUS

CN 2-Quinazolinemethanamine, N-[(2-fluorophenyl)methyl]-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-98-6 CAPLUS

CN 2-Quinazolinemethanamine, N-[(3-fluorophenyl)methyl]-N-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573687-99-7 CAPLUS

CN 2-Quinazolinemethanamine, N,N-bis(2-methoxyethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-00-3 CAPLUS

CN 2-Quinazolinemethanamine, N-ethyl-N-(2-methyl-2-propenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-01-4 CAPLUS


CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573688-02-5 CAPLUS
 CN 2-Quinazolinemethanamine, N-methyl-N-(1-phenylpropyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-03-6 CAPLUS
 CN 2-Quinazolinemethanamine, N-methyl-N-[(2-methylphenyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-04-7 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-1H-azepin-1-yl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573688-05-8 CAPLUS

CN 4-Quinazolinamine, 2-[(hexahydro-1(2H)-azocinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573688-06-9 CAPLUS


CN 2-Quinazolinemethanamine, N,N-di-2-propenyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-07-0 CAPLUS
 CN 2-Quinazolinemethanamine, N,N-dibutyl-7-[3-(trifluoromethyl)-2-pyridinyl]-
 4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 573688-08-1 CAPLUS
 CN 2-Quinazolinemethanamine, N,N-diethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-
 4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-09-2 CAPLUS
 CN 2-Quinazolinemethanamine, N,N-dihexyl-7-[3-(trifluoromethyl)-2-pyridinyl]-
 4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-10-5 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dimethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-11-6 CAPLUS

CN 2-Quinazolinemethanamine, N,N-dipentyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-[[6-(trifluoromethyl)-3-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-12-7 CAPLUS

CN 4-Quinazolinamine, 2-(1-piperidinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-13-8 CAPLUS

CN 4-Quinazolinamine, 2-(1-pyrrolidinylmethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-29-6 CAPLUS

CN Morpholine, 4-[[4-[[2-[(ethylpropylamino)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-30-9 CAPLUS

CN Morpholine, 4-[[4-[[2-[[methyl(1-methylethyl)amino]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)




RN 573688-31-0 CAPLUS

CN Morpholine, 4-[[4-[[2-[(methylpropylamino)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-32-1 CAPLUS

CN Morpholine, 4-[[4-[[2-[(dimethylamino)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-35-4 CAPLUS

CN Morpholine, 4-[[4-[[2-[(cyclopentyloxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-36-5 CAPLUS

CN Morpholine, 4-[[4-[[2-[(cyclopropylmethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-37-6 CAPLUS

CN Morpholine, 4-[[4-[[2-(ethoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-41-2 CAPLUS

CN Morpholine, 4-[[4-[[2-[(1-methylethoxy)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-45-6 CAPLUS

CN Morpholine, 4-[[4-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-46-7 CAPLUS

CN Morpholine, 4-[[4-[[2-[[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)




RN 573688-47-8 CAPLUS

CN Piperidine, 1-[[4-[[2-(hydroxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573688-51-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-(hydroxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 573688-53-6 CAPLUS


CN 4-Quinazolinamine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-[2-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573688-54-7 CAPLUS


CN Morpholine, 2,6-dimethyl-4-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]carbonyl]-, (2R,6S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573688-55-8 CAPLUS


CN 4-Quinazolinamine, N-(4-cyclopropylphenyl)-2-[(2,2-dimethyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-56-9 CAPLUS

CN 4-Quinazolinamine, N-(4-cyclopropylphenyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-57-0 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylpropyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573688-58-1 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[(1,1-dioxido-2-isothiazolidinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-60-5 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[2,6-dimethyl-4-morpholinyl)methyl]-7-(5-pyrimidinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-61-6 CAPLUS

CN 4-Quinazolinamine, 7-(2,4-dimethoxy-5-pyrimidinyl)-N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R, 6S)-2,6-dimethyl-4-morpholinyl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-62-7 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-2-[[(2R)-2-methyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-63-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[{(2R)-2-methyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-64-9 CAPLUS

CN 4-Quinazolinamine, 2-[[{(2R)-2-methyl-4-morpholinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-65-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-2-[[{(2S)-2-methyl-4-morpholinyl)methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-66-1 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[1-(2S)-2-methyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-67-2 CAPLUS

CN 4-Quinazolinamine, 2-[(2S)-1-propyl-2-pyrrolidinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-68-3 CAPLUS

CN 4-Quinazolinamine, 2-[[(2S)-2-methyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-69-4 CAPLUS

CN 4-Quinazolinamine, 2-(2S)-2-pyrrolidinyl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573688-70-7 CAPLUS


CN 4-Quinazolinamine, 2-[[(2S,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573688-71-8 CAPLUS

CN 4-Quinazolinamine, 2-[(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573688-72-9 CAPLUS

CN 4-Quinazolinamine, 2-(1-ethyl-4-piperidinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-73-0 CAPLUS

CN Piperidine, 1-(methylsulfonyl)-4-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 573688-74-1 CAPLUS

CN 4-Quinazolinamine, 2-(1-propyl-4-piperidinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-75-2 CAPLUS

CN 4-Quinazolinamine, 2-[1-(4-pyridinylmethyl)-4-piperidinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-76-3 CAPLUS


CN 4-Quinazolinamine, 2-[(2,2-dimethyl-4-morpholinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-78-5 CAPLUS

CN 4-Quinazolinamine, 2-[[(2R, 6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(2-methoxyphenyl)-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 573688-80-9 CAPLUS


CN 4-Quinazolinamine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573688-82-1 CAPLUS

CN 4-Quinazolinamine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573688-85-4 CAPLUS


CN 2-Quinazolinemethanamine, N,N-bis(ethoxymethyl)-7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 573688-86-5 CAPLUS
 CN 4-Quinazolinamine, 2-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]-
 N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573688-87-6 CAPLUS
 CN 4-Quinazolinamine, 2-[2-(2,6-dimethyl-4-morpholinyl)ethyl]-N-[4-
 (trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA
 INDEX NAME)




RN 573688-91-2 CAPLUS

CN 2-Quinazolinemethanamine, N,N-di(2-methyl-2-oxoethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-92-3 CAPLUS

CN 2-Quinazolineethanamine, N,N-dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-93-4 CAPLUS

CN 2-Quinazolinemethanamine, 7-(3-methyl-2-pyridinyl)-N,N-dipropyl-4-[[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 573688-95-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-ylmethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573688-96-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-piperidinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-97-8 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[(2,2-dimethyl-4-morpholinyl)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573688-98-9 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(1-methylethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573689-00-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 573689-01-7 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-2-quinazolinyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573689-02-8 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-2-quinazolinyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573689-03-9 CAPLUS

CN 3-Pyrrolidinol, 1-[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-2-quinazolinyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573689-04-0 CAPLUS


CN Ethanone, 1-[2-[2-[[(2R, 6S)-2,6-dimethyl-4-morpholinyl]methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-quinazolinyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573689-06-2 CAPLUS

CN Piperidine, 1-acetyl-4-[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 573689-07-3 CAPLUS

CN Piperidine, 1-(1-oxopropyl)-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 573689-08-4 CAPLUS

CN Ethanol, 2-[[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]propylamino]- (9CI) (CA INDEX NAME)




RN 573689-09-5 CAPLUS

CN 1-Propanol, 2-methyl-2-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 573689-10-8 CAPLUS

CN 2-Quinazolinecarboxamide, N,N-dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-11-9 CAPLUS


CN 2-Quinazolinecarboxamide, N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573689-12-0 CAPLUS
 CN 2-Quinazolinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573689-13-1 CAPLUS
 CN 2-Quinazolinecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 (CA INDEX NAME)




RN 573689-14-2 CAPLUS

CN 1,3-Propanediamine; N,N,N'-trimethyl-N'-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 573689-19-7 CAPLUS

CN 4-Quinazolinamine, 2-[[4-(dimethylamino)butoxy]methyl]-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-20-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[4-(4-morpholinyl)butoxy]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-26-6 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-N-[4-(1-methylethyl)phenyl]-7-(3-(trifluoromethyl)-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573689-27-7 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573689-30-2 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573689-31-3 CAPLUS

CN 4-Quinazolinamine, 2-(ethoxymethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[(6-(trifluoromethyl)-3-pyridinyl)]-(9CI) (CA INDEX NAME)



RN 573689-66-4 CAPLUS


CN 2-Propanol, 1-(dimethylamino)-3-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-2-quinazolinyl]methoxy]-(9CI) (CA INDEX NAME)



RN 573689-67-5 CAPLUS


CN 2-Quinazolineethanol, 4-[[4-(1,1-dimethylethyl)phenyl]amino]-β,β-

dimethyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573689-72-2 CAPLUS


CN 2-Quinazolinethanol, β,β -dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



IT 573680-46-3P, [2-Chloromethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine monohydrochloride
573680-90-7P, [2-[2-(Benzyloxy)ethyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine monohydrochloride
573680-94-1P, [2-(2-Chloroethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl] (4-trifluoromethylphenyl)amine monohydrochloride
573681-07-9P, 3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propionic acid ethyl ester
573681-10-4P, 3-[4-[(4-Trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-2-yl]propionic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain and for detecting receptors)

RN 573680-46-3 CAPLUS


CN 4-Quinazolinamine, 2-(chloromethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 573680-90-7 CAPLUS


CN 4-Quinazolinamine, 2-[2-(phenylmethoxy)ethyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 573680-94-1 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloroethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 573681-07-9 CAPLUS

CN 2-Quinazolinepropanoic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 573681-10-4 CAPLUS


CN 2-Quinazolinepropanoic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:376831 CAPLUS
DOCUMENT NUMBER: 138:385442
TITLE: Preparation of (anilino)quinazolines as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Pass, Martin; Bradbury, Robert Hugh
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 275 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040109	A2	20030515	WO 2002-GB4932	20021031
WO 2003040109	A3	20030626		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2465100	A1	20030515	CA 2002-2465100	20021031
AU 2002341158	A1	20030519	AU 2002-341158	20021031
EP 1444211	A2	20040811	EP 2002-774961	20021031
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002013843	A	20040831	BR 2002-13843	20021031
HU 200401994	A2	20050128	HU 2004-1994	20021031
JP 2005511603	T	20050428	JP 2003-542155	20021031
CN 1764651	A	20060426	CN 2002-826282	20021031
NZ 532523	A	20070223	NZ 2002-532523	20021031
ZA 2004003200	A	20050728	ZA 2004-3200	20040428
ZA 2004003203	A	20050728	ZA 2004-3203	20040428
NO 2004002288	A	20040603	NO 2004-2288	20040603
US 2005054662	A1	20050310	US 2004-494388	20041001
US 2007088044	A1	20070419	US 2006-443395	20060531
PRIORITY APPLN. INFO.:			GB 2001-26433	A 20011103
			WO 2002-GB4932	W 20021031
			US 2004-494388	B1 20041001
OTHER SOURCE(S):	MARPAT 138:385442			
GI				



I



II

AB Title compds. I [wherein m = 0-2; n = 1-2; L = a bond or [C(R22)2]n; R1 = halo, CF3, CN, NC, NO2, OH, SH, NH2, CHO, CO2H, CONH2, or (un)substituted alkyl(oxy), alkenyl(oxy), alkynyl(oxy), alkylthio, alkylsulfinyl, alkylsulfonyl, (di)alkylamino, alkoxy carbonyl, (di)alkylcarbamoyl, alkanoyl(oxy), (alkyl)alkanoylamino, (alkyl)alkenoylamino, (alkyl)alkynoylamino, (di)alkylsulfamoyl, (alkyl)alkanesulfonylamino, or Q3X1; or (R1)m = alkylenedioxy; with the proviso that adjacent alkylene C atoms within a R1 substituent are optionally interrupted by O, S, SO, SO2, NR5, CO, CHOR5, CONR5, NR5CO, SO2NR5, NR5SO2, CH=CH, or C.tplbond.C; R2 = H; R3, R4, R5, R11, R12, and R22 = independently H or alkyl; Q1 and Q3 = independently (un)substituted (hetero)aryl(alkyl), cycloalkyl(alkyl), cycloalkenyl(alkyl), or heterocyclyl(alkyl); with the proviso that adjacent alkylene C atoms within the Q1Z group are optionally interrupted by O, S, SO, NR12, CO, CHOR12, CONR12, NR12CO, SO2NR12, NR12SO2, CH=CH, or C.tplbond.C; Q2 = (un)substituted Ph, bicyclic (hetero)aryl, or bicyclic heterocyclyl; X1 = a bond, O, S, SO, SO2, NR4, CO, CHOR4, CONR4, NR4CO, SO2NR4, NR4SO2, OC(R4)2, SC(R4)2, or NR4C(R4)2; Z = a bond, O, S, SO, SO2, NR11, CO, CHOR11, CONR11, NR11CO, SO2NR11, NR11SO2, OC(R11)2, SC(R11)2, or NR11C(R11)2; and pharmaceutically acceptable salts thereof] were prepared for use in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. For example, coupling of 3-(R)-(+)-dimethylaminopyrrolidine with 3,4-dihydro-5-hydroxy-7-fluoroquinazolin-4-one•CF3CO2H in NMP gave the pyrrolidinylquinazolinone (41%). Addition of chloromethyl pivalate in the presence of NaH in DMF afforded the 3-substituted derivative (62%), which was condensed with 4-hydroxy-N-methylpiperidine using PPh3 and di-tert-Bu azodicarboxylate in DCM to give the piperidinyloxyquinazolinone (77%). Deprotection (66%) using NH3 in MeOH, followed by chlorination with POCl3 and di-disopropylethylamine in dichloroethane provided 4-chloro-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline (81%). Coupling of the chloroquinazoline with 3-bromoaniline in the presence of HCl and IPA in dioxane yielded II•HCl (43%). The biol. activity of the example compds. was assessed in five assays. Thus, I inhibited the phosphorylation of a tyrosine-containing polypeptide substrate by epidermal growth factor receptor (EGFR) kinase, erbB2 kinase, and erbB4 kinase with IC50 values in the range of 0.001 μ M - 10 μ M. I also inhibited the proliferation of both human naso-pharyngeal carcinoma KB cells and non-neoplastic epithelial H16N-2 cells with IC50 values in the range 0.001 μ M - 20 μ M. In addition, I inhibited the growth of colorectal adenocarcinoma LoVo and human mammary carcinoma BT-474 tumor cell xenografts in vivo with activities in the range of 1 mg/kg/day to 200 mg/kg/day with no physiol. unacceptable toxicity at the ED.

IT

525590-12-9P 525590-14-1P 525590-51-6P,
4-(3-Chloro-4-fluoroanilino)-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-


methylpiperidin-4-yloxy)quinazoline 525590-57-2P,
 4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline 525590-58-3P,
 4-(3-Chloroanilino)-7-(3-(S)-dimethylaminopyrrolidin-1-yl)-5-[(tetrahydropyran-4-yl)oxy]quinazoline 525593-38-8P,
 4-(3-Chloroanilino)-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline 525593-40-2P,
 4-(3-Bromoanilino)-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; preparation of (anilino)quinazolines as erbB receptor tyrosine kinase inhibitors for treatment of cancer)

RN 525590-12-9 CAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 525590-14-1 CAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 525590-51-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyloxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 525590-57-2 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 525590-58-3 CAPLUS
 CN 4-Quinazolinamine, N-(3-chlorophenyl)-7-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 525593-38-8 CAPLUS
 CN 4-Quinazolinamine, N-(3-chlorophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 525593-40-2 CAPLUS
 CN 4-Quinazolinamine, N-(3-bromophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)

CN(C)C1CCN(C1)c2ccc3c(c2)c4ncnc4Nc5ccc(Br)cc5Oc6ccccc6N7CCCCC7CC1CCN(C1)c2cc(F)c3c2nc4c3cnc4NCC5=CC=C6C(=C5)OC(=C6)O

I


IT 333400-61-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure-activity relationships of fluoroquinazolines: dual-acting compds. with inhibitory activities toward both TNF- α production and T cell proliferation in relation to treatment of rheumatoid arthritis and pharmacokinetics)

RN 333400-61-6 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-fluoro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:620025 CAPLUS

DOCUMENT NUMBER: 138:180219

TITLE: Structure-activity relationships of 6-nitroquinazolines: dual-acting compounds with inhibitory activities toward both TNF- α production and T cell proliferation

AUTHOR(S): Tobe, Masanori; Isobe, Yoshiaki; Tomizawa, Hideyuki; Nagasaki, Takahiro; Obara, Fumihiro; Matsumoto, Mitsuhiro; Hayashi, Hideya

CORPORATE SOURCE: Pharmaceuticals & Biotechnology Laboratory, Japan Energy Corporation, Toda, 335-8502, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2002), 50(8), 1073-1080

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:180219

AB We synthesized various 6-nitroquinazolines by modifying the structure of compound 1 and evaluated their inhibitory activities toward both TNF- α production and T cell proliferation responses. The presence of the unsubstituted piperazine ring at the C(7)-position was required for both inhibitory activities. In this series of compds., 5d and 5f, containing the 4-fluorophenyl and 3,4-difluorophenyl moiety, resp., at the C(4)-position, showed the suppressing effects toward both responses with low cell growth inhibition. Furthermore, the oral administration of these compds. mentioned above at doses of 30 and 100 mg/kg also resulted in significant inhibition of TNF- α production induced by LPS in vivo.


IT 333400-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure-activity relationships of nitroquinazolines as TNF- α production and T cell proliferation inhibitors)

RN 333400-69-4 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-nitro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:220580 CAPLUS

DOCUMENT NUMBER: 136:247606

TITLE: Preparation of 3-(4-pyrimidinylamino)pyrazole derivatives as protein kinase inhibitors; especially of Aurora-2 and GSK-3, for treating cancer, diabetes and Alzheimer's disease.

INVENTOR(S): Davies, Robert; Bebbington, David; Binch, Haley; Knegtel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022604	A1	20020321	WO 2001-US28792	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422371	A1	20020321	CA 2001-2422371	20010914
AU 200194558	A	20020326	AU 2001-94558	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
EP 1317450	A1	20030611	EP 2001-975210	20010914
EP 1317450	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200302172	A2	20030929	HU 2003-2172	20010914
ZA 2003001701	A	20040301	ZA 2003-1701	20010914

ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004512277	T	20040422	JP 2002-526857	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
US 2005004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
NZ 525009	A	20050527	NZ 2001-525009	20010914
ES 2242771	T3	20051116	ES 2001-1971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
AT 363284	T	20070615	AT 2001-977783	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219
AU 2002255452	A1	20020904	AU 2002-255452	20011219
CA 2432223	A1	20020906	CA 2001-2432223	20011219
AU 2001297619	A1	20020912	AU 2001-297619	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 200400842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
IN 2003KN00289	A	20050311	IN 2003-KN289	20030307
NO 2003001190	A	20030513	NO 2003-1190	20030314
MX 2003PA02292	A	20030606	MX 2003-PA2292	20030317
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125


HK 1057748	A1	20070615	HK 2003-108588	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 2006258658	A1	20061116	US 2006-492450	20060725

PRIORITY APPLN. INFO.:


US 2000-232795P	P	20000915
US 2000-257887P	P	20001221
US 2001-286949P	P	20010427
AU 2001-90944	A3	20010914
AU 2001-91013	A3	20010914
AU 2001-94558	A3	20010914
AU 2001-96871	A3	20010914
AU 2001-96875	A3	20010914
EP 2001-971082	A3	20010914
US 2001-952671	A3	20010914
US 2001-953471	A3	20010914
US 2001-955601	A3	20010914
WO 2001-US28792	W	20010914
EP 2001-273861	A	20011219
EP 2001-994323	A3	20011219
JP 2002-557938	A3	20011219
US 2001-26966	A1	20011219
WO 2001-US49139	W	20011219
WO 2001-US50312	W	20011219
US 2001-34019	A3	20011220
US 2001-34683	A1	20011220

OTHER SOURCE(S):
GI


MARPAT 136:247606



I



II



III

AB The preparation of title compds. I and their pharmaceutically acceptable salts or prodrugs is described [wherein: R1, R2 = dependently form (un)substituted fused, unsatd. or partially unsatd., 5-8 membered carbocyclo ring; R3, R4 = independently H, aliphatic, aryl, heteroaryl, heterocyclyl, or wide variety of functionalized sidechains; or dependently form a fused, 5-8 membered, unsatd. or partially unsatd. ring having 0-3 ring heteroatoms (N, S, O); R5 = fused, (un)substituted 5-7 membered monocyclic ring or 8-10 membered bicyclic ring (aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms (N, S, O))]. For example, chlorination of quinazolinone II with phosphorus oxychloride, followed by condensation with 3-amino-5-methylpyrazole afforded claimed compound III. Compds. I are inhibitors of GSK-3 and Aurora-2 protein kinases. The invention also relates to methods of treating diseases associated with these protein kinases, such as diabetes, cancer and Alzheimer's disease. In bioassays, compds. I inhibited the following kinases with Kis reported < 100 nM: GSK-3 β (163 compds.), AURORA-2 (65 compds.), CDK-2 (no data), ERK2 (8 compds.), AKT (no data), and Human Src kinase (21 compds.). Claims included 146 specific compds., and 188 examples were given. The syntheses of 6 compds. and 46 intermediates are described.


IT 404844-88-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404844-88-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-7-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:220578 CAPLUS

DOCUMENT NUMBER: 136:263164

TITLE: Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Knegtel, Ronald; Binch, Haley; Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 377 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022602	A2	20020321	WO 2001-US42162	20010914
WO 2002022602	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422299	A1	20020321	CA 2001-2422299	20010914
AU 200196875	A	20020326	AU 2001-96875	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		

EP 1318814	A2	20030618	EP 2001-977783	20010914
EP 1318814	B1	20070530		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509114	T	20040325	JP 2002-526855	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
US 2005004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-1971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
AT 363284	T	20070615	AT 2001-977783	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219
AU 2002255452	A1	20020904	AU 2002-255452	20011219
CA 2432223	A1	20020906	CA 2001-2432223	20011219
AU 2001297619	A1	20020912	AU 2001-297619	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 200400842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
MX 2003PA02297	A	20030606	MX 2003-PA2297	20030317
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		

US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 2006258658	A1	20061116	US 2006-492450	20060725




PRIORITY APPLN. INFO.:

US 2000-232795P	P	20000915
US 2000-257887P	P	20001221
US 2001-286949P	P	20010427
AU 2001-90944	A3	20010914
AU 2001-91013	A3	20010914
AU 2001-94558	A3	20010914
AU 2001-96871	A3	20010914
AU 2001-96875	A3	20010914
EP 2001-971082	A3	20010914
US 2001-952671	A3	20010914
US 2001-953471	A3	20010914
US 2001-955601	A3	20010914
WO 2001-US42162	W	20010914
EP 2001-273861	A	20011219
EP 2001-994323	A3	20011219
JP 2002-557938	A3	20011219
US 2001-26966	A1	20011219
WO 2001-US49139	W	20011219
WO 2001-US50312	W	20011219
US 2001-34019	A3	20011220
US 2001-34683	A1	20011220

OTHER SOURCE(S):

MARPAT 136:263164

GI



AB Triazolamines I and pyrazolamines II [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (heterocyclyl)triazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; R9 is defined above]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK-β3, Aurora-2, ERK, and Src. For instance, the N-(4-quinazolinyl)-1H-1,2,4-triazol-3-amine III was prepared and exhibited Ki values of < 0.1 μM for glycogen synthetase kinase 3β (GSK-3β) and 1.0-20 μM for Aurora-2.


IT 404891-25-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404891-25-4 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-7-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:904160 CAPLUS

DOCUMENT NUMBER: 136:20087

TITLE: Preparation of 4-anilinoquinazoline derivatives for the treatment of tumors

INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 234 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094341	A1	20011213	WO 2001-GB2424	20010601
WO 2001094341	A9	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2407371	A1	20011213	CA 2001-2407371	20010601
EP 1292594	A1	20030319	EP 2001-934176	20010601
EP 1292594	B1	20040901		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001011335	A	20030610	BR 2001-11335	20010601
HU 200301046	A2	20030828	HU 2003-1046	20010601
JP 2003535859	T	20031202	JP 2002-501890	20010601
JP 3774438	B2	20060517		
EE 200200673	A	20040615	EE 2002-673	20010601
NZ 522204	A	20040730	NZ 2001-522204	20010601
AT 275145	T	20040915	AT 2001-934176	20010601
PT 1292594	T	20041231	PT 2001-934176	20010601


ES 2225545	T3	20050316	ES 2001-1934176	20010601
RU 2276151	C2	20060510	RU 2002-135617	20010601
IN 2002MN01457	A	20050304	IN 2002-MN1457	20021021
US 2004214841	A1	20041028	US 2002-275382	20021105
US 7049438	B2	20060523		
ZA 2002009122	A	20040209	ZA 2002-9122	20021108
MX 2002PA11765	A	20030410	MX 2002-PA11765	20021128
BG 107332	A	20030731	BG 2002-107332	20021128
NO 2002005792	A	20021202	NO 2002-5792	20021202
HK 1053115	A1	20050408	HK 2003-105395	20030725

PRIORITY APPLN. INFO.:

EP 2000-401581	A	20000606
EP 2001-400297	A	20010207
EP 2001-400565	A	20010305
WO 2001-GB2424	W	20010601

OTHER SOURCE(S): MARPAT 136:20087

GI



AB The invention concerns quinazoline derivs. (I; e.g. 4-(2-chloro-5-methoxyanilino)-7-methoxy-5-(3-morpholinopropoxy)quinazoline (1)), processes for their preparation, pharmaceutical compns. containing them and their

use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease. Although biol. assay methods are described, no test results are reported. It is believed that the antitumor activity is due to inhibition of one or more of the non-receptor tyrosine-specific protein kinases of the Src family that are involved in the signal transduction steps that lead to the invasiveness and migratory ability of metastasizing tumor cells. In I, according to the 1st claim, m = 0-3; each R1 = halo, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonfylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonfylamino, or Q3-X1- (X1 = direct bond, O, S, SO, SO2, N(R4), CO, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, OC(R4)2, SC(R4)2 and N(R4)C(R4)2 (R4 = H or (1-6C)alkyl) and Q3 = aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-, (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl), or (R1)m is (1-3C)alkylenedioxy, with addnl. optional substitution and/or insertion possible. R2 = H or (1-6C)alkyl; R3 = H or (1-6C)alkyl; Z = direct bond, O, S, SO, SO2, N(R11), CO, CH(OR11), CON(R11), N(R11)CO, SO2N(R11), N(R11)SO2, OC(R11)2, SC(R11)2 and N(R11)C(R11)2 (R11 = H, or (1-6C)alkyl). Q1 = aryl, aryl-(1-6C)alkyl,

(3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or, when Z is a direct bond or O, Q1 may be (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, halo-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio-(1-6C)alkyl, (1-6C)alkylsulfinyl-(1-6C)alkyl or (1-6C)alkylsulfonyl-(1-6C)alkyl, with addnl. optional substitution and/or insertion possible. Q2 = substituted Ph. More than 50 example preps. are included. For example, 1 was obtained by adding di-tert-Bu azodicarboxylate (0.208 g) dropwise to a stirred mixture of 4-(2-chloro-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline (0.2 g), 4-(3-hydroxypropyl)morpholine, PPh3 (0.237 g) and CH2Cl2 (3 mL). The reaction mixture was stirred at ambient temperature for 1 h.

IT 379231-47-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilinoquinazoline derivs. for treatment of tumors)

RN 379231-47-7 CAPLUS

CN 4-Quinazolinamine, 7-[(2R,5R)-2,5-bis(methoxymethyl)-1-pyrrolidinyl]-N-(2-bromo-5-methoxyphenyl)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:312415 CAPLUS

DOCUMENT NUMBER: 134:326541

TITLE: Synthesis and use of substituted 4-(1H-indol-5-yl)aminoquinazoline derivatives and analogs for treatment of hyperproliferative disorders

INVENTOR(S): Sobolov-jaynes, Susan B.; Arnold, Lee D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 17 pp., Cont.-in-part of U.S. Ser. No. 953,078, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6225318	B1	20010501	US 1999-449855	19991126

PRIORITY APPLN. INFO.:

US 1996-28881P

P 19961017



US 1997-953078

B2 19971017

OTHER SOURCE(S):

MARPAT 134:326541

GI




AB The title compds. I [R1 is selected from CF3, halo, NO2, OH, NH2, cyano, (C1-C4)alkoxy, etc; Q1 is Ar-Y-X, where Ar is pyridyl, thiophenyl (i.e., thienyl) or pyrazinyl wherein Ar may have up to 3 substituents, X is C2 alkene, C2 alkyne or absent and Y is (CH2)0-5 and wherein one or two of the CH2 groups may optionally and independently be replaced by either O, S, SO2, CO, NH or NMe; R5 is selected from CH2F, CHF2, CF3, halo, NO2, OH, NH2, (C1-C4)alkyl, Ph, etc.; or two R5s together with the carbon atoms to which they are attached, form an imidazole, pyrrole or pyrazole; q is 0-3] and similarly substituted 4-quinazolones are prepared. More than 40 examples are provided. For example, heating (1H-indol-5-yl)-(6-iodo-7-methoxyquinazolin-4-yl)amine with 4-vinylpyridine, Pd acetate and NEt3 in MeCN gave (1H-indol-5-yl)-[7-methoxy-6-(2-pyridin-4-yl-vinyl)quinazolin-4-yl]amine (II). Compds. I are inhibitors of protein tyrosine kinase. In an EGFR kinase activity assay, I had IC50 values in the range of 0.0001-30 μ M. Inhibition of tumor growth was determined in mice (on tumors induced by injection of human MDA-MD-468 breast or human HN5 head and neck carcinoma cells) to be >50% at concns. of 10 μ M. Treatment of hyperproliferative diseases in a mammal is claimed.

IT 336624-87-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and use of substituted 4-(indol-5-yl)aminoquinazoline derivs. for treatment of hyperproliferative disorders)

RN 336624-87-4 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-7-(2-thienyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:265402 CAPLUS

DOCUMENT NUMBER: 134:275758

TITLE: Preparation and effect of novel quinazoline derivatives as TNF- α inhibitors

INVENTOR(S): Tobe, Masanori; Isobe, Yoshiaki; Tomizawa, Hideyuki; Matsumoto, Mitsuhiro; Nagasaki, Takahiro; Obara, Fumihiko

PATENT ASSIGNEE(S): Japan Energy Corporation, Japan

SOURCE: PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025218	A1	20010412	WO 2000-JP6666	20000927
W: AU, CA, JP, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2386163	A1	20010412	CA 2000-2386163	20000927
AU 200074465	A	20010510	AU 2000-74465	20000927
AU 763033	B2	20030710		
EP 1229025	A1	20020807	EP 2000-962890	20000927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 3868811	B2	20070117	JP 2001-528164	20000927
PRIORITY APPLN. INFO.:			JP 1999-282078	A 19991001
			WO 2000-JP6666	W 20000927

OTHER SOURCE(S): MARPAT 134:275758

GI



I

AB Title compds. [I; R1 is nitro or halo; R2 and R4 are each hydrogen, C1-4 alkyl, carboxyl, or C2-5 alkoxy carbonyl; R3 is hydrogen, amino, optionally substituted C1-4 alkyl, C1-4 alkanoyl, or C2-5 alkoxy carbonyl; W is carbon or nitrogen; Y = CH₂, CH₂CH₂, CH₂CH₂CH₂; Z = C₆H₅, 4-ClC₆H₄, 4-FC₆H₄, 3,4-OCH₂OC₆H₃, 2-thienyl, 2-furyl, 2-pyridinyl, 3-pyridinyl, 1-naphthyl; m is 0, 1, or 2] and pharmaceutically acceptable salts thereof are prepared as TNF- α inhibitors. Thus, the title compound I (R1 = NO₂; R2 = H; R3 = H; R4 = H; W = N; m = 1, Y = CH₂CH₂; Z = 4-ClC₆H₄) was prepared and biol. tested.


IT 333400-32-1P 333400-61-6P 333400-68-3P
333400-69-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and effect of novel quinazoline derivs.)


RN 333400-32-1 CAPLUS

CN 4-Quinazolinamine, 6-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 333400-61-6 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-fluoro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 333400-68-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluorophenyl)-6-nitro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 333400-69-4 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-nitro-7-(1-piperazinyl)- (9CI)
(CA INDEX NAME)



IT 333400-33-2P 333400-34-3P 333400-35-4P

333400-36-5P 333400-37-6P 333400-38-7P


333400-39-8P 333400-40-1P 333400-41-2P

333400-42-3P 333400-43-4P 333401-49-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and effect of novel quinazoline derivs.)


RN 333400-33-2 CAPLUS

CN 4-Quinazolinamine, N-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-6-nitro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 333400-34-3 CAPLUS

CN 4-Piperidinamine, 1-benzoyl-N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]-
(9CI) (CA INDEX NAME)




RN 333400-35-4 CAPLUS

CN 4-Quinazolinamine, N-[1-(1,3-benzodioxol-5-yl)-4-piperidinyl]-6-nitro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 333400-36-5 CAPLUS

CN 4-Piperidinamine, N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 333400-37-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 333400-38-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 333400-39-8 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-methoxyphenyl)-4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 333400-40-1 CAPLUS


CN 1-Piperidinecarbothioamide, 4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 333400-41-2 CAPLUS
 CN 4-Piperidinamine, N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 333400-42-3 CAPLUS
 CN 4-Piperidinamine, 1-[(4-methoxyphenyl)sulfonyl]-N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 333400-43-4 CAPLUS

CN 4-Piperidinamine, 1-[(4-fluorophenyl)sulfonyl]-N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 333401-49-3 CAPLUS

CN 4-Quinazolinamine, 6-fluoro-N-(4-fluorophenyl)-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)






REFERENCE COUNT:

6


THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:854415 CAPLUS
 DOCUMENT NUMBER: 133:362769
 TITLE: Preparation of 6-(thiomorpholinomethylfuranyl)-4-quinazolinamines as protein tyrosine kinase inhibitors
 INVENTOR(S): Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Brit. UK Pat. Appl., 151 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2345486	A	20000712	GB 1999-29973	19991217
PRIORITY APPLN. INFO.:			GB 1999-518	A 19990111
			GB 1999-15510	A 19990703
OTHER SOURCE(S):	MARPAT	133:362769		
GI				



- AB The title compds. (I) [wherein X = N or CH; V and Y = independently CR1, CR2, or N; and V ≠ Y; R1 = Q(CH2)qAr; m = 1 or 2; p = 1 or 2; q = 1-4; Ar = (un)substituted Ph, furanyl, thiophenyl, pyrrolyl, or thiazolyl; R2 = H, halo, OH, alkyl(amino) alkoxy, or dialkylamino; U = (un)substituted Ph, pyridyl, (benz)imidazolyl, (iso)indolyl, (iso)indolinyl, indazolyl, or benzotriazolyl] were prepared as protein tyrosine kinase inhibitors for the treatment of cancer and other disorders mediated by aberrant protein tyrosine kinase activity. For example, II•2HCl was formed in a multi-step sequence involving (1) reaction of 5-(1,3-dioxolan-2-yl)-2-(tributylstannyl)furan with (4-benzyloxyphenyl)(6-bromoquinazolin-4-yl)amine using Pd(PPh3)2Cl2 in dioxane, (2) conversion of the cyclic acetal to the aldehyde with HCl in THF, (3) addition of thiomorpholine-S-oxide in CH2Cl2 and conversion to the HCl salt. I inhibited EGFR and c-erbB-2 tyrosine kinase with IC50 < 0.10 μM and suppressed cell proliferation against a range of tumor cell lines.
- IT 202198-15-0P, (1-Benzyl-1H-indazol-5-yl)-[7-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine hydrochloride
- RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (preparation of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addition of thiomorpholine (oxides))
- RN 202198-15-0 CAPLUS
- CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:451297 CAPLUS

DOCUMENT NUMBER: 131:102288

TITLE: Bicyclic heteroaromatic compounds [quinazolinamines, pyridopyrimidines, and analogs] useful as protein tyrosine kinase inhibitors

INVENTOR(S): Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935146	A1	19990715	WO 1999-EP48	19990108
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2317589	A1	19990715	CA 1999-2317589	19990108
AU 9922783	A	19990726	AU 1999-22783	19990108
AU 749549	B2	20020627		
BR 9906904	A	20001017	BR 1999-6904	19990108
EP 1047694	A1	20001102	EP 1999-902522	19990108
EP 1047694	B1	20040707		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002015	T2	20010122	TR 2000-200002015	19990108
HU 200100941	A2	20010928	HU 2001-941	19990108
EE 200000411	A	20011217	EE 2000-411	19990108
EE 4616	B1	20060417		
JP 2002500225	T	20020108	JP 2000-527545	19990108
JP 3390741	B2	20030331		

JP 2002326990	A	20021115	JP 2002-92102	19990108
NZ 505456	A	20030630	NZ 1999-505456	19990108
CN 1134437	B	20040114	CN 1999-803887	19990108
AT 270670	T	20040715	AT 1999-902522	19990108
EP 1454907	A1	20040908	EP 2004-76762	19990108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1460072	A1	20040922	EP 2004-76761	19990108
EP 1460072	B1	20060405		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PT 1047694	T	20041130	PT 1999-902522	19990108
ES 2221354	T3	20041216	ES 1999-902522	19990108
AP 1446	A	20050930	AP 2000-1861	19990108
W: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW				
AT 322491	T	20060415	AT 2004-76761	19990108
PT 1460072	T	20060731	PT 2004-76761	19990108
ES 2262087	T3	20061116	ES 2004-76761	19990108
PL 192746	B1	20061229	PL 1999-341595	19990108
SK 285405	B6	20070104	SK 2000-1050	19990108
CZ 298047	B6	20070606	CZ 2000-2587	19990108
ZA 9900172	A	20000711	ZA 1999-172	19990111
TW 477788	B	20020301	TW 1999-88100388	19990112
US 6727256	B1	20040427	US 2000-582746	20000630
NO 2000003561	A	20000911	NO 2000-3561	20000711
NO 316176	B1	20031222		
MX 2000PA06824	A	20010405	MX 2000-PA6824	20000711
HR 2000000469	A1	20010630	HR 2000-469	20000712
HR 2000000469	B1	20070531		
IN 2000KN00130	A	20050311	IN 2000-KN130	20000712
BG 104668	A	20010430	BG 2000-104668	20000807
BG 64825	B1	20060531		
HK 1031883	A1	20050304	HK 2001-102589	20010411
US 2002147205	A1	20021010	US 2002-71358	20020208
US 6713485	B2	20040330		
US 2003176451	A1	20030918	US 2003-342810	20030115
US 2005130996	A1	20050616	US 2005-50033	20050203
US 7109333	B2	20060919		
US 2007015775	A1	20070118	US 2006-532926	20060919
PRIORITY APPLN. INFO.:				
			GB 1998-569	A 19980112
			EP 1999-902522	A3 19990108
			JP 2000-527545	A3 19990108
			WO 1999-EP48	W 19990108
			US 2000-582746	A1 20000630
			US 2003-342810	A1 20030115
			US 2005-50033	A1 20050203

OTHER SOURCE(S): MARPAT 131:102288
GI



AB Title compds. I and their salts and solvates are disclosed [wherein X = N or CH; Y = CR1 and V = N; or Y = N and V = CR1; or Y = CR1 and V = CR2; or Y = CR2 and V = CR1; R1 = MeSO₂CH₂CH₂NHCH₂-Ar-, wherein Ar = (un)substituted Ph, furan, thiophene, pyrrole, or thiazole; R2 = H, halo, OH, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamino, or di[C1-4 alkyl]amino; U = Ph, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by R3 and optionally by R4; R3 = (halo)benzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and (halo)benzyloxy, PhSO₂, (trihalomethyl)benzyl, (trihalomethyl)benzyloxy, (R5)n-substituted phthalimido; R4 = OH, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, (di)(alkyl)amino, C1-4 alkylthio, etc.; R5 = halo, C1-4 alkyl, C1-4 alkoxy; n = 0-3]. Also disclosed are methods for their preparation, pharmaceutical compns. containing them, and their use in medicine. The compds. are inhibitors of protein tyrosine kinases, and as such are useful in the treatment of cancer, psoriasis, and rheumatoid arthritis. Over 40 title compds. and numerous intermediates were prepared. For example, 4,6-dichloropyrido[3,4-d]pyrimidine was condensed with 4-[(4-fluorobenzyl)oxy]aniline at the 4-chloro position, followed by Pd-catalyzed coupling with 5-(1,3-dioxolan-2-yl)-2-(tributylstannyl)furan at the 6-chloro position, hydrolysis of the dioxolane protecting group to give an aldehyde, reductive amination of the latter with MeSCH₂CH₂NH₂, and finally S-oxidation with Oxone® and acidification, to give title salt II.2HCl. In a methylene blue growth inhibition assay against 5 tumor cell lines, II.2HCl had an IC₅₀ of < 5 μM against 4 of them, and an IC₅₀ of 25-50 μM against the 5th.


IT 202197-19-1P 202198-15-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 202197-19-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202198-15-0 CAPLUS

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:48710 CAPLUS

DOCUMENT NUMBER: 130:125085

TITLE: Preparation of quinazoline analogs and related compounds for treating inflammatory conditions

INVENTOR(S): Palanki, Moorthy S. S.; Suto, Mark J.

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901441	A1	19990114	WO 1998-US13483	19980629
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5939421	A	19990817	US 1997-886198	19970701
AU 9881754	A	19990125	AU 1998-81754	19980629

US 6150372
PRIORITY APPLN. INFO.:


A 20001121
MARPAT 130:125085

US 1999-340557
US 1997-886198
WO 1998-US13483
19990628
A 19970701
W 19980629


OTHER SOURCE(S):
GI




I




II



III



IV



V


AB The title compds. [I; R10 = II-IV; A = CR7, N; R1, R3 = H, (un)substituted C1-8 alkyl, C6-12 aryl; R2 = (un)substituted C1-8 alkyl, C6-12 aryl, etc.; R4 = H, C1-8 alkyl; R5-R8 = H, NO2, CN, etc.; R11 = H, (un)substituted C1-8 alkyl, C6-12 aryl; R12 = H, CO2R9, CONHR9; R9 = H, (un)substituted C1-8 alkyl, C6-12 aryl, etc.], having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory (such as rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, transplant rejection, sepsis, ARDS, and asthma) and autoimmune diseases (such as multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, uveitis, and chronic hepatitis), and trauma, oxidative stress, cell death, irradiation damage, ischemia, reperfusion, cancer and viral infection, were prepared Thus, reaction of 4-chloro-2-(2'-thienyl)quinazoline (preparation given) with hydrazine in THF followed by treatment of the resulting intermediate with citraconic anhydride in chloroform afforded 98% V which showed IC50 of 0.07 μ M against AP-1 and IC50 of 0.04 μ M against NF κ B.

IT 219774-04-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline analogs and related compds. for treating inflammatory conditions)

RN 219774-04-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[7-(1-piperidinyl)-2-(trifluoromethyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 29 OF 34. CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:71133 CAPLUS
 DOCUMENT NUMBER: 128:140716
 TITLE: Preparation of azolylquinazolines and related compounds as protein tyrosine kinase inhibitors.
 INVENTOR(S): Cockerill, George Stuart; Carter, Malcolm Clive; Guntrip, Stephen Barry; Smith, Kathryn Jane
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Cockerill, George Stuart; Carter, Malcolm Clive; Guntrip, Stephen Barry; Smith, Kathryn Jane
 SOURCE: PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9802434	A1	19980122	WO 1997-EP3672	19970711
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9706147	A	19990111	ZA 1997-6147	19970710
AU 9737668	A	19980209	AU 1997-37668	19970711
EP 912559	A1	19990506	EP 1997-934458	19970711
EP 912559	B1	20021106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000514806	T	20001107	JP 1998-505596	19970711
AT 227283	T	20021115	AT 1997-934458	19970711
PT 912559	T	20030331	PT 1997-934458	19970711
ES 2186908	T3	20030516	ES 1997-934458	19970711
IN 1997CA01314	A	20050311	IN 1997-CA1314	19970711
US 6391874	B1	20020521	US 1998-214267	19981231
US 2002147214	A1	20021010	US 2002-62647	20020131
US 6828320	B2	20041207		
PRIORITY APPLN. INFO.:			GB 1996-14755	A 19960713
			GB 1996-25458	A 19961207
			WO 1997-EP3672	W 19970711

OTHER SOURCE(S):

MARPAT 128:140716

GI




AB Title compds. [I; U = substituted Ph, mono- or bicyclic 5-10 membered (hetero)cyclcyl; X = N, CH; Y = W(CH₂), (CH₂)W, W; W = O, S(O)_m, NR_a; R_a = H, alkyl; m = 0-2; R₁ = (substituted) Ph, 5- or 6-membered heterocyclcyl containing 1-4 heteroatoms selected from N, O, S(O)_m with the provision that the ring does not contain two adjacent O or S(O)_m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring; R₃ = H, amino, halo, OH, NO₂, CO₂H, CHO, cyano, CF₃, OCF₃, carbamoyl, alkoxy carbonyl, Ph, PhO, pyridonyl, pyrrolidinyl, imidazolyl, dioxolanyl, arylsulfonyl, alkylsulfonyl, alkylcarbamoylalkyl, piperidinoalkoxy, thiomorpholino, etc.; 2 adjacent R₃ = methylenedioxy, ethylenedioxy; p = 0-3], were prepared Thus, (S)-1-[5-[4-(1-benzyl-1H-indazol-5-ylamino)quinazolin-6-yl]furan-2-ylmethyl]pyrrolidine-2-carboxylic acid amide dihydrochloride (preparation given) inhibited BT474 human breast cancer cell proliferation with IC₅₀ = 2 nM.

IT 202197-15-7P 202197-16-8P 202197-17-9P
202197-18-0P 202197-19-1P 202197-20-4P
202197-21-5P 202198-13-8P 202198-14-9P
202198-15-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)


RN 202197-15-7 CAPLUS

CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-16-8 CAPLUS

CN 4-Quinazolinamine, 7-(1-methyl-1H-imidazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-17-9 CAPLUS

CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 202197-18-0 CAPLUS

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-
1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-19-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-
quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-20-4 CAPLUS


CN 4-Quinazolinamine, 7-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202197-21-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[[5-[4-[[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202198-13-8 CAPLUS


CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-14-9 CAPLUS


CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-15-0 CAPLUS


CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:568104 CAPLUS
 DOCUMENT NUMBER: 127:220671
 TITLE: Preparation of 4-anilino-7-heteroarylquinazolines as tyrosine kinase inhibitors.
 INVENTOR(S): Barker, Andrew John; Johnstone, Craig
 PATENT ASSIGNEE(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730044	A1	19970821	WO 1997-GB345	19970210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9716127	A	19970902	AU 1997-16127	19970210
EP 880517	A1	19981202	EP 1997-902497	19970210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000505441	T	20000509	JP 1997-529074	19970210
AT 212022	T	20020215	AT 1997-902497	19970210
PT 880517	T	20020731	PT 1997-902497	19970210
ES 2171884	T3	20020916	ES 1997-902497	19970210
US 5814630	A	19980929	US 1997-800830	19970213
PRIORITY APPLN. INFO.:			GB 1996-3097	A 19960214
			WO 1997-GB345	W 19970210
OTHER SOURCE(S): MARPAT 127:220671				
GI				




AB Title compds. [I; Q1 = (substituted) (benzo-fused) 5-6 membered heteroaryl; m = 1, 2; R1 = H, halo, CF3, OH, amino, NO2, cyano, CO2H, carbamoyl, alkoxy, etc.; Q2 = (substituted) Ph], having antiproliferative activity, were prepared Thus, 7-bromo-4-(3-chloro-4-fluoroanilino)quinazoline hydrochloride reacted with diisopropyl 5-morpholinomethylthien-3-ylboronate to give 4-(3-chloro-4-fluoroanilino)-7-(5-morpholinomethylthien-3-yl)quinazoline. The latter inhibited EGF-stimulated growth of KB cells with IC50 = 0.12 μ M.

IT 194851-13-3P 194851-14-4P 194851-15-5P 194851-21-3P 194851-22-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-anilino-7-heteroarylquinazolines as tyrosine kinase inhibitors)


RN 194851-13-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 194851-14-4 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 194851-15-5 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)




RN 194851-21-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 194851-22-4 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:23238 CAPLUS

DOCUMENT NUMBER: 122:31545

TITLE: Preparation of aminoquinazolines useful in the treatment of cancer

INVENTOR(S): Barker, Andrew John; Brown, Dearg Sutherland

PATENT ASSIGNEE(S): Zeneca, UK

SOURCE: Eur. Pat. Appl., 39 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 602851	A1	19940622	EP 1993-309680	19931203
EP 602851	B1	19961009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9350728	A	19940623	AU 1993-50728	19931116
AU 664496	B2	19951116		
ZA 9308594	A	19940610	ZA 1993-8594	19931117
CA 2103383	A1	19940611	CA 1993-2103383	19931118
CA 2103383	C	20050125		
IL 107678	A	19990312	IL 1993-107678	19931119
HU 65622	A2	19940728	HU 1993-3328	19931124
FI 9305431	A	19940611	FI 1993-5431	19931203
AT 143956	T	19961015	AT 1993-309680	19931203
ES 2093367	T3	19961216	ES 1993-309680	19931203
CZ 283612	B6	19980513	CZ 1993-2651	19931206
NO 9304504	A	19940613	NO 1993-4504	19931209
JP 06336481	A	19941206	JP 1993-309184	19931209
JP 3330706	B2	20020930		
CN 1094043	A	19941026	CN 1993-120872	19931210
US 5580870	A	19961203	US 1993-164725	19931210

PRIORITY APPLN. INFO.:

GB 1992-25765 A 19921210
GB 1993-10248 A 19930518

OTHER SOURCE(S): MARPAT 122:31545

GI




AB The title compds. [I; Q = 9- or 10-membered bicyclic heterocyclic moiety containing 1-2 N atoms; R1 = OH, NH2, ureido, hydroxyamino, trifluoromethoxy, (un)substituted C1-4 alkyl, C1-4 alkoxy, pyrrolidin-1-yl, piperidino, etc.; m = 1-3], useful in the treatment of cancer (no data), are prepared and I-containing formulations presented. Thus, 4-chloro-6,7-dimethoxyquinazoline was reacted with 5-aminoquinoline, producing 6,7-dimethoxy-4-(5-quinolylamino)quinazoline, m.p. > 240°, in 35% yield.

IT 159768-39-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as anticancer agent)

RN 159768-39-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 34 CAPLUS. COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:217715 CAPLUS

DOCUMENT NUMBER: 120:217715

TITLE: Quinazoline tyrosine kinase-inhibiting anticancer agents

INVENTOR(S): Barker, Andrew J.

PATENT ASSIGNEE(S): Zeneca Ltd., UK

SOURCE: Can. Pat. Appl., 99 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2086968	A1	19930721	CA 1993-2086968	19930108
CA 2086968	C	19980623		
ZA 9300015	A	19930720	ZA 1993-15	19930104
AU 9331010	A	19930722	AU 1993-31010	19930104
AU 661533	B2	19950727		
HU 63153	A2	19930728	HU 1993-94	19930115

HU 221622	B1	20021228		
EP 566226	A1	19931020	EP 1993-300270	19930115
EP 566226	B1	19951108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 130000	T	19951115	AT 1993-300270	19930115
ES 2078798	T3	19951216	ES 1993-300270	19930115
CZ 282038	B6	19970416	CZ 1993-43	19930118
NO 9300178	A	19930721	NO 1993-178	19930119
NO 301541	B1	19971110		
RU 2127263	C1	19990310	RU 1993-4423	19930119
SK 281551	B6	20010510	SK 1993-16	19930119
FI 111631	B1	20030829	FI 1993-208	19930119
KR 229294	B1	19991101	KR 1993-645	19930120
IL 104479	A	19991222	IL 1993-104479	19930121
JP 06073025	A	19940315	JP 1993-26577	19930216
JP 2994165	B2	19991227		
US 5457105	A	19951010	US 1994-284293	19940802
US 5616582	A	19970401	US 1995-490666	19950615

PRIORITY APPLN. INFO: GB 1992-1095 A 19920120
 GB 1992-13572 A 19920626
 GB 1992-23735 A 19921112
 US 1993-5280 B1 19930119
 US 1994-284293 A1 19940802

OTHER SOURCE(S): MARPAT 120:217715
 GI



AB The title compds. I [R1 = HO, (un)substituted amino, carboxy, carbamoyl, ureido, etc.; R2 = H, HO, halogen, CF3, NH2, NO2, CN, (un)substituted C1-4 alkyl, etc.; m = 1-3; n = 1, 2], useful as tyrosine kinase-inhibiting anticancer agents (no data), are prepared and I-containing formulations presented. Thus, 4-chloro-6,7-dimethoxyquinazoline was condensed with 3-MeC6H4NH2, producing 6,7-dimethoxy-4-(3'-methylanilino)quinazoline hydrochloride, m.p. 248-249°.


IT 153437-62-8P 153437-64-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of, as intermediate in preparation of quinazoline tyrosine kinase-inhibiting anticancer agents)

RN 153437-62-8 CAPLUS


CN 4,6-Quinazolinediamine, N4-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 153437-64-0 CAPLUS
 CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)-6-nitro- (9CI)
 (CA INDEX NAME)




IT 153437-63-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of, as tyrosine kinase-inhibiting anticancer agent)
 RN 153437-63-9 CAPLUS
 CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX
 NAME)




L4 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:505445 CAPLUS
 DOCUMENT NUMBER: 115:105445
 TITLE: Studies on cardiotonic agents. VII. Potent
 cardiotonic agent KF15232 with myofibrillar calcium
 sensitizing effect
 AUTHOR(S): Nomoto, Yuji; Takai, Haruki; Ohno, Tetsuji; Kubo,
 Kazuhiro

CORPORATE SOURCE: Pharm. Res. Lab., Fuji, Kyowa Hakko Kogyo Co., Ltd.,
Shizuoka, 411, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1991), 39(4),
900-10
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:105445
GI



I, R=H, alkyl, cycloalkyl, etc., R¹=H, RR¹=alkylene



II, R=NH₂, alkyl, Ph, etc.

AB A series of novel 4,5-dihydro-5-methyl-6-(4-substituted 7-quinazolinyl)-3-(2H)pyridazinones (I) was synthesized and examined for cardiotoxic activity in anesthetized dogs. The 4-substituted aminoquinazolines generally showed potent and long-lasting inotropic activity. Fall in the activity was observed on the introduction of substituent at the 2-position of the quinazoline ring. The 3-substituted 4-(3H)quinazolinimines (II) generally exhibited weak activity. Ca²⁺ sensitizing effect of the 4-substituted amino derivs. was also examined in chemical skinned fiber from papillary muscle of guinea pig. The alkylamine derivs. exhibited small sensitizing effect, while the benzylamino derivs. exhibited large effect. Among them, KF15232 (Ix) was found to have the most potent cardiotoxic and Ca²⁺ sensitizing activities.


IT 124294-39-9P 124294-40-2P 124294-41-3P
124294-42-4P 124294-54-8P 124294-55-9P
124294-56-0P 135678-13-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and cardiotoxic activity of, structure in relation to)


RN 124294-39-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(cyclopropylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-40-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(cyclopentylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-41-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(cyclohexylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-42-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(cyclooctylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-54-8 CAPLUS

CN 3(2H)-Pyridazinone, 4,5-dihydro-5-methyl-6-[4-(phenylamino)-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 124294-55-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-[(3-chlorophenyl)amino]-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-56-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-[(4-chlorophenyl)amino]-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 135678-13-6 CAPLUS
 CN 3(2H)-Pyridazinone, 4,5-dihydro-5-methyl-6-[4-(3-pyridinylamino)-7-quinazolinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:21004 CAPLUS
 DOCUMENT NUMBER: 112:21004
 TITLE: Preparation, testing, and formulation of
 4,5-dihydro-6-aryl-2-oxopyridazines as cardiotonics
 and antihypertensives
 INVENTOR(S): Nomoto, Yuji; Takai, Haruki; Ohno, Tetsuji; Kubo,
 Kazuhiro
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 48 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 326307	A2	19890802	EP 1989-300611	19890123
EP 326307	A3	19900912		
EP 326307	B1	19940817		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 02022274	A	19900125	JP 1989-7055	19890113
US 5063227	A	19911105	US 1990-462914	19900111


GI



- AB The title compds. [I; R1,R2 = H, (substituted) alkyl, alkenyl, aralkyl, aryl, amino, alkoxy, carbonylamino, pyridylalkyl; NR1R2 = heterocyclyl; R3 = H, alkyl; R4 = H, SH, OH, (substituted) alkyl, alkylthio, alkoxy, NR1R2; R5 = H, alkyl, NR1R2; X = Y = CH2NH, R5C=N, Q1, etc.; n = 2,3], useful as cardiotonics and antihypertensives, were prepared. Thus, 3-(4-bromo-3-nitrobenzoyl)butyric acid (prepn given) was cyclocondensed with N2H4 in HOAc to give 100% 6-(4-bromo-3-nitrophenyl)-4,5-dihydro-5-methyl-3(2H)pyridazinone. The latter was cyanated with CuCN in DMF (44%) followed by reduction with SnCl2/HCl to give 87% 6-(3-amino-4-cyanophenyl)-4,5-dihydro-5-methyl-3(2H)pyridazinone. This was condensed with (EtO)3CH to give 24% of the 3-ethoxymethyleneamino derivative, which was cyclized in MeOH containing MeNH2 to give the corresponding pyridazinone, which was heated with 2N NaOH to give 76% 4,5-dihydro-5-methyl-6-(4-methylaminoquinazolin-7-yl)-3(2H)pyridazinone. The latter at 0.03 mg/kg i.v. in dogs increased myocardial contractility with a $\Delta dp/dt$ of 78.3%.
- IT 124294-39-9P 124294-40-2P 124294-41-3P
124294-42-4P 124294-54-8P 124294-55-9P
124294-56-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cardiotonic and antihypertensive)
- RN 124294-39-9 CAPLUS
- CN 3(2H)-Pyridazinone, 6-[4-(cyclopropylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




- RN 124294-40-2 CAPLUS
- CN 3(2H)-Pyridazinone, 6-[4-(cyclopentylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-41-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(cyclohexylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-42-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(cyclooctylamino)-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124294-54-8 CAPLUS

CN 3(2H)-Pyridazinone, 4,5-dihydro-5-methyl-6-[4-(phenylamino)-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 124294-55-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-[(3-chlorophenyl)amino]-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 124294-56-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-[(4-chlorophenyl)amino]-7-quinazolinyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 05:27:01 ON 13 JUL 2007)

FILE 'REGISTRY' ENTERED AT 05:27:13 ON 13 JUL 2007

L1 STRUCTURE UPLOADED

L2 25 S L1
L3 740 S L1 FULL

FILE 'CAPLUS' ENTERED AT 05:34:09 ON 13 JUL 2007

L4 34 S L3 FULL

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
183.88	370.89

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-26.52	-26.52

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 05:40:21 ON 13 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 6, 2007 (20070706/UP).

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.38	372.27

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-26.52

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 05:53:51 ON 13 JUL 2007